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ABSTRACT 
 
Polymeric double-walled microspheres were developed by coaxial electrohydrodynamic 
atomization (CEHDA) and precision particle fabrication (PPF) techniques. Here, we focus on 
double-walled microspheres consisting of a poly(D,L-lactic-co-glycolic acid) (PLGA) core 
surrounded by a poly(D,L-lactic acid) (PDLLA) or poly(L-lactic acid) (PLLA) shell layer. 
 
The first study involves bridging the experimental work on the fabrication of double-walled 
microspheres from CEHDA and the simulation work on the generation of compound droplets 
from the same process. Process conditions and solution parameters were investigated to ensure 
the formation of double-walled microspheres with a doxorubicin-loaded PLGA core surrounded 
by a relatively drug-free PDLLA shell layer. Numerical simulation of CEHDA process was 
performed based on a computational fluid dynamics (CFD) model in Fluent. The simulation 
results were compared with the experimental work to illustrate the capability of the CFD model 
to predict the production of consistent double-walled microspheres. 
 
The second study involves drug release and degradation behavior of two double-walled 
microsphere formulations consisting of a doxorubicin-loaded PLGA core surrounded by a 
PDLLA shell layer. It was postulated that different molecular weights of the shell layer could 
modulate the erosion of the outer coating and limit the occurrence of water penetration into the 
inner drug-loaded core on various time scales, and therefore control the drug release from the 
microspheres. For both microsphere formulations, the drug release profiles were observed to be 
similar. Interestingly, both microsphere formulations exhibited occurrence of bulk erosion of 
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PDLLA on a similar time scale despite different PDLLA molecular weights forming the shell 
layer. The shell layer of the double-walled microspheres served as an effective diffusion barrier 
during the initial lag phase period and controlled the release rate of the hydrophilic drug 
independent of the molecular weight of the shell layer. 
 
The third study involves designing and evaluating double-walled microspheres loaded with 
chitosan-p53 nanoparticles (chi-p53, gene encoding p53 tumor suppressor protein) and/or 
doxorubicin in the shell and core phases, respectively, for combined gene therapy and 
chemotherapy. The microspheres were monodisperse with a mean diameter of 65 to 75 μm and 
uniform shell thickness of 8 to 17 μm. The encapsulation efficiency of doxorubicin was 
significantly higher when it was encapsulated alone compared to co-encapsulation with chi-p53. 
However, the encapsulation efficiency of chi-p53 was not affected by the presence of 
doxorubicin. As desired, chi-p53 was released first, followed by simultaneous release of chi-p53 
and doxorubicin at a near zero-order rate. Next, the therapeutic efficiencies of doxorubicin 
and/or chi-p53 in microsphere formulations were compared to free drug(s) and evaluated in 
terms of growth inhibition, and cellular expression of tumor suppressor p53 and apoptotic 
caspase 3 proteins in human hepatocellular carcinoma HepG2 cells. Overall, the combined 
doxorubicin and chi-p53 treatment exhibited enhanced cytotoxicity as compared to either 
doxorubicin or chi-p53 treatments alone. Moreover, the antiproliferative effect was more 
substantial when cells were treated with microspheres than those treated with free drugs. Overall, 
double-walled microspheres present a promising dual anticancer delivery system for combined 
chemotherapy and gene therapy. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background and Motivation 
Polymeric drug delivery systems are designed to encapsulate therapeutic agents and provide their 
release in a predesigned manner. The main purpose for controlling the drug delivery process is to 
achieve more effective therapies while eliminating the potential for both under- and over-dosing. 
Polymeric drug delivery systems such as biodegradable microspheres are relatively simple to 
fabricate. Moreover, they offer facile administration via different routes including oral, 
pulmonary and parenteral injection, and they do not need surgical removal after release of the 
drug is completed. 
 
Since an important goal of drug delivery systems is to attain well-controlled drug release rates, 
double-walled microspheres with a particle core surrounded by a shell layer are fabricated. The 
ability to form double-walled microspheres exhibiting a predefined core diameter and shell 
thickness may offer several additional advantages in drug delivery, including: i) drug 
encapsulated in the core of double-walled microspheres may overcome the problem of high 
initial burst release which is commonly encountered in traditional single-polymer microspheres, 
ii) higher drug loads with improved drug stability may be achieved by using materials in the core 
phase that offer increased drug solubility while stabilizing fragile therapeutics such as proteins 
and DNA, iii) advanced drug release schedules may be possible by selectively varying the shell 
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material or thickness, and iv) drugs can be released in various stages by selectively loading them 
into the core or shell phase, thereby potentially enhancing drug efficacy. 
 
Here, efforts are focused in developing a combined therapy strategy for cancer treatment on the 
basis of combining chemotherapy and gene therapy using double-walled microspheres as 
delivery carriers for controlled and sustained release. When a therapeutic gene is administered, 
certain anticancer drugs can be delivered to the cancer cells simultaneously with the aim to keep 
targeted cells sensitive to the drug during the entire treatment period. The rationales for the 
proposed combined modality cancer treatment are as follows: i) the combination of agents can 
result in increased efficacy without increased overall toxicity to the patient, ii) the combination 
of agents may thwart the development of resistance to the usage of single agents, iii) the 
combination of agents may provide a solution to the problem of heterogeneous tumor cell 
populations with various drug sensitivity profiles, and iv) the combination of agents allows one 
to take advantage of possible synergies between drugs, resulting in increased anticancer efficacy 
in patients. 
 
1.2. Studies and Objectives 
The research goals of this dissertation are: i) to bridge the experimental work on the fabrication 
of double-walled microspheres from coaxial electrohydrodynamic atomization (CEHDA) and the 
simulation work on the generation of compound droplets from the same process, ii) to examine 
the drug release and degradation behavior of two double-walled microsphere formulations 
consisting of a drug-loaded core surrounded by a shell layer with different molecular weights, 
 3 
 
 
and lastly, iii) to explore the therapeutic potential of double-walled microspheres for combined 
gene therapy and chemotherapy. The hypotheses are: i) the development of computational fluid 
dynamics (CFD) model for CEHDA based on experimental process conditions and fluid 
properties could predict the production of consistent compound droplets, and hence, the expected 
core-shell structured microspheres, ii) the variation of molecular weight of the shell layer of 
double-walled microspheres could modulate the erosion of the outer coating and limit the 
occurrence of water penetration into the drug-loaded core on various time scales, and therefore 
control the drug release from the microspheres, and finally, iii) the double-walled microspheres 
could deliver drug and gene simultaneously for improved treatment of human hepatocellular 
carcinoma. Specific studies and their corresponding objectives are listed as follows: 
a) This study aims to bridge the experimental and simulation work of the CEHDA process. 
• To investigate effect of process conditions, including nozzle voltage and polymer 
solution flow rates, as well as solution parameters, such as polymer 
concentrations, on the production of double-walled microspheres with a 
doxorubicin-loaded poly(D,L-lactic-co-glycolic acid) (PLGA) core surrounded by 
a poly(D,L-lactic acid) (PDLLA) shell layer. 
• To characterize microspheres in terms of their surface morphology, drug 
distribution, encapsulation efficiency and in vitro release. 
• To examine formation of liquid cone-jet and generation of compound droplets by 
employing the process conditions and fluid properties in a CFD model in Fluent 
to simulate the CEHDA process. 
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• To compare simulation results with experimental work to illustrate the capability 
of the CFD model to predict the production of consistent compound droplets, and 
estimate particle size together with its corresponding core diameter and shell 
thickness of the expected double-walled microspheres. 
b) This study examines the drug release and degradation behavior of two double-walled 
microsphere formulations consisting of a doxorubicin-loaded PLGA core (~46 kDa) 
surrounded by a PDLLA shell layer (~55 and 116 kDa). 
• To produce doxorubicin-loaded double-walled microspheres using the precision 
particle fabrication (PPF) technique. 
• To determine in vitro release profile of doxorubicin. 
• To examine changes in surface morphology of microspheres using scanning 
electron microscopy. 
• To examine changes in drug distribution and erosion extent of PDLLA and PLGA 
polymers using laser scanning confocal microscopy. 
• To examine changes in polymer molecular weight of microspheres using gel 
permeation chromatography. 
c) This study focuses on the design and evaluation of double-walled microspheres for 
combined gene therapy and chemotherapy. 
• To produce monodisperse double-walled microspheres loaded with doxorubicin 
and gene delivery vectors comprising chitosan and a plasmid DNA encoding p53 
(chi-p53) in the PLGA core and PLA shell phases, respectively, using the PPF 
technique. 
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• To characterize microspheres in terms of their surface morphology, drug 
distribution, encapsulation efficiency and in vitro release. 
• To compare and evaluate therapeutic efficiencies of delivering doxorubicin and/or 
chi-p53 as free drug or microsphere formulations in terms of growth inhibition, 
and cellular expression of tumor suppressor p53 and apoptotic caspase 3 proteins 
in human hepatocellular carcinoma (HepG2) cells. 
• To determine growth inhibition of HepG2 cells by cell viability assay. 
• To analyze expressions of p53 and caspase 3 in HepG2 cells by enzyme-linked 
immunosorbent assay (ELISA) and immunofluorescence staining of treated cells. 
 
1.3. Structure of the Thesis 
The thesis is divided into 6 chapters. The introduction is presented in Chapter 1, while the 
literature review is presented in Chapter 2. Chapter 3 focuses on the experimental and simulation 
work of the CEHDA process. Chapter 4 focuses on the mechanism of drug release from double-
walled PDLLA(PLGA) microspheres. Chapter 5 focuses on the production of monodisperse 
double-walled microspheres loaded with chi-p53 nanoparticles and doxorubicin for combined 
gene therapy and chemotherapy. Lastly, Chapter 6 concludes the thesis and proposes possible 
improvements to the existing work along with future research direction. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Drug Delivery 
Unfavorable pharmacokinetics of the chemotherapeutic drug is a limiting problem for many 
conventional routes of administration which include oral and intravenous injection. In the case of 
oral administration in the form of tablets or capsules, the bioavailability of the drug may be 
severely reduced by poor absorption from the digestive system or subsequent degradation by the 
body’s metabolic pathways. As a result, unnecessarily large dose will be required which 
increases the risk of toxicity. Intravenous injection allows the drug to bypass metabolism, but 
may non-specifically accumulate in many tissues besides the target tumor site. There is no doubt 
that many of the available chemotherapeutics are highly cytotoxic drugs which have great 
potential in killing tumor cells. However, this means that they are just as dangerous to normal 
cells and the unintended uptake by these cells is the cause of the many side effects experienced 
by patients undergoing chemotherapy. 
 
There is a huge interest in developing novel methods of administration to augment the 
effectiveness of the drug. The encapsulation of drugs in carrier systems like nanoparticles or 
microparticles is a widely investigated approach and many drug formulations have already been 
approved by the US Food and Drug Administration (FDA). Some representative drug delivery 
systems which have received regulatory approval have been summarized in Table 2.1. 
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2.1.1. Drug delivery systems 
Two key aims most drug delivery systems attempt to achieve are i) to minimize drug entering the 
normal cells, and ii) to maintain drug concentration within the therapeutic window. The 
therapeutic window of the drug is bordered by a ceiling of maximum tolerable dose where there 
will be significant toxicity if exceeded and a minimum therapeutic dose for its effectiveness. 
These are difficult to achieve with conventional administration which usually produces a sharp 
rise in drug concentration in the blood, followed by a peak often exceeding the maximum 
tolerable dose, and then a decline falling below the minimum therapeutic dose. 
 
2.1.1.1. Advantages of drug delivery systems 
2.1.1.1.1. Improved specificity and selectivity 
To reduce undesirable side effects from the drug, systemic drug delivery systems must be able to 
target tumor cells specifically and at the same time selectively avoid normal cells. Targeting 
methods can be categorized into passive and active targeting. In general, passive targeting 
nanoparticles are less than 200 nm and they capitalize on the enhanced permeation and retention 
(EPR) effect associated with solid tumors. Like normal tissue, tumors build blood vessels to 
ensure a supply of oxygen and nutrients. However, these newly formed blood vessels 
surrounding the tumors are very different in architecture from those of normal tissues. They have 
been characterized as irregular in shape, dilated and leaky. Moreover, tumors have poor 
lymphatic drainage. Together, the EPR phenomenon is quite exclusive to tumors because these 
anatomical defects lead to extensive permeation of blood plasma components including the drug 
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loaded nanoparticles into the tumors and retention due to poor lymphatic clearance (Iyer et al., 
2006). 
 
Active targeting involves conjugating the carrier with a ligand. Cell specificity and uptake are 
enhanced through the interaction with a particular and usually overexpressed receptor found on 
the surfaces of tumor cells. For instance, the folate receptor is found to be overexpressed in more 
than 90% of ovarian carcinomas. By coupling folic acid to the nanoparticles, this increases the 
targeting to cancer cells by its high affinity to the receptor and lower level of receptor expression 
in normal cells (Sudimack and Lee, 2000). Overall, by allowing selective drug uptake to tumor 
cells, this can greatly reduce the toxicity on normal cells and improve drug efficacy. 
 
2.1.1.1.2. Sustained drug concentration 
Drug delivery systems with sustained release mechanisms could allow continual drug infusion 
with less patient inconvenience. In doing so, the drug concentration can be maintained at levels 
above the minimum therapeutic dose. This imposes greater design requirements because of the 
need in controlling the rate of drug release from the encapsulating device. One strategy is to 
develop triggered-release systems in which drug release at the desired site of action is triggered 
by biological, chemical, photo, thermal, electrical or magnetic mechanism (Esser-Kahn et al., 
2011). 
 
Alternatively, the release of drug can be tuned to achieve a desired kinetic profile through the 
precise control of the drug carrier architecture. Assuming the rate of drug elimination is constant, 
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the ideal release profile is a rapid ascent to the therapeutic dose followed by steady or zero-order 
release rate so that the local drug concentration remains constant (Figure 2.1). Several drug 
delivery systems such as polymeric microspheres and fibers have succeeded in attaining such 
characteristics. Factors affecting the drug release rate from polymeric microspheres (Freiberg 
and Zhu, 2004) include polymer molecular weight, polymer blend composition, crystallinity, 
drug distribution, microsphere porosity and size. 
 
Having control over the release is a tremendous advantage because the release rates can be tuned 
to the requirements of very specific applications like matching the drug schedules for the greatest 
therapeutic efficacy. Additional benefits of controlled and sustained release systems are 
increasing patient comfort and compliance by reducing the number of repeated injections. 
 
2.1.1.2. Biodegradable polymeric materials 
Biodegradable polymers have entered the arena of controlled release since they are 
biocompatible and biodegradable. They can degrade into monomer units in the human body, 
which are finally excreted without causing toxicity and inflammatory response. Various synthetic 
biodegradable polymers have been examined widely for their applications in drug delivery. 
These polymers are accomplished by incorporating hydrolytically unstable linkages into the 
backbone of the polymers. The most common types of biodegradable polymers are polyesters. 
Other types of polymers such as polyanhydrides, polyorthoesters, polyamides, polyurethanes, 
polyphosphoesters, polyphosphazenes and polyacrylates have also been utilized for controlled 
release applications. 
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2.1.1.2.1. Polyesters 
Polyesters based on poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymers 
poly(lactic-co-glycolic acid) (PLGA) have been extensively employed for drug delivery (Fig. 
2.2). These polymers have received a lot of attention in the field of biomedical applications since 
they have been approved by FDA in several products. Polyesters are characterized by the 
presence of ester bonds in the polymer chain that are hydrolytically degradable. 
 
2.1.1.2.1.1. Poly(glycolic acid) 
PGA is the simplest linear aliphatic polyester, and was used to develop the first totally synthetic 
absorbable suture (Dexon®) in the 1960s by Davis and Geck (Middleton and Tipton, 2000). The 
glycolide monomer is synthesized from the dimerization of glycolic acid. Ring-opening 
polymerization yields high molecular weight materials with a density of 1.50-1.69 g/cm3 (Ikada 
and Tsuji, 2000). PGA is highly crystalline (45-55%), has a high melting point of 220-225°C and 
a glass transition temperature of 35-40°C (Middleton and Tipton, 2000). PGA fibers exhibit high 
strength and modulus, and are too stiff to be used as sutures except in the form of braided 
material. Typically, sutures of PGA lose ~50% of their strength after two weeks and ~100% at 
four weeks, and are completely absorbed in 4-6 months (Middleton and Tipton, 2000). Glycolide 
has been copolymerized with other monomers such as lactides to reduce the stiffness of the 
resulting fibers. 
 11 
 
 
2.1.1.2.1.2. Poly(lactic acid) 
The lactide monomer is the cyclic dimer of lactic acid that exists as two optical isomers, D-
lactide and L-lactide. L-lactide is the naturally occurring isomer, while D,L-lactide is the 
synthetic blend of D-lactide and L-lactide. The formation of PLA follows a similar ring-opening 
polymerization process as PGA. Since only L-lactide can be metabolized in the body, poly(L-
lactic acid) (PLLA) or poly(D,L-lactic acid) (PDLLA) is usually employed for medical 
applications (Conti et al., 1992). The homopolymer of PLLA is a semi-crystalline polymer 
(~37%) with a melting point of 175-178°C and a glass transition temperature of 60-65°C 
(Middleton and Tipton, 2000). It has a density of 1.25-1.29 g/cm3 (Ikada and Tsuji, 2000). These 
materials exhibit a strong optical rotation, high tensile strength and low elongation-at-break, and 
consequently a high modulus (Ikada and Tsuji, 2000). The high crystallinity and hydrophobic 
properties are the reasons why PLLA shows the slowest degradation rate of all resorbable PLAs. 
On the other hand, PDLLA is an amorphous polymer exhibiting a random distribution of both 
isomeric forms of lactic acid, and accordingly hinders the orientation of the chains into a 
crystalline domain. PDLLA shows no obvious melting point, but with a glass transition 
temperature of 50-60°C (Ikada and Tsuji, 2000). It has a density of 1.27 g/cm3 (Ikada and Tsuji, 
2000). These materials show no optical activity, low tensile strength and low elongation-at-break 
(Ikada and Tsuji, 2000). Due to the amorphous structure, water can easily intrude into the bulk 
polymer, and the degradation rate of PDLLA is therefore faster than that of PLLA (Bendix, 
1998). 
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2.1.1.2.1.3. Poly(lactic-co-glycolic acid) 
PLGA is prepared from the copolymerization of glycolide with L-lactide or D,L-lactide, and has 
been developed for both device and drug delivery applications. There is no linear relationship 
between the copolymer composition and the mechanical and degradation properties of PLGA. In 
particular, a copolymer of 50% glycolide and 50% D,L-lactide degrades faster than either 
homopolymer of PGA or PDLLA (Miller et al., 1977). Degree of crystallinity and melting point 
of the polymers are directly related to the molecular weight of the polymer. Copolymers of D,L-
lactide and glycolide are up to 70% glycolide amorphous compounds with glass transition 
temperatures of 40-50°C (Bendix, 1998). This is above the physiological temperature of 37°C 
and hence PLGA is glassy in nature and exhibits fairly rigid chain structure. It is also reported 
that the glass transition temperature of PLGA decreases with a decrease of lactide content in the 
copolymer composition and with a decrease in molecular weight (Passerini and Craig, 2001). 
 
PLGA undergoes bulk erosion in the aqueous medium through cleavage of ester bonds in the 
polymer chain. Upon contact with water, random scission of ester bonds and subsequent 
decrease in molecular weight would occur. This leads to the formation of acids, which further 
catalyze the hydrolysis process (Shenderova et al., 1999). This auto-catalytic phenomenon is 
known to cause heterogeneous degradation inside PLGA matrices (Li and McCarthy, 1999), in 
which there is faster degradation at the center of the PLGA matrix than at the surface. Erosion, 
that is mass loss of the polymer, starts when the dissolved polymer degradation products are able 
to diffuse into the release medium. Dissolution of polymer degradation products and erosion 
create pores. Small pores, formed by water absorption or polymer erosion, grow as contact with 
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water leads to hydrolysis, and the locally produced acids catalyze degradation and cause polymer 
dissolution inside the pores, leading to subsequent erosion. Small pores may coalesce with 
neighboring pores to form fewer, larger pores (Batycky et al., 1997). Pores may also be closed 
(Kang and Schwendeman, 2007). This phenomenon is related to the mobility of the polymer 
chains, and their ability to rearrange (Yamaguchi et al., 2002). The mobility of polymer chains 
depends on the glass transition temperature. The degradation of PLGA is affected by the 
properties of the drug delivery device and the surrounding environment as illustrated in Fig. 2.3. 
 
2.1.2. Gene delivery systems 
Gene delivery systems can be divided into two categories: viral and non-viral vectors. Viral 
vectors such as retrovirus, lentivirus, adenovirus and adeno-associated virus, are typically very 
efficient in gene transfer. They can be transformed into effective gene delivery systems by 
replacing part of their genome with a therapeutic gene. However, safety concerns remain the 
main bottleneck to the clinical application of viral gene delivery. Retroviruses, for instance, 
suffer from oncogenic risks associated with insertional mutagenesis, leading to the development 
of malignant cells. Moreover, viral vectors may also elicit a series of inflammatory or immune 
responses as a result of repeated administration. Besides, the packaging capacity of viral vectors 
is limited and current production methods are difficult to scale up to manufacture relevant 
quantities for commercial and clinical applications. 
 
Non-viral vectors, on the other hand, have captured significant interest due to their improved 
safety, greater flexibility and ease of synthesis. They consist of complexes formed by either 
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cationic lipids or cationic polymers, which are able to protect DNA from nuclease degradation 
and deliver them to the cells. However, complexes formed by cationic liposomes, also known as 
lipoplexes, have several limitations in gene delivery. They include difficulty in reproducibly 
fabricating liposomes and lipoplexes, toxicity in vitro and in vivo, and colloidal stability, 
especially upon systemic administration (Filion and Philips, 1998). Thus, non-viral vectors based 
on cationic polymers or complexes formed by cationic polymers, also known as polyplexes, are 
being researched extensively for gene delivery (Li and Huang, 2000). Here, we review 
polyethylenimine (PEI), chitosan and poly(amidoamine) (PAMAM) dendrimers based 
formulations for gene delivery. 
 
2.1.2.1. Polyethylenimine 
PEI has been widely used for non-viral transfection in vitro and in vivo, and has an advantage 
over other polycations in that it combines strong DNA compaction capacity with an intrinsic 
endosomolytic activity (Fig. 2.4). 
 
2.1.2.1.1. Branched polyethylenimine 
The efficacy of branched PEI (bPEI)-derived vectors and their cytotoxic effects depend to a 
remarkable extent on material characteristics (von Harpe et al., 2000; Kunath et al., 2003; 
Fischer et al., 1999), including: i) molecular weight, ii) degree of branching, iii) cationic charge 
density and buffer capacity, iv) polyplex properties, such as DNA content, particle size and zeta 
potential, and v) experimental conditions, such as polyplex concentration, presence or absence of 
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serum during transfection, incubation time and transfection model chosen for the gene delivery 
experiment. 
 
High molecular weight bPEI up to 800 kDa has been used for non-viral gene transfer, exhibiting 
a superior capability to form compact and stable bPEI/DNA complexes and an increased 
transfection efficiency, compared to lower molecular weight derivatives (Godbey et al., 1999). 
However, at the same time, the cell viability decreases remarkably with increasing molecular 
weight. This effect can be moderated by transfecting with low molecular weight bPEIs (5 to 48 
kDa) (Kunath et al., 2003; Fischer et al., 1999; Turunen et al., 1999), but ampliﬁed polymer 
concentrations are needed to achieve comparable efficacy. Due to their reduced cytotoxicity, the 
high N/P ratios were tolerated and added to the superior performance in vitro, irrespective of the 
absence or presence of serum. 
 
The success of bPEI-based transfection systems is derogated by the cytotoxic effects, which arise 
from the presence of free polymer. In vivo experiments revealed that bPEI/DNA complexes and, 
to a lesser extent, free bPEI (25 kDa) activates genes involved in the Th1/Th2 immune response 
and adaptive immune responses (Regnström et al., 2003). The systemic administration of 
unshielded bPEI (800 kDa) had a lethal effect in animal models (Gharwan et al., 2003; 
Wightman et al., 2001), demonstrating the need for materials allowing for the design of less 
harmful but effective non-viral vectors. 
 16 
 
 
2.1.2.1.2. Linear polyethylenimine 
Several in vitro and in vivo studies have investigated the potential of linear PEI (lPEI)-derived 
vectors. Most of these experiments have been done in direct comparison to the corresponding 
bPEI/DNA complexes, revealing remarkable differences between both transfection systems in 
terms of DNA compaction (Boussif et al., 1995), nuclear uptake (Brunner et al., 2000, 2002), 
transfection efficiency and toxicity (Gharwan et al., 2003; Wightman et al., 2001; Wiseman et 
al., 2003). 
 
While bPEI/DNA complexes retain a rather small size in the range up to a few hundred 
nanometers, which only slightly changes with respect to the complexation medium applied, 
mixing lPEI with DNA forms rather large particles extending into the micrometer range in salt-
containing buffers, which are prone to aggregation due to the weakened repulsion between the 
cationic particles (Wightman et al., 2001; Goula et al., 1998). Only preparation under salt-free 
conditions with increasing N/P ratios yields small spherical or toroid shaped particles, which 
grow rapidly upon the addition of salt. The application of small polyplexes has been shown to 
improve transgene expression up to 100-fold in vivo, but reduces the transfection efficiency in 
vitro, compared to the larger complexes (Wightman et al., 2001). 
 
2.1.2.2. Chitosan 
Chitosan is a linear polysaccharide which consists of randomly distributed 2-N-acetyl-2-deoxy-
glucose (N-acetyl-glucosamine) and 2-amino-2-deoxy-glucose (glucosamine) residues with β-
1,4-linkage as shown in Fig. 2.5. The primary amine of chitosan has a pKa value of about 6.5 
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(Liu et al., 2005). Thus, chitosan is soluble in a variety of acids, but insoluble at neutral and 
alkaline pH values. Besides pH, the solubility of chitosan is also significantly influenced by the 
degree of deacetylation, molecular weight and ionic strength of the solution. To date, chitosan 
has been widely used as a carrier for drug and gene delivery in various applications (Bowman 
and Leong, 2006). 
 
Chitosan is one of the most reported non-viral naturally-derived cationic gene polymers, due to 
its biodegradability, biocompatibility, non-allergenicity, mucoadhesive property and strong 
affinity with DNA. Chitosan has been shown to have low cytotoxicity in a series of tests 
performed on both experimental animals (Rao and Sharma, 1997) and humans (Aspden et al., 
1997). Its excellent soft tissue compatibility has also been demonstrated. It is found that the zeta 
potential of chitosan with 100% deacetylation is not highly positive, but very close to zero 
(Tomihata and Ikada, 1997). This suggests that chitosan is so bio-inert that it may not give any 
strong stimulus to the surrounding tissue. At acidic pH values, chitosan has been shown to 
effectively bind DNA via electrostatic interactions and protect them from nuclease degradation 
(Mao et al., 2001). At neutral or alkaline conditions, in which chitosan is slightly charged, non-
electrostatic interactions, such as hydrogen bonding and hydrophobic interactions could be 
responsible for the binding between chitosan and DNA (Messai et al., 2005). 
 
Multiple studies have shown that the binding affinity of chitosan for DNA, the stability and the 
transfection efficiency of chitosan-DNA complex are dependent on several parameters, 
including: i) molecular weight (Sato et al., 2001; Köping-Höggård et al., 2003; MacLaughlin et 
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al., 1998; Lavertu et al., 2006; Huang et al., 2005; Ishii et al., 2001; Zhao et al., 2006), ii) degree 
of deacetylation (Lavertu et al., 2006; Huang et al., 2005; Kiang et al., 2004), iii) N/P ratio (Sato 
et al., 2001; Köping-Höggård et al., 2003; MacLaughlin et al., 1998; Lavertu et al., 2006; Ishii et 
al., 2001; Erbacher et al., 1998), iv) plasmid concentration (Sato et al., 2001; MacLaughlin et al., 
1998; Ishii et al., 2001; Zhao et al., 2006), v) serum concentration (Sato et al., 2001; 
MacLaughlin et al., 1998; Ishii et al., 2001; Erbacher et al., 1998), and vi) pH of transfection 
medium (Sato et al., 2001; Köping-Höggård et al., 2003; Lavertu et al., 2006; Ishii et al., 2001; 
Zhao et al., 2006). The variation of these parameters can significantly influence the cellular 
uptake and endosomal escape of the complex, and subsequently, the gene expression. 
Nevertheless, in comparison with PEI, chitosan has a lower transfection efficiency. The 
effectiveness of PEI has been attributed to its high buffering capacity, especially at the acidic pH 
found in the endosomal vesicles, which leads to trapping of positive ions by the amines (proton 
sponge effect), followed by subsequent endosomal rupture and escape into the cytoplasm 
(Köping-Höggård et al., 2001). The difference in the buffering capacities of PEI and chitosan has 
been confirmed from acid/base titration (Köping-Höggård et al., 2001). In particular, PEI shows 
a high buffering capacity over a wide range of pH values. In contrast, the buffering capacity of 
chitosan is modest and is restricted to the pH interval between 5 and 7. 
 
2.1.2.3. Poly(amidoamine) dendrimers 
PAMAM dendrimers are a relatively new class of polymers that are highly branched with well-
defined and three-dimensional structures. They consist of tertiary amines in the core, primary 
amines on the surface and an amide backbone as shown in Fig. 2.6. With the addition of a new 
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layer, the molecular weight of the dendrimer increases exponentially, the number of primary 
amine groups on the dendrimer surface doubles, and the diameter increases by about 10 Å 
(Eichman et al., 2000). In addition, PAMAM dendrimers have a low polydispersity. As the 
dendrimer generation increases, the density of the surface branching units begins to impart 
various structural effects on the dendrimer shape. In particular, dendrimers of lower generations 
have a planar and elliptical shape whereas dendrimers of higher generations have a spherical 
conformation (Eichman et al., 2000). For the latter case, the interior core of the dendrimer 
develops a hydrophobic space which is useful for the encapsulation of compounds for various 
pharmaceutical applications (Eichman et al., 2000). 
 
PAMAM dendrimers have attracted the interest of many researchers over the past few years. In 
comparison with other types of delivery systems, the advantages of using dendrimers include: i) 
controllable structure and size, ii) high chemical and structural homogeneity, and iii) high ligand 
and functionality density, all of which can be optimized for specific delivery purpose. While 
PAMAM dendrimers do not induce significant cytotoxicity in vitro (Kukowska-Latallo et al., 
1996; Bielinska et al., 1996) or in vivo (Qin et al., 1998; Roberts et al., 1996), the 
biocompatibility of these polymers is dependent on the size, surface charge and concentration 
(Duncan and Izzo, 2005; El-Sayed et al., 2002, 2003; Jevprasesphant et al., 2003a; Kitchens et 
al., 2006). PAMAM dendrimers are also found to be able to mediate transport through the 
epithelial barrier, indicating their potential as carriers for oral delivery (Kitchens et al., 2005, 
2006; Jevprasesphant et al., 2003b; Wiwattanapatapee et al., 2000). Besides, PAMAM 
dendrimers are also known to be efficient gene delivery systems. They have been shown to be as 
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efficient as or more efficient than other cationic carriers such as polylysine for gene transfer (Qin 
et al., 1998). PAMAM dendrimers have primary and tertiary amine groups, which differ in their 
pKa values. The surface primary amine groups have a pKa value in the range of 7 to 9, whereas 
the interior tertiary amine groups have a pKa value in the range of 3 to 6 (Kleinman et al., 2000). 
The surface primary amine groups participate in DNA binding and promote cellular uptake of 
these complexes. On the other hand, the interior tertiary amine groups exert endosome buffering 
effect and enhance the release of DNA in the cytoplasm. 
 
2.2. Techniques in Microsphere Fabrication 
2.2.1. Solvent extraction/evaporation 
The emulsion-solvent extraction/evaporation methods are most commonly used to prepare 
polymeric microspheres (McGinity and O’Donnell, 1997). The polymer and drug are mixed in a 
water-immiscible, organic solvent to produce a solution or dispersion of drug particles. The 
mixture is sonicated or homogenized, before emulsifying in a non-solvent phase containing a 
emulsifier. The components are chosen such that the organic solvent is slightly soluble in the 
non-solvent phase. The resultant mixture is then stirred under optimized conditions to allow the 
evaporation of the organic solvent. Due to loss of solvent, the dispersed phase is enriched in 
polymer and the droplets will eventually harden to form microspheres. The microspheres may 
then be filtered, washed and lyophilized. 
 
There are several disadvantages of the emulsion-solvent extraction/evaporation methods that 
often limit their application. One problem is that the encapsulation efficiency of hydrophilic 
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drugs is low and it is associated with the diffusion of drugs into the aqueous continuous phase. 
Various methods have been introduced to improve the encapsulation efficiency for the entrapped 
drugs, including: i) controlling the evaporation temperature (Yang et al., 2000), ii) adjusting the 
pH of the external phase (Leo et al., 1998; Blanco-Príeto et al., 1997), iii) using salt-containing 
external phase (Uchida et al., 1996), and iv) adding additives into the inner phase (Blanco-Príeto 
et al., 1997). Another problem is the shear stress originated from stirring and the direct contact of 
drug with the polymer-solvent system is always involved. These effects may destroy the activity 
of some sensitive drugs such as proteins. Another critical problem is that size distributions of 
particles are generally reproducible but with a wide size distribution. Since the size of the 
microspheres directly affects the drug release rate and syringability, it is important that size 
distributions be relatively narrow. 
 
2.2.2. Electrohydrodynamic 
In electrohydrodynamic (EHD) processing (Chakraborty et al., 2009), a polymer solution is 
subjected to a high electrical potential difference, normally applied between the nozzle and a 
grounded collector. Given that the liquid is electrically conductive, it will result in the formation 
of a fine jet. The jet eventually breaks up into charged droplets, that are attracted towards the 
collector or, if the liquid is highly viscous or solidifies at the onset of jetting, fibers can be 
formed. 
 
The geometrical features of the jet and the various types encountered as a function of the 
operating parameters have been classified previously by Jaworek and Krupa (1999). Various 
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parameters, including liquid parameters (e.g. density, viscosity, conductivity and surface tension) 
and process parameters (e.g. electric field strength and flow rate) will determine the EHD mode 
(Paine et al., 2007). At low voltages, there is only partial or intermittent jet formation resulting in 
a dripping mode. Within a stable voltage range, a sustained and continuous jet can be formed and 
a stable Taylor cone-jet mode is observed (Fig. 2.7). At higher voltages, a multi-jet mode may be 
observed. In these modes, under the influence of large voltages, the jet usually breaks up into 
particles a few millimeters below the nozzle. The conical shape observed is the result of the 
balance between electrostatic forces and surface tension (Fig. 2.8). 
 
The main advantage of using EHD to fabricate particles is that it involves a single step, requires 
no solvents other than those normally present in the polymer solutions being processed and is 
carried out under normal ambient conditions, thus overcoming the problems associated with 
defunctionalization of drugs. In addition, it is capable of preparing particles from a few tens of 
nanometers to millimeters in size, with a narrow distribution. 
 
For droplets emitted from a Taylor cone-jet, the following scaling relation has been developed 
(Jaworek and Sobczyk, 2008). 
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where d is the droplet diameter, Q is the volume flow rate, ε0 is the permittivity of free space, ρ is 
the liquid density, γ is the liquid surface tension, K is the liquid bulk conductivity, and β is a 
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coefficient depending on liquid permittivity. The remaining coefficients vary with different 
studies as shown in Table 2.2. 
 
The creation of fibers by electrospinning occurs in a process similar to electrospraying (Rutledge 
and Fridrikh, 2007). Steady-state equations describing the jet diameter, velocity, surface charge 
density, current and electric field have been developed (Feng, 2002). These equations reveal that 
the jet diameter is strongly dependent on the surface charge density and the local electric field. 
As charge quickly migrates to the jet surface upon exiting the nozzle, both of these quantities 
reach their maximum value, leading to rapid thinning of the jet. Beyond this rapidly thinning 
region, a scaling relation has been developed to describe the decreasing diameter of the jet 
(Rutledge and Fridrikh, 2007). 
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where d is the jet diameter, Q is the volume flow rate, ρ is the liquid density, E∞ is the electric 
field strength, I is the electric current, and z is the axial coordinate. 
 
By using a coaxial nozzle, coaxial electrospraying or electrospinning could circumvent technical 
limitations of monoaxial electrospraying or electrospinning by their core-shell design, allowing 
sensitive proteins to be dissolved in aqueous solution for encapsulation. Encapsulated proteins 
released from core-shell structured particles or fibers have maintained high bioactivity over an 
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extended period of time (Xie et al., 2008; Liao et al., 2006; Jiang et al., 2006). The core-shell 
design also allows better control over the release kinetics of the drug. For instance, changes in 
core and shell material properties via variation in polymer molecular weight, polymer type and 
addition of porogen can fine-tune the release profile (Liao et al., 2006; Srikar et al., 2008). 
 
2.2.3. Acoustic excitation 
The precision particle fabrication (PPF) apparatus is designed to pass a polymer solution, and the 
drug to be encapsulated, through a small nozzle to form a smooth, cylindrical jet (Fig. 2.9). The 
nozzle is vibrated by a piezoelectric transducer driven by a wave generator at a frequency tuned 
to match the flow rate and the desired drop size. The mechanical excitation launches an acoustic 
wave along the liquid jet generating periodic instabilities that, in turn, break the stream into a 
train of uniform droplets. An annular flow of a non-solvent phase is employed around the 
polymer jet. The annular stream is pumped at a linear velocity greater than that of the polymer 
stream. Thus, frictional contact between the two streams generates an additional downward force 
that effectively pulls the polymer solution away from the tip of the nozzle. The polymer stream is 
accelerated by this force and, therefore, thinned to a degree depending on the difference in the 
linear velocities of the two streams. 
 
The diameter of the droplet is predicted as follows (Berkland et al., 2007). 
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where rj is the radius of the undisturbed jet (approximately equal to, but typically slightly larger 
than, the diameter of the nozzle orifice), vj is the linear velocity of the liquid jet, and f is the 
frequency of the acoustic wave. 
 
The microsphere fabrication methodology can be extended to produce uniform double-walled 
microspheres with controllable size and shell thickness. In this case, three coaxial nozzles are 
employed to produce a liquid jet, comprising core, annular shell and carrier streams, which is 
acoustically excited to break up into uniform core-shell droplets. As before, the non-solvent 
carrier stream surrounding the coaxial jet accelerates and makes it thinner before its breakup. 
The orientation of the jets, material flow rates, and rate of solvent extraction are controlled to 
vary the shell thickness (Berkland et al., 2004a, 2004b; Pollauf et al., 2005a). 
 
2.3. Double-Walled Microspheres 
Since an important goal of drug delivery systems is to attain well-controlled drug release rates, 
double-walled microspheres are introduced. These double-walled microspheres often exhibit a 
reduction in the initial burst release as compared to single-polymer microspheres (Lee et al., 
2002; Rahman and Mathiowitz, 2004; Tan et al., 2005; Zheng, 2009), and provide a sustained 
drug release that is tunable by adjusting the shell material or thickness (Berkland et al., 2004a, 
Pollauf et al., 2005a). In addition, these microspheres enable the encapsulation of multiple drugs 
in the core and shell phases, and allow their release in various stages, thus achieving synergistic 
therapeutic effects (Choi et al., 2010; Nie et al., 2010a, 2010b). Here, we make use of the 
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advantages of double-walled microspheres to provide combination therapies for the treatment of 
cancer. Among various combination therapies, studies on chemotherapy and p53 gene therapy 
are of particular interest, and are discussed in the following sections. 
 
2.4. Doxorubicin 
Doxorubicin is an anthracycline first isolated in 1969 from Streptomyces peucetius subsp caesius 
(Arcamone et al., 1969). It is used to treat a wide range of cancers, including non-Hodgkin’s and 
Hodgkin’s lymphoma, multiple myeloma, lung, ovarian, gastric, thyroid, breast, sarcoma, and 
pediatric cancers (Cortés-Funes and Coronado, 2007). Many studies have attributed the 
antitumor activity of doxorubicin to its ability to intercalate with DNA and inhibit progression of 
topoisomerase II. The stabilization of topoisomerase II complex presents an initial event which 
leads to cell death (Bodley et al., 1989). Moreover, doxorubicin imposes its antineoplastic effect 
by generating reactive oxygen species (ROS). The oxidative stress imposed can trigger apoptotic 
pathways leading to cell death (Tsang et al., 2003). 
 
However, a chronic side effect of doxorubicin is its dose-dependent cardiotoxicity. As the 
lifetime accumulative dose approaches 500 mg/m2 and beyond, iatrogenic life-threatening 
cardiomyopathy becomes more likely, which can lead to dilated cardiomyopathy and congestive 
heart failure in up to 20% of cases (Chatterjee et al., 2010). Another limitation is drug resistance 
from the cancer cells which decreases its drug efficacy. The major mechanism of drug resistance 
is thought to involve an energy-dependent drug efflux pump, known as P-glycoprotein (Pgp), 
causing drug efflux (Kaye and Merry, 1985). With efflux pumps expressed on the surfaces of 
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malignant cells, the drugs are released back into the extracellular environment, preventing drug 
accumulation and reducing cytotoxic effect. 
 
2.5. p53 Gene Therapy 
2.5.1. Tumor suppressor pathway 
Cancer arises through a series of mutations in selected oncogenes, tumor suppressor genes, or 
genes involved in DNA repair or replication. The tumor suppressor gene products frequently 
monitor the efficiency of cellular duplication by populating checkpoints in the process of cell 
division. When defective, the tumor suppressor genes can lead to inherited predispositions in the 
development of cancers. Almost every human cancer contains mutations in the tumor suppressor 
pathways of p53. The pathway receives a complex set of signals and reports from the 
extracellular and intracellular environments of a cell and in response regulate “go-no go” 
decisions in the cell cycle. 
 
The tumor suppressor p53 gene is located on chromosome 17p13.1 and encodes p53 protein 
(named in reference to its apparent molecular mass of 53 kDa on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE)). The human p53 protein is 393 amino acids 
long. Protein domains, defined as independently folding units of a protein, typically have a size 
of between 40 and 200 amino acids (Koonin et al., 2002). This suggests that p53 contains more 
than one protein domain, a prediction that has been confirmed by structural and functional 
studies (Vogelstein et al., 2000). As shown in Fig. 2.10, three domains are recognized in p53, 
mainly, i) a transactivation domain (residues 1-70), ii) a sequence-specific DNA binding domain 
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(residues 94-293), and iii) a tetramerization domain (residues 324-355). These domains are 
flanked by linker regions. A proline-rich region (residues 71-93) links the transactivation and 
sequence-specific DNA binding domains; a second proline-rich region (residues 294-323) links 
the sequence-specific DNA binding and tetramerization domains; and a basic region (residues 
356-393) forms the very C-terminus of the protein. 
 
p53 is a master transcriptional regulator that preserves genomic stability by controlling several 
main cellular pathways. The levels of p53 are critical to its activity and are strictly regulated 
within the cells. Several stress sensors that converge at p53 lead to phosphorylation, acetylation, 
ubiquitylation and methylation of specific p53 residues (Kruse and Gu, 2008; Appella and 
Anderson, 2001; Bode and Dong, 2004; Tang et al., 2008). These modifications elicit 
downstream p53 responses that counteract the deleterious consequences of DNA damage, 
hypoxia, metabolic stress or oncogene activation. As a transcription factor, p53 binds to specific 
response elements in DNA and modulates the transcription of genes that govern the main 
defenses against tumor growth, which include cell cycle arrest, apoptosis, maintenance of genetic 
integrity, inhibition of angiogenesis and cellular senescence (Vogelstein and Kinzler, 2004). In 
addition, p53 interacts with many cellular proteins, including many that control programmed cell 
death, which contribute to the inhibitory role of p53 in tumorigenesis (Erster et al., 2004; 
Marchenko et al., 2000; Mihara et al., 2003; Dumont et al., 2003; Chipuk et al., 2005; Prives and 
Hall, 1999). Some of the more intensively studied activators, regulators and effectors of p53 are 
shown in Fig. 2.11. 
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Under normal, unstressed conditions, MDM2 (murine double minute 2 or the human homologue 
HDM2) is responsible for the regulation of p53 by binding to the transcriptional activation 
domain in the N-terminus of p53 (Momand et al., 1992). It can also promote the degradation of 
p53 by the ubiquitin-proteasome system (Haupt et al., 1997; Kubbutat et al., 1997). Since p53 
transcriptionally activates MDM2, the expression levels of p53 and MDM2 are balanced through 
a negative feedback loop, which is altered by an increase in p53 levels following cellular stresses 
such as DNA damage (Hu et al., 2007). MDM4 (or MDMX) also modulates p53 activity (Marine 
and Jochemsen, 2004), and the interaction between p53, MDM2 and MDM4 at the molecular 
level is complex. For instance, MDM2 could bind to p53 mRNA, regulating the translation rate 
(Candeias et al., 2008), while MDM2 regulates the levels of itself, MDM4 and p53 (Marine and 
Jochemsen, 2004; Marine et al., 2006; Toledo and Wahl, 2006). In the presence of cellular 
stresses such as DNA damage, p53 gets imported into the nucleus via its nuclear localization 
signal and undergoes tetramerization (el-Deiry et al., 1992), binds and activates DNA damage-
response genes (Jimenez et al., 1999). The tetramer state of p53 obscures its nuclear export 
signal, thereby blocking nuclear export (Stommel et al., 1999). 
 
2.5.1.1. Apoptosis 
Many apoptosis-related genes that are transcriptionally regulated by p53 have been identified. 
Apoptosis mediated by p53 may occur either through the intrinsic mitochondrial pathway or the 
extrinsic death receptor pathway. 
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For the mitochondrial pathway, p53 has the ability to activate transcription of various 
proapoptotic genes, including those encoding members of the Bcl-2 family, such as the BH-3 
proteins Bax, PUMA and Noxa (Nakano and Vousden, 2001; Oda et al., 2000; Yu et al., 2001). 
Besides, the Bid protein is also a member of the BH3 family of proteins that promote apoptosis. 
It has been suggested that regulation of Bid by p53 promotes the cell death response to 
chemotherapy (Sax et al., 2002). All these genes are strongly induced by p53 and lead to a rapid 
apoptotic response. The mechanism of apoptosis induction via these proteins appears to work 
through cytochrome c release from the mitochondria. Alternatively, p53 can also trigger 
apoptosis by repression of antiapoptotic genes, such as survivin, thus promoting caspase 
activation (Hoffman et al., 2002). 
 
For the death receptor pathway, overexpression of p53 increases cell surface levels of Fas by 
promoting its trafficking from Golgi complex (Bennett et al., 1998). Moreover, p53 activates 
DR5, the death domain-containing receptor for TRAIL; DR5 is induced upon DNA damage (Wu 
et al., 1997) and thereby promotes cell death through caspase-8. The PIDD that bears homology 
to the FADD, DAPK and RAIDD death domains is also a transcriptional target of p53 (Lin et al., 
2000). Besides, p53 is also involved in the activation of the apoptosome via induction of Apaf1 
expression. Apaf1 is part of a holoenzyme that associates with caspase-9 that awaits cytochrome 
c to allow activation of the caspase cascade (Li et al., 1997; Srinivasula et al., 1998; Zou et al., 
1997). Both Apaf1 and caspase-9 are required for p53-dependent apoptosis (Soengas et al., 
1999). 
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Together, the activated initiator caspases 8 and 9 activate the effector caspases by performing an 
essential proteolytic cleavage of procaspases 3, 6 and 7. The active caspases 3, 6 and 7 are also 
known as executioner caspases because they are the main contributors in causing extensive 
cellular changes to finally result in apoptosis (Shen and White, 2001). 
 
2.5.1.2. Cell cycle arrest 
Cells respond to DNA-damaging agents by activating cell cycle checkpoints. Such control 
mechanisms provide a temporary arrest at a specific stage of the cell cycle to allow the cell to 
correct possible defects (Hartwell and Weinert, 1989; Hartwell and Kastan, 1994). There are two 
main checkpoints to monitor DNA damage: one at the G1/S transition and the other at the G2/M 
transition. The G1 checkpoint prevents replication of damaged DNA, whereas the G2/M 
transition is inhibited by damaged and/or incompletely replicated DNA (Hartwell and Weinert, 
1989; Hartwell and Kastan, 1994). In the presence of DNA damage, p53 expression is elevated 
and this increase determines a transient arrest of cell cycle progression in the G1 phase (Kastan et 
al., 1991; Kuerbitz et al., 1992), or triggers apoptosis (Clarke et al., 1993; Lowe et al., 1993a). 
The arrest in G1 is thought to give the cells time to repair critical damage before DNA replication 
occurs, thereby avoiding the propagation of genetic lesions to progeny cells. The cell cycle can 
resume once the damage has been repaired or, if the damage is too extensive, the cells will 
undergo apoptosis. 
 
The p21 protein functions as a regulator of cell cycle progression at G1, and the expression of 
this gene is tightly controlled by p53 protein. The p21 gene is independently and simultaneously 
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identified as a gene that inhibits cyclin/cyclin-dependent kinase (cyclin/CDK) complexes and is 
differentially expressed during cellular senescense (Harper et al., 1993; Xiong et al., 1993; Gu et 
al., 1993; Noda et al., 1994; el-Deiry et al., 1993). The p21 protein could bind to the cyclin 
E/CDK2 and cyclin D/CDK4 or cyclin D/CDK6 complexes and inhibit the kinase activity of the 
CDKs. One target of CDK2 is the pRb protein, another prominent tumor suppressor whose 
phosphorylation by CDK is required for progression from G1 to the S phase. Thus, by binding to 
the cyclin/CDK complex, p21 inhibits phosphorylation of pRb and produces a G1/S arrest. 
 
The mechanism by which p53 blocks cells at the G2 checkpoint involves inhibition of Cdc2, the 
CDK required to enter mitosis (Innocente et al., 1999). Cdc2 is inhibited simultaneously by three 
transcriptional targets of p53, Gadd45, p21 and 14-3-3σ (Maeda et al., 2002; Bunz et al., 1998; 
Hermeking et al., 1997). Binding of Cdc2 to cyclin B1 is required for its activity, and repression 
of the cyclin B1 gene by p53 also contributes to blocking entry into mitosis (Innocente et al., 
1999). The p53 also represses the Cdc2 gene, to ensure that cells do not escape the initial block 
(Innocente et al., 1999). Genotoxic stress also activates p53-independent pathways that inhibit 
Cdc2 activity, activation of the protein kinases Chk1 and Chk2 by the protein kinases Atr and 
Atm (Sancar et al., 2004). Chk1 and Chk2 inhibit Cdc2 by inactivating Cdc25, the phosphatase 
that normally activates Cdc2 (Boutros et al., 2007). Chk1, Chk2, Atm and Atr also contribute to 
the activation of p53 in response to genotoxic stress and therefore play multiple roles (Sancar et 
al., 2004). Overall, multiple overlapping p53-dependent and p53-independent pathways regulate 
the G2/M transition in response to genotoxic stress. 
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2.5.2. Implications for cancer 
Cells with p53 functional deficiencies are not capable of responding properly to stresses and thus 
accumulate DNA damage, whereas the abilities to activate cell cycle arrest and apoptosis are 
generally lost. These conditions act synergistically to favor the transformation of normal cells 
into malignant cells (Millau et al., 2009). In addition, treatments of cancers are largely based on 
genotoxic stresses in order to induce apoptosis through different pathways. Therefore, the loss of 
p53-mediated apoptosis drastically reduces the response to these treatments (Millau et al., 2009). 
The loss of gene regulations achieved by p53 is thus a double problem because it is involved in 
the carcinogenesis process and in the insensitivity and resistance to cancer treatments (Millau et 
al., 2009). 
 
The malfunction of the p53 pathway is a well-known feature of many human tumors (Vogelstein 
et al., 2000; Vousden and Lane, 2007). It is estimated that about 50% of the human tumors 
contain mutations in the p53 gene, of which 80% are missense mutations found 97% of the time 
within the DNA-binding domain (Olivier et al., 2002). The direct loss of properly functioning 
p53 is also associated with poor prognosis and/or poor response to treatments for a variety of 
cancers including: i) breast cancer (Takahashi et al., 2008; Berns et al., 2000), ii) colorectal 
cancer (Vidaurreta et al., 2008; Børresen-Dale et al., 1998), iii) gastric cancer (Migliavacca et al., 
2004), iv) head and neck squamous-cell carcinoma (Poeta et al., 2007), v) hepatocellular 
carcinoma (Ng et al., 1995), and vi) lymphoma (Young et al., 2007). 
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2.6. Figures 
 
      
 
Figure 2.1: Scheme illustrating drug release and local drug concentration from three theoretical implant 
types. A zero-order release implant (A) releases drug at a constant rate, but it may take a long period of 
time to reach the therapeutic concentration. A burst-release implant (B) releases large amounts of drug 
early, but may not provide extended release to maintain a therapeutic concentration. A dual-release 
implant (C) combines an early burst of drug to accelerate the rise to therapeutic concentrations with 
sustained release to maintain therapeutic concentrations (Adapted from Weinberg et al., 2008). 
 
 
 
 
Figure 2.2: Chemical structures of PLA, PGA and PLGA polymers. (n: number of repeat units in PLA 
and PGA; x and y: number of lactic and glycolic units in PLGA respectively) (Adapted from Vey et al., 
2011). 
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Figure 2.3: The complex picture of the different factors that influence drug release from PLGA matrices. 
The effects of the properties of the drug delivery device and the surrounding environment on the 
processes that, in turn, influence drug release are illustrated by arrows (Adapted from Fredenberg et al., 
2011). 
 
 
 
 
Figure 2.4: Chemical structure of (a) linear polyethylenimine and (b) branched polyethylenimine 
(Adapted from Intra and Salem, 2008). 
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Figure 2.5: Repeat units for chitin and chitosan. Chitin consists of mainly n units and chitosan consists of 
mainly m units distributed in a random fashion (Adapted from Xu et al., 2010). 
 
 
 
 
Figure 2.6: Structure of PAMAM dendrimer: (a) PAMAM Generation 1, (b) PAMAM Generation 2, and 
(c) PAMAM Generation 3 (Adapted from Xu et al., 2010). 
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Figure 2.7: Schematic diagram of the experimental setup for electrohydrodynamic jetting (Adapted from 
Enayati et al., 2009). 
 
 
 
 
Figure 2.8: Schematic representation of the cone-jet mode in EHD processing indicating the controlling 
forces (Adapted from Enayati et al., 2011a). 
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Figure 2.9: (a) Schematic diagram of the precision particle fabrication apparatus portraying acoustic 
excitation with carrier stream for microsphere production. (b) Schematic diagram indicating the variables 
used for acoustic excitation theory development (Adapted from Berkland et al., 2001). 
 
 
 
 
Figure 2.10: Domains of human p53. Linear diagram of human p53 showing its three major domains, the 
proline-rich regions and the C-terminal basic region. The codon numbers indicate the boundaries of the 
various domains and regions (Adapted from Stavridi et al., 2005). 
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Figure 2.11: The p53 pathway. Under normal cellular conditions, MDM2 represses p53 by binding and 
sequestering p53, and by ubiquitylating p53, targeting it for degradation. Under high levels of stress, the 
interactions between MDM2, MDM4 and p53 are disrupted by post-translational modifications of these 
proteins. This allows activated p53 to act as a transcription factor, activating or repressing genes involved 
in apoptosis, cell cycle arrest and senescence (Adapted from Whibley et al., 2009). 
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2.7. Tables 
 
Table 2.1: Selected examples of drug delivery systems that have received regulatory approval (Adapted from Allen and Cullis, 2004). 
 
Drug or therapeutic agent (trade name), 
manufacturer(s) 
Indication Year of approval Reference 
Liposomal amphotericin B (AmBisome), 
Gilead, Fujisawa 
Fungal infections 
Leishmaniasis 
1990 (Europe), 1997 
2000 
Adler-Moore, 1994 
PEG-adenosine deaminase (Adagen), Enzon Severe combined 
immunodeficiency disease 
1990 Bory et al., 1991 
Styrene maleic acid and neocarzinostatin 
copolymer in Ethiodol (SMANCS/Lipiodol, 
Zinostatin stimalamer), Yamanouchi 
Hepatocellular carcinoma 1993 (Japan) 
1996 (Japan) 
Seymour et al., 1998 
Fang et al., 2003 
Stealth (PEG-stabilized) liposomal doxorubicin 
(Doxil/Caelyx), ALZA, Schering Plough 
Kaposi’s sarcoma 
Refractory ovarian cancer 
Refractory breast cancer 
1995 
1999 
2003 (Europe, Canada) 
Northfelt et al., 1996 
Muggia and Hamilton, 2001 
Liposomal cytosine arabinoside (DepoCyt), 
SkyePharma 
Lymphomatous meningitis 
Neoplastic meningitis 
1999 
Phase IV 
Glantz et al., 1999a, 1999b 
 
 
Denileukin diftitox or interleukin 2-diptheria 
toxin fusion protein (ONTAK), Seragen 
Cutaneous T-cell lymphoma 1999 Olsen et al., 2001 
Liposomal doxorubicin (Myocet), Elan Metastatic breast cancer in 
combination with 
cyclophosphamide 
2000 (Europe) Batist et al., 2001 
 
 41 
 
 
Table 2.2: Values of the coefficients in Eq. 2.1 (Adapted from Jaworek and Sobczyk, 2008). 
 
Authors aQ aε aρ aγ aK 
Fernández de la Mora and 
Loscertales (1994) 1/3 1/3 0 0 1/3 
Gañan-Calvo (1999) and 
Gañan-Calvo et al. (1997) 1/2 1/6 1/6 1/6 1/6 
Hartman et al. (2000) 1/2 1/6 1/6 1/6 1/6 
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CHAPTER 3 
COAXIAL ELECTROHYDRODYNAMIC ATOMIZATION PROCESS 
FOR PRODUCTION OF POLYMERIC DOUBLE-WALLED 
MICROSPHERES 
 
3.1. Introduction 
The electrohydrodynamic atomization (EHDA) technology has gained considerable attention in 
several fields (Fenn et al., 1989; Yoon et al., 2011; Chakraborty et al., 2009; Bock et al., 2012). 
Much attention has concentrated on the operation of electrospray process in the Taylor cone-jet 
mode, which can produce uniform micro- or nano-sized particles (Hu et al., 2012; Rosell-
Llompart and Fernández de la, 1994; Chen et al., 1995). A typical EHDA setup consists of a 
metallic nozzle connected to a high-voltage power supply and a grounded collector placed 
beneath the nozzle. There are three main stages in the EHDA process. The first stage involves 
acceleration of liquid and formation of liquid cone-jet. This phenomenon is a result of the 
balance of various forces, including surface tension, gravity, electrical stresses in the liquid cone, 
and inertial and viscous stresses. The second stage involves jet breakup into droplets due to 
interfacial instability. The third stage involves development of spray after droplet production. 
Electrical interaction between highly charged droplets with different sizes, and thus different 
inertia, causes a size segregation effect. Small droplets, also called satellite droplets, are located 
at the edge of the spray, while the larger droplets, also called main droplets, are located in the 
spray centre (Gañán-Calvo et al., 1994). The highly charged droplets will become unstable with 
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evaporation past the Rayleigh limit. In such a case, droplet fission can occur which may change 
the produced size distribution. 
 
The EHDA technique has been widely employed in the encapsulation of therapeutic agents in 
biodegradable polymeric particles for controlled and sustained drug release applications (Xie et 
al., 2006; Naraharisetti et al., 2007). It is a powerful and advantageous technique allowing 
uniform drug distribution within the particles, high loading capacity and minimal drug loss 
(Chakraborty et al., 2009; Bock et al., 2012) as compared to conventional particulate formation 
methods (Jain, 2000). Moreover, the technique can be scaled up easily by employing an array of 
electrospray atomizers to increase the production rate (Rulison and Flagan, 1993; Regele et al., 
2002; Bocanegra et al., 2005). Since Loscertales’s pioneering use of coaxial EHDA (CEHDA) 
(Loscertales et al., 2002), the coating of solid particles, liquid or gas phase with a solid shell in 
the form of micro- or nano-capsules can be accomplished (Pareta and Edirisinghe, 2006; Xie et 
al., 2008; Hwang et al., 2008; Chen et al., 2008; Wu et al., 2009; Lee Y.H. et al., 2010; Zhang et 
al., 2011; Enayati et al., 2011b). This technique of producing core-shell structured particles as 
drug carriers offer several advantages, including low initial burst release, tunable and near 
uniform drug release rate, and their suitability to deliver a broad class of biomolecules 
(Chakraborty et al., 2009). Such double-walled microspheres can also encapsulate multiple 
agents, allow their releases in different stages and be useful in tissue engineering (Choi et al., 
2010) or cancer therapy (Nie et al., 2010a, 2010b) applications. Recently, the EHDA technique 
has been extended to a triaxial nozzle system which is capable of producing multilayered 
polymeric particles (Ahmad et al., 2008; Lee Y.H. et al., 2011; Kim and Kim, 2010, 2011). 
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A few studies on the CEHDA process and the scaling law have been reported. However, our 
knowledge on the stability of coaxial micro-jet in an electric field is still quite limited. López-
Herrera et al. (2003) presented the driving liquid concept and showed that the current scaling law 
of compound-jet electrospraying was in good agreement with that of single-jet electrospraying 
(Gañán-Calvo et al., 1997). Chen et al. (2005) experimentally examined the effect of viscosity 
and flow rates on various coaxial electrospraying modes. They proposed a simple physical model 
in which the electrical forces acting on the thin liquid film near the Taylor cone surface drove the 
inner liquid by viscosity. Mei and Chen (2007) proposed a set of criteria for producing core-shell 
structured particles based on ratio of charge relaxation lengths of inner and outer jets as well as 
ratio of inertial breakup lengths of inner and outer jets. 
 
A number of computational fluid dynamics (CFD) based numerical simulations on the formation 
of Taylor cone-jet from a single nozzle system have been reported. Yan et al. (2003) presented a 
two-dimensional axi-symmetric model of the electrostatically driven meniscus for ethylene 
glycol and 1-octanol. The model was able to compute the shape of the liquid cone and the 
resulting jet, the velocity and electric fields, and the surface charge density at the liquid surface. 
The simulation results compared well with the experimental observations of the cone shape and 
jet formation. Similarly, Lastow and Balachandran (2006) proposed a two-dimensional axi-
symmetric model for atomization of heptane and ethanol in an electric field. The operating 
window of heptane was observed to be consistent with published data. Although droplet breakup 
was not modeled, the droplet size was obtained from the jet diameter. The droplet size of ethanol 
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compared well with the experimental results. By considering an interface tracking method, the 
CFD model could well be developed for a CEHDA process to simulate cone-jet formation and 
droplet breakup, and this has not yet been reported in the literature. 
 
The present study aims to bridge the experimental work on the fabrication of double-walled 
microspheres from CEHDA and the simulation work on the generation of compound droplets 
from the same process. For the experimental work, double-walled microspheres with a 
doxorubicin-loaded poly(D,L-lactic-co-glycolic acid) (PLGA) core surrounded by a poly(D,L-
lactic acid) (PDLLA) shell layer were fabricated by CEHDA process. Doxorubicin was the 
hydrophilic fluorescent model drug used for encapsulation. The effect of process conditions 
(nozzle voltage and polymer solution flow rates) and solution parameters (polymer 
concentrations) on the production of double-walled microspheres were investigated, and the 
microspheres were characterized in terms of their drug distribution, encapsulation efficiency and 
in vitro release. For the simulation work, the formation of liquid cone-jet and the generation of 
compound droplets were examined by employing the process conditions and fluid properties in a 
CFD model in Fluent. The Navier-Stokes equation, including the electrical stresses and the 
surface tension force, is applied. The volume of fluid (VOF) technique is employed to track the 
interface of the core and shell fluids as well as the liquid and gas. Finally, the simulation results 
are compared with the experimental work to illustrate the capability of the CFD model to predict 
the production of consistent compound droplets, and estimate particle size with its corresponding 
core diameter and shell thickness of the expected double-walled microspheres. 
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3.2. Experiments 
3.2.1. Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA) copolymer (50:50 lactic acid:glycolic acid; inherent 
viscosity (i.v.) = 0.61 dL/g in hexafluoroisopropanol) and poly(D,L-lactic acid) (PDLLA) (i.v. = 
0.37 and 0.70 dL/g in chloroform) were purchased from Lactel Absorbable Polymers (Pelham, 
AL). Doxorubicin, in the form of hydrochloride salt, was purchased from Boryung, Inc. (Seoul, 
Korea). Dichloromethane (DCM) and dimethyl sulfoxide (DMSO) were acquired from Tedia 
Company, Inc. (Fairfield, OH) and Sigma-Aldrich Corp. (St. Louis, MO), respectively. 
Phosphate-buffered saline (PBS) with a pH of 7.4 was acquired from Mediatech, Inc. (Manassas, 
VA). 
 
3.2.2. Preparation of double-walled PDLLA(PLGA) microspheres 
Double-walled PDLLA(PLGA) microspheres consisting of a PLGA core surrounded by a 
PDLLA shell were produced by the CEHDA technique (Fig. 3.1). PLGA and PDLLA were 
individually dissolved in DCM to prepare polymer concentrations that ranged from 5 to 20% 
(w/v). The polymer solutions were delivered using syringe pumps (KD Scientific, Inc.; Holliston, 
MA) into a coaxial nozzle (Popper and Sons, Inc.; Lake Success, NY) to produce a compound jet 
of core PLGA and annular PDLLA. To create an electric field, the nozzle was connected to a 
high-voltage generator (Glassman High Voltage, Inc.; High Bridge, NJ). The collector plate 
(aluminum foil) was grounded and maintained at 15 cm from the nozzle tip. The nozzle voltage 
was varied in order to achieve a stable Taylor cone-jet mode and produce a cloud of highly 
charged droplets. The Taylor cone-jet mode was captured using a FASTCAM MC2.1 high-speed 
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video camera (Photron Ltd., Tokyo, Japan) with a 105 mm F/2.8D AF Micro Nikkor Lens 
(Nikon Corp.; Tokyo, Japan) at a resolution of 512 x 512 pixels and a frame rate of 2000 fps. 
During the process, the solvent would evaporate from the droplets, and the microspheres were 
deposited on the aluminum foil. The samples were then freeze-dried and stored at -20°C under 
desiccant. To load microspheres with drug, the core phase polymer solution was prepared by 
emulsifying doxorubicin solution in PLGA/DCM solution at 2.5% (w/w) drug to polymer ratio. 
The amount of water used was maintained at 1:10 (v/v) water to DCM ratio. 
 
3.2.3. Microscopy 
The surface morphology was examined using a Leica DM IL LED inverted microscope (Leica 
Microsystems GmbH; Wetzlar, Germany) and a JEOL JSM-6060LV scanning electron 
microscope (SEM) (JEOL Ltd.; Tokyo, Japan). For optical imaging, the particles were collected 
on a SEM sample holder with carbon tape and sputter-coated with platinum. Images were taken, 
and the mean particle size was determined using ImageJ software. The intraparticle distribution 
of doxorubicin was examined using a Fluoview FV1000 laser scanning confocal microscope 
(Olympus Corp.; Tokyo, Japan) equipped with diode laser tuned to 473 nm. Briefly, the drug-
loaded microspheres were collected on a glass cover slip and visualized using a 60x water 
immersion objective lens with 1.00 numerical aperture under the following calibrations: 4.0 
μs/pixel sampling speed, line Kalman integration, laser at 720 V and transmissivity of 10%. The 
fluorescence emission was collected at 490 to 540 nm. The focus was adjusted to observe the 
drug distribution at the centerline of the microspheres, and images were taken using Olympus 
Fluoview software. 
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3.2.4. Drug loading 
The drug loading was evaluated by adding ~50 mg of microspheres in 1 ml of DMSO. After the 
microspheres were dissolved, the doxorubicin concentration was measured by analyzing its 
absorbance (λabs = 480 nm) in triplicate in a 96-well plate in an Infinite M200 Pro 
spectrophotometer (Tecan Group Ltd.; Männedorf, Switzerland). 
 
3.2.5. In vitro drug release 
The drug release was performed by suspending ~150 mg of microspheres in 5 ml of PBS in 
centrifuge tubes and incubating them in a water bath (37°C, 120 rpm). At selected time points, 
the samples were centrifuged at 10,000 rpm for 10 min before 1 ml of supernatant was collected 
and 1 ml of fresh PBS was replaced. The doxorubicin concentration was measured by analyzing 
its fluorescence (λex = 480 nm, λem = 590 nm) in the spectrophotometer. 
 
3.2.6. Viscosity measurement 
The flow behavior of polymer solution was measured by using a Haake Rheostress 600 
rheometer (Thermo Electron Corp.; Newington, NH) with rotary parallel plates (60 mm diameter 
and 0.5 mm gap distance) at shear rates ranging from 50 to 100 s-1 at room temperature. The 
viscosity of each sample was calculated from the average of three repeated measurements. 
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3.3. Numerical Simulation 
3.3.1. Mathematical formulation 
3.3.1.1. Fluid flow 
The mass conservation and Navier-Stokes equations are solved to simulate the fluid flow. Three 
fluid phases are considered: the liquid core phase, the liquid shell phase and the gas phase (air). 
Here, the liquid is assumed to be DCM, but is distinguished as core and shell phases. To model 
the flow dynamics in the presence of the electric field, the multiphase flow is coupled with the 
applied electric potential field and electrical charging on the liquid-gas interface. Assuming the 
fluids are incompressible, the mass conservation equation can be expressed as follows. 
 
0=⋅∇ u                       (3.1) 
 
where u is the velocity of the fluid. 
 
The Navier-Stokes equation includes the electrical stresses from the electric field (FES), the 
surface tension force on the liquid-gas interface (FST) and the gravitational force, and the 
resulting equation can be written as follows. 
 
( )gFFupuu
t
u
gSTES


ρρµρ −+++∇+−∇=




 ∇⋅+
∂
∂ 2                    (3.2) 
 
where ρ is the density of the fluid, p is the pressure of the fluid, μ is the viscosity of the fluid, and 
g is the gravitational acceleration. The subscript g refers to gas phase. 
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The electrical stresses can be computed from the divergence of the Maxwell stress tensor (σM) as 
follows. 
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where qv is the volume charge density at the liquid-gas interface, E is the electric field, and ε is 
the electrical permittivity of the fluid. The subscript T  refers to temperature. 
 
The first term is the coulombic force, which is the result of interaction of electrical charges at the 
liquid-gas interface with the electric field and is acting in the direction of the electric field. The 
second and third terms are the dielectric and electrostrictive forces, respectively. The dielectric 
force acts in the normal direction of the interface due to the ε∇  term. The electrostrictive force 
is associated with changes in fluid density, and is neglected due to incompressibility of the fluid. 
 
The surface tension force acting on the liquid-gas interface is formulated using a continuum 
surface force model (Brackbill et al., 1992), where the surface curvature is computed from local 
gradients in the surface normal at the interface. The surface normal (n) is defined as the gradient 
of αi, the volume fraction of the ith phase. 
 
in α∇=                       (3.4) 
 51 
 
 
The surface curvature (κ) is defined in terms of the divergence of the unit surface normal ( nˆ ). 
 








⋅∇=⋅∇=
n
nnˆκ                              (3.5) 
 
The surface tension can be written in terms of the pressure jump across the surface. By 
expressing the force at the surface as a volume force using the divergence theorem, the surface 
tension force has the following form. 
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where γij is the surface tension coefficient between fluid phases i and j. 
 
The above expression allows for a smooth superposition of forces near cells where more than 
two phases are present. If only two phases are present in a computational cell, then ji κκ −=  and 
ji αα −∇=∇ , and Eq. 3.6 can be simplified as follows. 
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where ρ is the volume-averaged density. 
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3.3.1.2. Electric field 
The governing equation defining electric potential (φ) in terms of charge density is Poisson’s 
equation given as follows. 
 
( ) vq−=∇⋅∇ ϕε                           (3.8) 
 
The electric field is defined as follows. 
 
ϕ−∇=E

                       (3.9) 
 
Here, qv has a finite value due to the localization of the electrical charges at the liquid-gas 
interface. Moreover, ε varies as it crosses the liquid-gas interface. Thus, the electric field will 
vary both in strength and magnitude as it crosses the interface. 
 
3.3.1.3. Volume charge density 
It is a challenging task to estimate the volume charge density at the liquid-gas interface. For the 
initial calculation of the electric field, no liquid phase is considered, and charge density is set to 
zero. After the electric field is computed, the volume charge density at the liquid-gas interface 
can be estimated using a leaky dielectric model based on Gauss’s Law as follows. 
 
( )Eqv

ε⋅∇=                        (3.10) 
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The interfacial volume charge density and its distribution are influenced by the charge relaxation 
time (τE) which is defined as the ratio of the electrical permittivity over the electrical 
conductivity (K). 
 
K
E ετ =                    (3.11) 
 
The flow physics of EHDA is dominated by viscous flow and surface tension time scales. At the 
nozzle tip, the viscous force dominates Taylor cone formation, while the surface tension force 
governs jet formation and droplet breakup. By considering L to be the length scale for liquid 
flow, then the viscous flow and surface tension time scales can be approximated by the following 
two equations. 
 
µ
ρτ
2
~ LV                     (3.12) 
γ
ρτ γ
3
~ L                       (3.13) 
 
Typically, the leaky dielectric model (Melcher and Taylor, 1969; Saville, 1997) applies when the 
charge relaxation time is small as compared to the viscous flow and surface tension time scales 
described in this problem (Lim et al., 2011; Hua et al., 2008). For a highly conducting fluid, the 
electric charges may localize at the liquid-gas interface instantly as compared to the time scales 
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of fluid motion or droplet breakup. However, for a weakly conducting fluid, it may act like a 
perfect insulator, and there is no available electric charge flowing through the material. 
 
The relevant physical properties of DCM are given by ε = 8.73, K = 2.75 x 10-8 S/m, ρ = 1360 
kg/m3, μ = 4.3 x 10-4 Pa s, and γ = 0.0254 N/m. By approximating L to be the nozzle or droplet 
diameter (~100 µm), the time scales are given by τE ~ 0.00281 s, τV ~ 0.0316 s, and τγ ~ 0.000231 
s. In this case, the charge relaxation time scale is smaller than the viscous flow time scale, but 
larger than the surface tension time scale. This implies that the induced charges cannot be 
distributed at the liquid-gas interface instantaneously, particularly when the effect of surface 
tension force is taking place. Moreover, in our previous work (Lim et al., 2011), we reported that 
DCM has a relativity low electrical conductivity, and the charge relaxation time scale associated 
with this fluid has been shown to be much larger than the past work (Gañán-Calvo et al., 1997; 
Lastow and Balachandran, 2006) where leaky dielectric model is used. Therefore, the traditional 
leaky dielectric model may not be entirely appropriate in this problem. The actual volume charge 
density should be a value less than the one predicted by Gauss’s Law. Here, a modified leaky 
dielectric model is proposed in this study. 
 
( )Eqv

ελ ⋅∇=                         (3.14) 
 
where λ is a value ranges from 0 to 1. The value of λ that gives the best fit of the Taylor cone-jet 
profile observed experimentally is selected to compute the volume charge density via a trial-and-
error method. The value of λ used in this simulation work is 1/7. 
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3.3.1.4. Tracking evolution of interface 
The VOF model is employed for tracking the evolution of the liquid-liquid and liquid-gas 
interfaces due to its capabilities of dealing with free surfaces interactions. The interface is 
tracked by the solution of a continuity equation for the volume fraction of one (or more) of the 
phases (ith phase) as shown below. 
 
( ) 0=⋅∇+
∂
∂
ii
i u
t

α
α                            (3.15) 
 
The volume fraction equation will not be solved for the primary phase. Instead, the primary 
phase volume fraction will be computed based on the following constraint. 
 
1
1
=∑
=
n
i
iα                     (3.16) 
 
In each computational cell, all of the volume fractions add up to one. All variables and properties 
are shared by the phases and represent volume-averaged values, as long as the volume fractions 
at each position have been calculated. Therefore, the variables and properties in any given cell 
are representative of either of the phases, or a mixture of them, depending upon the volume 
fraction values. Here, the gas phase (air) is represented by the primary phase whereas the liquid 
core and shell phases (DCM) are represented by two secondary phases. 
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3.3.2. Geometry and boundary conditions 
A large domain comprising a coaxial nozzle and collector in the actual experimental setup is 
used to calculate the electric field (Fig. 3.1, Domain A). The two-dimensional axi-symmetric 
electric field can be solved without considering the presence of liquid flow at the nozzle tip. 
After determining the electric potential distribution, the electric potential values are extracted 
and imposed as the boundary conditions of the smaller domain that is confined to the region near 
the nozzle tip, and the CFD calculations are performed based on a two-dimensional axi-
symmetric model (Fig. 3.2). This procedure is done since it is computationally expensive to 
simulate flow dynamics on the large domain, and the domain of interest for the flow dynamics is 
much smaller as compared to that for the electric field calculation. Moreover, the electric field is 
only influenced by the liquid flow locally and is almost unaffected by the presence of the liquid 
far away from the nozzle. The electrostatic and hydrodynamic boundary conditions of the CFD 
domain in Fig. 3.2 are listed in Table 3.1. The initial liquid geometry consists of a coaxial 
hemispherical core-shell droplet at the nozzle tip. 
 
3.3.3. Numerical procedure 
Transient simulation of the CEHDA process was performed using Fluent 14.0 software (ANSYS, 
Inc.; Canonsburg, PA) via High Performance Computing, National University of Singapore. The 
liquid phase is assumed to be DCM. For comparison with the experimental results, the polymer 
solutions are assumed to have similar physical properties of the pure solvent. This assumption 
may be valid if the polymer solutions considered are dilute. The liquid phase follows the physical 
properties of DCM: density ρ = 1360 kg/m3, viscosity μ = 4.3 x 10-4 Pa s, relative electrical 
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permittivity ε = 8.73, and surface tension γ = 0.0254 N/m. The gas phase follows the physical 
properties of air: density ρg = 1.25 kg/m3, viscosity μg = 1.8 x 10-5 Pa s, and relative electrical 
permittivity εg = 1. The gravitational acceleration is 9.81 m/s2, while the electrical permittivity of 
vacuum is 8.85 x 10-12 F/m. The CFD domain (Domain B) is discretized into 10 μm square 
elements, and the time step used is 2 x 10-7 s. The fluid pressure and velocity are updated by 
solving the continuity and momentum equations using the Coupled scheme. The QUICK 
differencing scheme is used for solving the momentum equations, whereas the PRESTO scheme 
is adopted for the pressure correction equation. The QUICK scheme computes a higher-order 
value of the convected variable and is based on a weighted average of second-order upwind and 
central interpolations of the variable (Leonard and Mokhtari, 1990). The PRESTO uses the 
discrete continuity balance for a “staggered” control volume about the face to compute the 
“staggered” (i.e., face) pressure. This procedure is similar in spirit to the staggered-grid schemes 
used with structured meshes (Patankar,1980). The Geometric Reconstruction scheme is used to 
represent the interface between fluids using a piecewise-linear approach. It assumes that the 
interface between two fluids has a linear slope within each cell and uses this linear shape for 
calculation of the advection of fluid through the cell faces. 
 
The simulation procedure is described as follows: 
a) The electric field for Domain A is determined by solving the Poisson’s equation 
based on a two-dimensional axi-symmetric model. No liquid is present at the 
nozzle outlet. 
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b) The electric potential values from Domain A are extracted and imposed as the 
boundary conditions of Domain B. The Poisson’s equation is solved for Domain 
B based on a two-dimensional axi-symmetric model with the boundary electric 
potential values, and the presence of liquid at the nozzle outlet and interfacial 
volume charge density. 
c) The electrical stresses and surface tension force are calculated, and the continuity 
and momentum equations are solved to obtain the new pressure and velocity 
fields. 
d) The liquid-liquid and liquid-gas interfaces are advected to a new location. Based 
on the new interface location, the fluid physical properties such as density, 
viscosity and electrical permittivity are redistributed throughout Domain B. At 
this point, the interfacial volume charge density is also imposed at the liquid-gas 
interface. 
e) The stability of the Taylor cone-jet mode is verified by determining whether the 
cone angle and the jet diameter reach their steady values with increasing 
simulation times. If it is unstable, steps b) to d) are repeated based on a new value 
of interfacial volume charge density. 
 
3.3.4. Droplet size 
From the simulation results, the droplet size is estimated by determining the equivalent spherical 
diameter. At various simulation times, the flights of various droplets produced from the CEHDA 
process are monitored. The images of several droplets and their corresponding core phases are 
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captured and analyzed using the image processing commands in Matlab software, and their 
volumes are calculated through numerical integration by revolving the half-area about the 
symmetric axis. The size of the droplet and its corresponding core phase may be determined 
through the volume of a sphere formula. 
 
3.4. Results and Discussion 
3.4.1. Experimental study of CEHDA process 
3.4.1.1. Double-walled PDLLA(PLGA) microspheres 
Fig. 3.1 shows the CEHDA process for producing uniform double-walled microspheres. The 
nozzle consists of two coaxially aligned capillaries in which PLGA core and PDLLA shell 
solutions were pumped. A polymer jet, consisting of core PLGA and annular PDLLA, was 
produced. Upon jet breakup by the electric field into droplets, the solvent evaporated rapidly to 
form double-walled PDLLA(PLGA) microspheres. Here, we first examine the formation of 
double-walled PDLLA(PLGA) microspheres based on varying core and shell polymer 
concentrations, shell flow rates and nozzle voltages. Here, the inherent viscosities of PLGA and 
PDLLA used were 0.61 and 0.37 dL/g, respectively. 
 
3.4.1.1.1. Effect of core and shell polymer concentrations 
In the first series of experiments, the core polymer concentration was varied from 5 to 20% (w/v) 
(Fig. 3.3a and 3.3b). Here, the nozzle voltage (4.5 kV), the shell polymer concentration (5% 
(w/v)), and the core and shell flow rates (0.5 and 2.5 ml/h) were maintained. By increasing the 
PLGA core phase concentration from 5 to 20% (w/v), microspheres were more spherical with 
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rough and porous surfaces. Next, the shell polymer concentration was varied from 10 to 20% 
(w/v) (Fig. 3.3c and 3.3d). Here, the nozzle voltage (4.5 kV), the core polymer concentration 
(20% (w/v)), and the core and shell flow rates (1.0 and 5.0 ml/h) were maintained. By increasing 
the PDLLA shell phase concentration from 10 to 20% (w/v), microspheres had smoother 
surfaces with lesser and smaller pores. 
 
Polymer concentration is a key factor in influencing the structure and morphology of the 
microspheres. Spherical and smooth microspheres could not be achieved when the polymer 
solution is below a critical concentration. A high polymer concentration provides rapid phase 
inversion and yields a tight structure due to chain entanglement. Overall, the structure and 
morphology of the double-walled microspheres are mainly controlled by the core and shell 
polymer concentrations, respectively. 
 
3.4.1.1.2. Effect of shell flow rate 
Fig. 3.4 shows the electrosprayed microspheres when the shell flow rate was varied from 3.0 to 
7.0 ml/h. Here, the nozzle voltage (4.5 kV), the core and shell polymer concentrations (20% 
(w/v)) and the core flow rate (1.0 ml/h) were maintained. The shell flow rate is selected to be 
higher than the core flow rate in order to ensure that there is sufficient PDLLA shell phase 
solution to encapsulate the PLGA core phase solution. For various flow rates, there was a stable 
formation of the Taylor cone, and uniform microspheres were obtained. Besides, the particle size 
increased almost linearly from ~20 to 40 μm with increasing shell flow rate (Fig. 3.5a). Since the 
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core flow rate was kept constant, the core diameter of the double-walled microspheres should 
remain the same, while the shell thickness presumably increased with increasing shell flow rate. 
 
3.4.1.1.3. Effect of nozzle voltage 
Fig. 3.6 shows the electrosprayed microspheres when the nozzle voltage was varied from 4.0 to 
6.0 kV. Here, the core and shell polymer concentrations (20% (w/v)), and the core and shell flow 
rates (1.0 and 3.0 ml/h) were maintained. For various nozzle voltages, the polymer jet was stable, 
and the monodispersity of the microspheres was maintained. The particle size decreased slightly 
with increasing nozzle voltage, although it was not significantly different (Fig. 3.5b). Above 6.0 
kV, the polymer jet became unstable. 
 
3.4.1.2. Fabrication of drug-loaded double-walled PDLLA(PLGA) microspheres 
Based on the optimized solution parameters and process conditions, three formulations of 
doxorubicin-loaded double-walled PDLLA(PLGA) microspheres were fabricated (Table 3.2). 
Formulation A and B microspheres differ in the molecular weight of the PDLLA shell layer. In 
particular, formulation B had a higher shell molecular weight (0.70 dL/g) than formulation A 
(0.37 dL/g). Formulations A and C differ in the concentration of the PDLLA shell phase solution 
used. In particular, a higher shell polymer concentration was used to produce formulation C 
(20% (w/v)) than formulation A (10% (w/v)). For all the three formulations, the nozzle voltage 
varied between 5.0 and 5.6 kV, while the core and shell flow rates were maintained at 1.0 and 
3.5 ml/h, respectively. 
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3.4.1.2.1. Surface morphology and drug distribution 
Fig. 3.7a to 3.7c and 3.7d to 3.7f show the optical and scanning electron micrographs of various 
formulations of doxorubicin-loaded double-walled microspheres, respectively. The microspheres 
had a particle size of ~30 μm (Table 3.2). Formulation C showed a smooth surface morphology, 
while formulations A and B showed a slightly porous outer layer. The variation in the surface 
morphology among the microspheres may be attributed to the different PDLLA concentrations 
used to form the shell layer. From the confocal micrographs in Fig. 3.7g to 3.7i, doxorubicin was 
encapsulated in the PLGA core region surrounded by a relatively drug-free PDLLA shell layer, 
thus indicating the production of double-walled PDLLA(PLGA) microspheres. 
 
3.4.1.2.2. Encapsulation efficiency 
An encapsulation efficiency as high as 90% could be obtained from double-walled 
PDLLA(PLGA) microspheres (Table 3.2). The encapsulation efficiency increased with 
increasing molecular weight and polymer concentration of the PDLLA shell phase. By using a 
higher shell molecular weight, the encapsulation efficiency improved from ~71% (formulation 
A) to ~91% (formulation B). Moreover, by using a higher shell polymer concentration, the 
encapsulation efficiency improved from ~71% (formulation A) to ~87% (formulation C). 
 
3.4.1.2.3. Release of doxorubicin 
The drug release profiles for all the three formulations were found to be similar (Fig. 3.8). In 
particular, they exhibited a small initial burst release of drug (~2 to 6%), followed by a period of 
minimal drug release for ~19 days. After the lag phase, the drug continued to release at a zero-
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order rate (~41 to 51%) from day 19 to 43. From day 43 onwards, the drug was released at a 
slower but zero-order rate (~36 to 42%) until near complete release at day 152. Formulation C 
microspheres exhibited the smallest initial burst (~2%) as compared to formulations A or B 
(~6%). Interestingly, the lag phase period and the subsequent drug release rate were independent 
of the molecular weight of the shell layer. 
 
The outer layer morphology of the microspheres could contribute to slightly different degrees of 
initial burst release of drug. Since both formulations A and B had a porous outer layer as 
compared to formulation C (Fig. 3.7), the solid drug may either be loosely associated on the 
external surface or embedded in the porous shell layer. Thus, the drug could potentially escape 
from the porous surface layer, resulting in a higher burst release of drug. 
 
During the lag phase from day 0 to 19, the PDLLA shell layer could serve as an effective barrier 
preventing the premature release of doxorubicin into the aqueous medium. At this point, water 
penetration and degradation of the shell layer would occur, facilitating the creation of water-
filled pores though the layer. After the lag phase from day 19 to 43, the drug-loaded PLGA core 
would be exposed to water dissolution, and the degradation of the PLGA core could account for 
the drug release after the lag phase period. Here, the drug was released at a zero-order rate. From 
day 43 onwards, significant agglomeration of microspheres was observed, and this could lead to 
the release of the drug at a slower but zero-order rate. 
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Despite having the shell layer with different molecular weights, the lag phase period and the 
subsequent drug release rate were not significantly affected. It is postulated that the water 
penetration through the PDLLA shell layer of different molecular weights could be occurring at 
the same rate, resulting in the exposure of the drug-loaded PLGA core to water dissolution. 
Moreover, the degradation rate of PLGA core could dominate the subsequent drug release rate 
after the lag phase. Thus, these factors could explain the similar lag phase period and the 
subsequent drug release rate for various microsphere formulations. 
 
3.4.2. Computational study of CEHDA process 
3.4.2.1. Electrical field 
Based on the experimental work described in the previous section, double-walled microspheres 
with a drug-loaded PLGA core surrounded by a drug-free PDLLA shell layer were produced 
successfully from the CEHDA process. Here, the experimental parameters of the CEHDA 
process, including the nozzle voltage (5.0, 5.5 and 5.6 kV), the core and shell flow rates (1.0 and 
3.5 ml/h), and the nozzle-to-collector distance (15 cm), and the fluid properties of DCM and air, 
such as density, viscosity, electrical permittivity and surface tension, are employed in the CFD 
model. The core and shell fluids considered here are DCM. The cone-jet formation and droplet 
breakup process are simulated. Before validating the model with the experimental findings, the 
electric field near the nozzle tip is investigated since the electric field strength and charge density 
play critical roles in the CEHDA process. 
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The electric field is first computed by solving the Poisson’s equation for the entire domain, 
which consists of the nozzle and collector (Fig. 3.1, Domain A). From the developed field, the 
electric potential values are imposed on the right and bottom boundaries of the CFD domain 
(Fig. 3.2), and the Poisson’s equation is solved again. The electric potential and electric field 
strength profiles based on nozzle voltages of 5.0, 5.5 and 5.6 kV are shown in Fig. 3.9. From the 
contour lines, the electric field is observed to be non-uniform with the equipotential lines 
packing densely near the nozzle tip but spacing sparsely far away from the nozzle (Fig. 3.9a). 
During the cone-jet formation and droplet breakup process, the equipotential lines are distorted 
by the low conductivity fluid due to the electrical permittivity difference between DCM and air, 
and the localization of electric charges at the liquid-gas interface. When the nozzle voltage 
increases from 5.0 to 5.6 kV, the potential difference over the domain is higher, thus 
experiencing a slight increase in electric field strength (Fig. 3.9b and 3.9c). The distributions of 
electric charges at the liquid-gas interface under various nozzle voltages are shown in Fig. 3.10. 
The volume charge density ranges from 2.68 to 2.72 C/m3, and most of the charges are 
accumulated at the cone apex, which are consistent with literature results (Lastow et al., 2006). 
By substituting the calculated electrical field strength and estimated volume charge density 
values into the Maxwell stresses, the electrical forces acting on the liquid surface could be 
obtained, and the droplet breakup process could be monitored. 
 
3.4.2.2. Taylor cone-jet formation and droplet breakup process 
Similar to a single nozzle system (Lim et al., 2011), the simulation for a coaxial nozzle system 
could portray the features of cone-jet formation and droplet breakup process reasonably well 
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(Fig. 3.11a(ii) and 3.11b(ii)). The initial liquid geometry is a hemispherical droplet comprising of 
core and shell fluids at the nozzle tip. When there is an electric field, the liquid is accelerated 
towards the collector while a cone shape is developed. A jet is gradually formed at the cone apex 
before it breaks up into relatively monodisperse micron-sized droplets as a result of interfacial 
instability. 
 
Fig. 3.11b(i) demonstrates the development of the velocity field within the liquid cone. As 
compared to the single nozzle system (Lim et al., 2011), the velocity field for a coaxial nozzle 
system shows the presence of two toroid-shaped vortexes due to fluids flowing out from core and 
shell channels of the nozzle. The smaller vortex is located near the outlet of the shell channel 
whereas the larger vortex is located below the cone surface. It is observed that there is significant 
liquid circulation, but only the liquid located very near to the liquid surface is pulled towards jet 
formation. Since the electric charges are localized at the liquid surface, their interaction with the 
electric field causes liquid to flow parallel along the interface. At the center of the jet, there is no 
liquid circulation, and the velocity vector is unidirectional. 
 
If the core and shell fluids are marked as different phases, then the effect of velocity field on the 
distributions of core and shell fluids could be tracked. The distributions of core and shell fluids 
inside the Taylor cone, and the subsequent formation of compound droplets during stable cone-
jet mode at different time points under various nozzle voltages are presented in Fig. 3.12. At the 
center of the liquid jet, reverse flow of the shell fluid into the core channel is observed. The core 
fluid is scattered to flow along the inner wall of the core channel before dispersing into the 
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Taylor cone as a result of liquid circulation. If the core fluid is found near the cone surface, the 
core fluid would be accelerated towards the cone apex and combined with the shell fluid to form 
compound droplets. For a nozzle voltage of 5.0 kV, a small amount of core fluid is found 
circulating within the vortex (Fig. 3.12a). In contrast, for nozzle voltages of 5.5 and 5.6 kV, the 
core fluid no longer stays within the vortex (Fig. 3.12b and 3.12c). For all the three cases, the 
core fluid is pulled towards jet formation, and there is consistent formation of compound 
droplets. 
 
Fig. 3.13 shows the representative compound droplets that are produced during stable cone-jet 
mode at different time points under various nozzle voltages. For all the three cases, consistent 
compound droplets are produced, with each droplet showing the distributions of the core and 
shell fluids. Since electric field plays a dominant role in driving the core fluid towards jet 
formation, we expect that a nozzle voltage above a critical value may be necessary in producing 
the desired compound droplets. 
 
3.4.2.3. Prediction of particle size, core diameter and shell thickness 
Suppose the core fluid of the compound droplet will form the core phase of the final particle, the 
droplet size (equivalent spherical diameter, ddroplet) and its corresponding core fluid diameter 
(dcore,droplet) and shell fluid thickness (τshell,droplet) can be measured directly from the compound 
droplets simulated. If the core and shell fluids are the respective PLGA and PDLLA solutions 
instead of DCM, and assuming complete solvent evaporation has taken place, the particle size is 
closely related to the concentration of polymer solution used in each phase and is proportional to 
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the size of droplet obtained from jet breakup. Thus, from the measurements of the compound 
droplets, we could predict the particle size (dparticle), PLGA core diameter (dcore,particle) and 
PDLLA shell thickness (τshell,particle) of the double-walled microspheres. 
 
For the double-walled microspheres obtained experimentally, the shell thickness (tshell) can be 
calculated from the measured overall particle diameter and known flow rates of the polymer 
solutions. For the case of blank double-walled PDLLA(PLGA) microspheres, the ratio of core 
diameter (Dcore) to overall particle diameter (Dparticle) is related to the volume fraction of PLGA 
in the microsphere as follows. 
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where νPLGA and νPDLLA are the flow rates of PLGA and PDLLA respectively (cm3 of polymer/h), 
xPLGA and xPDLLA are the volume fractions of PLGA and PDLLA in the core and shell solutions 
respectively, Fcore and Fshell are the flow rates of core and shell solutions respectively (cm3 of 
polymer solution/h), CPLGA and CPDLLA are the concentrations of PLGA and PDLLA in DCM 
respectively (g of polymer/cm3 of DCM), and ρPLGA and ρPDLLA are the densities of PLGA and 
PDLLA respectively (g/cm3). 
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For the case of drug-loaded double-walled microspheres with the creation of water-in-oil 
emulsion in the core phase, Eq. 3.17 is modified to include the pore volume originally occupied 
by the water phase that contributed to the total volume of the microsphere as follows. 
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where νwater,core is the flow rate of water in the core phase (cm3 of water/h), xwater,core is the 
volume fraction of water in the core solution, and Vwater,core is the volume ratio of water to DCM 
used to create the emulsion in the core solution. 
 
Then, the shell thickness (tshell) can be calculated as follows. 
 
( )coreparticleshell DDt −×= 2
1                     (3.19) 
 
For the compound droplets obtained from the simulation results, the particle size (dparticle) can be 
predicted from the droplet size (ddroplet) by considering the volume fraction of polymers in the 
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droplet. In addition, by taking into account the water phase from the emulsion that could 
contribute to the pore volume in the core phase, the total volume fraction of PLGA, PDLLA and 
water (xPLGA+PDLLA+water) is calculated as follows. 
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where vPLGA, vPDLLA and vwater,core are the flow rates of PLGA, PDLLA and water respectively 
(cm3/h), xPLGA, xPDLLA and xwater,core are the volume fractions of PLGA, PDLLA and water in the 
respective solutions respectively, Fcore and Fshell are the flow rates of core and shell solutions 
respectively (cm3 of polymer solution/h), CPLGA and CPDLLA are the concentrations of PLGA and 
PDLLA in DCM respectively (g of polymer/cm3 of DCM), ρPLGA and ρPDLLA are the densities of 
PLGA and PDLLA respectively (g/cm3), and Vwater,core is the volume ratio of water to DCM used 
to create the emulsion in the core solution. 
 
Then, the particle size is related to the droplet size as follows. 
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Since the total volume fraction of PLGA and water (xPLGA+water) in the core solution is 
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Then, the PLGA core diameter (dcore,particle) is related to the core fluid diameter (dcore,droplet) as 
follows. 
 
( ) dropletcorewaterPLGAparticlecore dxd ,,
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Finally, the shell fluid thickness (τshell,droplet) and the PDLLA shell thickness (τshell,particle) can be 
calculated as follows. 
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Fig. 3.14 shows the size distributions of the simulated droplets that are produced under various 
nozzle voltages. The size distribution is plotted in the form of a probability density function. The 
droplet sizes are fitted with Gaussian and Poisson distributions, and the goodness of fit is 
evaluated using the chi-squared statistic test at a 5% significance level. Overall, the droplet sizes 
produced from nozzle voltages of 5.0, 5.5 and 5.6 kV seem to follow a Gaussian distribution 
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fairly well (p = 0.154 at nozzle voltage of 5.0 kV; p = 0.628 at nozzle voltage of 5.5 kV; p = 
0.962 at nozzle voltage of 5.6 kV). 
 
Table 3.3 shows the comparison of experimental and simulation results on the particle size 
together with its PLGA core diameter and PDLLA shell thickness of the double-walled 
microspheres. The experimental results show that formulations A to C were ~30 μm, core 
diameter was ~22 μm and shell thickness was ~4 μm. The simulation results show that the 
droplet size is ~105 μm for formulations A and B, and ~111 μm for formulation C. By 
considering the core and shell polymer concentrations used to produce these microspheres, the 
particle size, core diameter and shell thickness can be estimated. The predicted particle size is 
~49 μm for formulations A and B, and ~59 μm for formulation C. The core diameter is ~32 μm 
for all the three formulations. As such, the shell thickness for formulation C (~13 μm) is larger 
than that for formulation A or B (~8 μm). Based on the process conditions considered, the 
particle size, core diameter and shell thickness predicted from the simulated compound droplets 
compare well with those obtained experimentally, although the predicted sizes overestimate the 
sizes of the microspheres that were obtained experimentally. 
 
The observed deviation between simulation and experimental results may be attributed to the 
usage of physical properties of DCM for the liquid phase in the CFD model. Polymer solutions 
may have slightly different fluid properties as compared to the pure solvent properties, and the 
assumption based on pure solvent properties may only be valid for dilute polymer solutions (Fig. 
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3.15 and Table 3.4). The viscosity of polymer solution, for instance, increases with the polymer 
concentration, and this may influence the cone-jet formation and droplet breakup process. 
 
3.5. Conclusions 
Monodisperse double-walled PDLLA(PLGA) microspheres with well defined spherical structure 
and smooth morphology were fabricated via CEHDA based on the optimized process conditions 
and solution parameters. Doxorubicin was successfully encapsulated in the PLGA core 
surrounded by a relatively drug-free PDLLA shell layer. High encapsulation efficiency of the 
drug was achieved, while the release profiles typically exhibited two stages of constant drug 
release rates after a short duration of lag phase. Numerical simulation of CEHDA process using a 
CFD model indicates that the velocity field developed inside the Taylor cone has a considerable 
impact on the distributions of core and shell fluids. In order to produce the desired compound 
droplets, a nozzle voltage above a critical value may be necessary in driving the core fluid away 
from the toroid-shaped vortex and towards jet formation. Based on the process conditions 
considered, the particle size, core diameter and shell thickness predicted from the simulated 
compound droplets compare well with those obtained experimentally, although the predicted 
sizes overestimate the sizes of the microspheres that were obtained experimentally. 
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3.6. Figures 
 
 
 
Figure 3.1: CEHDA process for producing uniform double-walled microspheres. Domain A consists of 
the coaxial nozzle and the collector, and is used to calculate the electric field. Domain B consists of the 
region near the nozzle tip and is used to simulate the CEHDA process. The coaxial nozzle consists of core 
and shell capillaries with inner and outer diameters as indicated above, and the dimensions are given in 
millimeters. 
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Figure 3.2: Size of Domain B used to simulate the CEHDA process. A: symmetry line; B: core inlet; C: 
wall of core channel; D: shell inlet; E: wall of shell channel; F: top; G: right; H: bottom; r: r-axis; z: z-
axis. The dimensions are given in millimeters. 
 
 
 
 
Figure 3.3: SEM of electrosprayed double-walled PDLLA(PLGA) microspheres prepared using different 
core and shell polymer concentrations. The nozzle voltage (4.5 kV), the core/shell flow rates ((a) and (b): 
0.5/2.5 ml/h; (c) and (d): 1.0/5.0 ml/h) and the nozzle-to-collector distance (15 cm) were maintained. 
Scale bar = 25 µm. 
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Figure 3.4: SEM of electrosprayed double-walled PDLLA(PLGA) microspheres prepared based on a 
constant core flow rate (1.0 ml/h), but different shell flow rates. The nozzle voltage (4.5 kV), the core and 
shell polymer concentrations (20% (w/v)), and the nozzle-to-collector distance (15 cm) were maintained. 
Scale bar = 25 µm. 
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Figure 3.5: The effect of (a) shell flow rate and (b) nozzle voltage on the mean particle size. For (a), the 
nozzle voltage (4.5 kV), the core polymer solution (20% (w/v) at 1.0 ml/h), the shell polymer solution 
(20% (w/v)) and the nozzle-to-collector distance (15 cm) were maintained. For (b), the core polymer 
solution (20% (w/v) at 1.0 ml/h), the shell polymer solution (20% (w/v) at 3.0 ml/h) and the nozzle-to-
collector distance (15 cm) were maintained. Data represent mean ± standard deviation, n = 10. 
 
 
 
 
Figure 3.6: SEM of electrosprayed double-walled PDLLA(PLGA) microspheres prepared using different 
nozzle voltages. The core and shell polymer concentrations (20% (w/v)), the core/shell flow rates (1.0/3.0 
ml/h), and the nozzle-to-collector distance (15 cm) were maintained. Scale bar = 25 µm. 
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Figure 3.7: Transmitted light, scanning electron and confocal micrographs depicting doxorubicin-loaded 
double-walled PDLLA(PLGA) microspheres. The green color shows the distribution of doxorubicin. 
Scale bar = 50 µm. 
 
 
 
 
Figure 3.8: In vitro release of doxorubicin from double-walled PDLLA(PLGA) microspheres. Data 
represent mean ± standard deviation, n = 3. 
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Figure 3.9: (a(i)), (a(ii)) and (a(iii)) are the electric potential profiles represented by equipotential lines in 
the CFD domain containing the cone-jet and droplet breakup based on nozzle voltages of 5.0, 5.5 and 5.6 
kV, respectively. (b(i)) to (b(iii)) and (c(i)) to (c(iii)) are the electric field strength profiles before and 
after cone-jet formation based on nozzle voltages of 5.0 to 5.6 kV, respectively. In all cases, the core/shell 
flow rates (1.0/3.5 ml/h) and the nozzle-to-collector distance (15 cm) are maintained. 
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Figure 3.10: (a), (b) and (c) are the volume charge density profiles at the liquid-gas interface during cone-
jet formation based on nozzle voltages of 5.0, 5.5 and 5.6 kV, respectively. In all cases, the core/shell 
flow rates (1.0/3.5 ml/h) and the nozzle-to-collector distance (15 cm) are maintained. 
 
 
 
 
Figure 3.11: (a(i)) and (a(ii)) are the droplet formation and the stable cone-jet mode observed 
experimentally when the nozzle voltages were fixed at 0 and 4.5 kV, respectively. For the experiments, 
the core/shell flow rates (1.0/3.5 ml/h) and the nozzle-to-collector distance (15 cm) were maintained. 
(b(i)) Velocity field is plotted on the left of the liquid cone. Streamline is plotted on the right of the liquid 
cone. Scale bar = 100 μm. (b(ii)) The location of the plotted region in the CFD domain. For the 
simulation, the nozzle voltage (5.6 kV), the core/shell flow rates (1.0/3.5 ml/h) and the nozzle-to-collector 
distance (15 cm) are maintained. 
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Figure 3.12: Distributions of core and shell fluids inside the Taylor cone and subsequent formation of compound droplets during stable cone-jet 
mode at different time points under various nozzle voltages. The time interval is 0.5 ms. The red, green and blue colors represent the core, shell 
and air phases, respectively. In all cases, the core/shell flow rates (1.0/3.5 ml/h) and the nozzle-to-collector distance (15 cm) are maintained. 
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Figure 3.13: Representative compound droplets that are produced during stable cone-jet mode at different time points under various nozzle 
voltages. The time interval is 0.5 ms. The red, green and blue colors represent the core, shell and air phases, respectively. In all cases, the 
core/shell flow rates (1.0/3.5 ml/h) and the nozzle-to-collector distance (15 cm) are maintained. Scale bar = 100 µm. 
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Figure 3.14: (a), (b) and (c) are the droplet size distributions produced from stable cone-jet mode under 
nozzle voltages of 5.0, 5.5 and 5.6 kV, respectively. The droplet sizes are fitted with Gaussian and 
Poisson distributions, and the goodness of fit is evaluated using the chi-squared statistic test at a 5% 
significance level. The mean and standard deviation for the fitted distribution is indicated above. For (a), 
the p values for the Gaussian and Poisson distribution fits are 0.154 and 0.027, respectively. For (b), the p 
values for the Gaussian and Poisson distribution fits are 0.628 and 0.016, respectively. For (c), the p 
values for the Gaussian and Poisson distribution fits are 0.962 and 0.037, respectively. In all cases, the 
core/shell flow rates (1.0/3.5 ml/h) and the nozzle-to-collector distance (15 cm) are maintained. 
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Figure 3.15: (a) Shear stress as a function of shear rate for various polymer solutions. (b) Viscosity as a 
function of shear rate for various polymer solutions. 
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3.7. Tables 
 
Table 3.1: The electrostatic and hydrodynamic boundary conditions of Domain B. The boundaries are 
labeled in Fig. 3.2. φ: voltage; u: velocity of fluid; p: pressure of fluid; Vnozzle: nozzle voltage; Vright: 
voltage profile determined from Domain A; Vbottom: bottom voltage determined from Domain A; Qcore: 
volumetric flow rate of core phase; Qshell: volumetric flow rate of shell phase; Acore: cross-sectional area of 
core channel; Ashell: cross-sectional area of shell channel. The subscripts r and z represent the r- and z-
components, respectively. 
 
Boundary Electrostatic Hydrodynamic 
A 0=rϕ  0=ru  
B nozzleV=ϕ  corecorez AQu /=  
C nozzleV=ϕ  0=u  
D nozzleV=ϕ  shellshellz AQu /=  
E nozzleV=ϕ  0=u  
F 0=zϕ  0=p  
G rightV=ϕ  0=p  
H bottomV=ϕ  0=p  
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Table 3.2: Mean particle size and encapsulation efficiency of doxorubicin-loaded double-walled PDLLA(PLGA) microspheres. The nozzle voltage 
ranged from 5.0 to 5.6 kV, the core and shell flow rates were 1.0 and 3.5 ml/h, respectively, and the nozzle-to-collector distance was 15 cm. Data 
represent mean ± standard deviation. 
 
Formulation 
PLGA  
core phase 
PDLLA  
shell phase Nozzle 
voltage 
(kV) 
Core 
flow rate 
(ml/h) 
Shell 
flow rate 
(ml/h) 
Particle 
size1 
(μm) 
E.E.2 
 
(%) Con. 
(% (w/v)) 
I.V. 
(dL/g) 
Con. 
(% (w/v)) 
I.V. 
(dL/g) 
A 20 0.61 10 0.37 5.5 1.0 3.5 28.1 ± 5.2 71.1 ± 1.9 
B 20 0.61 10 0.70 5.6 1.0 3.5 31.5 ± 5.4 91.4 ± 1.5 
C 20 0.61 20 0.37 5.0 1.0 3.5 31.3 ± 4.5 87.1 ± 0.9 
1Average particle size was based on at least 20 microspheres. 
2Average E.E. was based on three samples of microspheres. 
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Table 3.3: Comparison of experimental and simulation results on the particle size, PLGA core diameter and PDLLA shell thickness of the double-
walled microspheres. Data represent mean ± standard deviation. 
 
Formulation 
Nozzle 
voltage 
 
(kV) 
Experimental results Simulation results 
Particle 
size1 
 
Dparticle 
(µm) 
PLGA 
core 
diameter2 
Dcore 
(µm) 
PDLLA 
shell 
thickness3 
tshell 
(µm) 
Droplet 
size4 
 
ddroplet 
(µm) 
Core 
fluid 
diameter4 
dcore,droplet 
(µm) 
Shell 
fluid 
thickness4,5 
τshell,droplet 
(µm) 
Particle 
size4,6 
 
dparticle 
(µm) 
PLGA 
core 
diameter4,7 
dcore,particle 
(µm) 
PDLLA 
shell 
thickness4,8 
τshell,particle 
(µm) 
A 5.5 28.1 ± 5.2 21.7 3.2 106.2 ± 13.1 54.7 ± 8.3 25.7 ± 5.2 49.3 ± 6.1 32.4 ± 4.9 8.5 ± 2.5 
B 5.6 31.5 ± 5.4 24.3 3.6 104.3 ± 13.1 53.3 ± 8.7 25.5 ± 5.0 48.4 ± 6.1 31.5 ± 5.2 8.4 ± 2.4 
C 5.0 31.3 ± 4.5 21.3 5.0 110.8 ± 13.7 55.2 ± 10.4 27.8 ± 4.4 58.5 ± 7.2 32.7 ± 6.1 12.9 ± 2.3 
1Average size was based on at least 20 microspheres. 
2Computed from Eq. 3.18. 
3Computed from Eq. 3.19. 
4Average size was based on at least 20 compound droplets. 
5Computed from Eq. 3.24. 
6Computed from Eq. 3.20 and 3.21. 
7Computed from Eq. 3.22 and 3.23. 
8Computed from Eq. 3.25. 
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Table 3.4: Viscosities of DCM and various polymer solutions. 
 
Sample Viscosity1 (mPa s) 
DCM 0.43 
10% (w/v) PLA (i.v. = 0.37 dL/g) 3.05 
20% (w/v) PLA (i.v. = 0.37 dL/g) 17.55 
10% (w/v) PLA (i.v. = 0.70 dL/g) 27.45 
20% (w/v) PLGA (i.v. = 0.61 dL/g) 89.34 
1Average viscosity was based on shear rate ranging from 50 to 100 s-1 except for PLGA solution which 
was based on shear rate ranging from 75 to 100 s-1. 
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CHAPTER 4 
MECHANISM OF DRUG RELEASE FROM DOUBLE-WALLED 
PDLLA(PLGA) MICROSPHERES 
 
4.1. Introduction 
With the advent of biocompatible and biodegradable polymers, much research has focused on the 
development of suitable polymeric drug delivery systems and their design for sustained drug 
release applications. Polymeric drug delivery systems have the potential to protect drugs from 
degradation, and at the same time, provide their release at the targeted site in a predesigned 
manner to achieve more effective therapies while eliminating the potential for both under- and 
over-dosing. Polymeric drug delivery systems such as biodegradable polymer microspheres are 
simple to fabricate. Moreover, they offer facile administration via routes including oral, 
pulmonary and parenteral injection, and they do not need surgical removal upon complete drug 
release. However, the use of conventional single-polymer microspheres is severely undermined 
by several limitations, including the initial burst release caused by rapid release of drug found on 
or near the external surface, difficulty in achieving zero-order drug release, and a lack of time-
delayed or pulsatile release of drugs (Pekarek et al., 1994a, 1994b). 
 
Since an important goal of drug delivery systems is to attain well-controlled drug release rates, 
double-walled microspheres with a drug-encapsulating particle core surrounded by a drug-free 
shell layer are introduced (Lee T.H. et al.,  2002; Rahman et al., 2004; Berkland et al., 2004a, 
2004b; Pollauf et al., 2005a; Tan et al., 2005; Zheng, 2009; Choi et al., 2010; Nie et al., 2010a, 
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2010b). These double-walled microspheres often exhibit a reduction in the initial burst release as 
compared to single-polymer microspheres (Lee T.H. et al., 2002; Rahman et al., 2004; Tan et al., 
2005; Zheng, 2009), and provide a sustained drug release that is tunable by adjusting the shell 
material or thickness (Berkland et al., 2004a; Pollauf et al., 2005a). In addition, these 
microspheres enable the encapsulation of multiple drugs in the core and shell phases, and allow 
their release in various stages, thus achieving synergistic therapeutic effects (Choi et al., 2010; 
Nie et al., 2010a, 2010b). For example, the parallel or sequential release of multiple drugs would 
be useful for expediting a variety of growth factor driven tissue regenerative processes in tissue 
engineering (Choi et al., 2010) or formulating a successful tumor inhibition strategy in cancer 
therapy (Nie et al., 2010a, 2010b). Recently, the development of triple-walled microspheres have 
also gained significant interest, and such multi-layered drug delivery systems could provide a 
versatile approach to deliver several drugs and control their respective drug release profiles 
(Ahmad et al., 2008; Lee Y.H. et al., 2011; Kim and Kim., 2011; Lee W.L. et al., 2010, 2012a, 
2012b). 
 
Drug release from biodegradable polymeric delivery systems is intricately linked to the 
degradation of the polymer matrix, and is dependent on the degree of crystallinity of the polymer 
(Tsuji et al., 2000) and the release condition (Zolnik and Burgess, 2007). Polymer degradation is 
often preceded by a sequence of processes including water absorption, polymer hydrolysis and 
matrix erosion that occur simultaneously (Fredenberg et al., 2011). For common materials such 
as polyesters, the process of polymer degradation involves hydrolytic chain scission, during 
which polymer chains are cleaved into oligomers and monomers. This leads to the mass loss of 
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the polymer matrix that is characteristic for erosion (Tamada and Langer; 1993). Degradable 
polymers are typically classified into bulk- and surface-eroding materials (Alexis, 2005). For 
bulk-eroding polymers such as polyesters (Park, 1994, 1995), the rate of water penetration into 
the polymer matrix is higher than the rate of hydrolysis. In this case, water diffuses into the 
polymer inducing swelling and degradation throughout the matrix simultaneously. For surface-
eroding polymers such as polyanhydrides (Shieh et al., 1994; Dang and Saltzman, 1994) and 
poly(ortho esters) (Heller et al., 2002), the rate of hydrolysis is higher than the rate of water 
penetration. In this case, hydrolysis is confined to the outer polymer surface, and the interior of 
the matrix remains relatively unchanged. 
 
Many groups have produced double-walled microspheres from a variety of materials including 
bulk- and surface-eroding polymers, and investigated their degradation behavior (Pekarek et al., 
1996; Leach et al., 1993a, 1993b; Yang et al., 2003; Shi et al., 2003; Pollauf et al., 2005b). In 
one study, the degradation of double-walled microspheres with a core of poly(1,3-bis-(p-
carboxyphenoxypropane)-co-(sebacic anhydride)) 20:80 (P(CPP:SA)20:80) and an external coat 
of poly(L-lactic acid) (PLLA) was monitored in vitro and in vivo for 6 months (Leach et al., 
1993a, 1993b). The inner core of the more hydrolytically labile P(CPP:SA)20:80 degraded first 
while the shell layer remained relatively intact. In another study, the degradation of double-
walled microspheres consisting of a poly(ortho ester) (POE) core surrounded by a poly(D,L-
lactic-co-glycolic acid) 50:50 (PLGA) shell layer was examined (Yang et al., 2003). Similar to 
the previous study, preferential degradation of the POE core was observed, and formation of 
hollow microspheres became pronounced after the first week of incubation. In an attempt to limit 
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water penetration into the inner core phase, a surface-eroding polymer, poly(1,6-bis-(p-
carboxyphenoxyhexane)) (PCPH), was used to encapsulate a PLGA core (Pollauf et al., 2005b). 
However, the slow eroding PCPH shell layer could not prevent water penetration, and the PLGA 
core was completely eroded by 6 weeks of incubation. 
 
Overall, these studies showed that the preferential degradation of the inner core is highly 
dependent on the occurrence of water penetration through the shell layer. It would be interesting 
if different molecular weights of the shell layer could modulate the erosion of the outer coating 
and limit the occurrence of water penetration into the inner drug-loaded core on various time 
scales, and therefore control the drug release from the microspheres. Thus, the main focus of this 
study is to investigate the effect of molecular weight of polymer shell on the drug release and 
degradation behavior of double-walled microspheres. 
 
Here, the drug release and degradation behavior of double-walled microspheres consisting of a 
doxorubicin-loaded PLGA core surrounded by a poly(D,L-lactic acid) (PDLLA) shell layer were 
reported. Doxorubicin was employed as a hydrophilic model drug loaded selectively in the core 
phase of the microspheres. For the purpose of this study, two different PDLLA molecular 
weights were used to form the shell layer of the double-walled microspheres since they exhibited 
different trends of time-dependent molecular weight change (Park, 1994). The in vitro release 
profile of doxorubicin was determined, while the degradation behavior of the microspheres was 
monitored using scanning electron microscopy, laser scanning confocal microscopy and gel 
permeation chromatography. The compilation of the results from the three analytical tools would 
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allow elucidation of the dominant mechanism controlling drug release at different stages of the 
degradation process and account for the drug release profiles obtained experimentally. 
 
4.2. Materials and Methods 
4.2.1. Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA) copolymer (50:50 lactic acid:glycolic acid; inherent 
viscosity (i.v.) = 0.61 dL/g in hexafluoroisopropanol (HFIP)), and poly(lactic acid) (PLA) 
polymers including poly(D,L-lactic acid) (PDLLA) (i.v. = 0.37 and 0.70 dL/g in chloroform) and 
poly(L-lactic acid) (PLLA) (i.v. = 1.05 dL/g in chloroform) were purchased from Lactel 
Absorbable Polymers (Pelham, AL). Poly(vinyl alcohol) (PVA) (Mw = 25,000 Da), 88 mol% 
hydrolyzed, was purchased from Polysciences, Inc. (Warrington, PA). Doxorubicin, in the form 
of hydrochloride salt with more than 99% purity, was purchased from LC Laboratories (Woburn, 
MA). Dichloromethane (DCM) and HFIP were acquired from Sigma-Aldrich Corp. (St. Louis, 
MO) while HPLC-grade tetrahydrofuran (THF) was acquired from Tedia (Fairfield, OH). 
Phosphate-buffered saline (PBS) with a pH of 7.4 was acquired from Mediatech, Inc. (Manassas, 
VA). 
 
4.2.2. Fabrication of double-walled PLA(PLGA) microspheres 
Double-walled PLA(PLGA) microspheres consisting of a PLGA core surrounded by a PLA shell 
were produced by using the established precision particle fabrication (PPF) technique (Fig. 4.1). 
Solutions containing 20 to 40% (w/v) PLGA and 5% (w/v) PLA in DCM were individually 
prepared. In this technique, a coaxial nozzle was used to produce a jet of core PLGA surrounded 
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by an annular stream containing PLA. The core-shell polymer jet, protected by a non-solvent 
0.5% (w/v) PVA carrier stream, was disrupted into uniform nascent double-walled droplets by an 
ultrasonic transducer controlled by a frequency generator. In order to control monodispersity of 
the double-walled microspheres, the fabrication process was monitored to ensure there was a 
steady disruption of the core-shell polymer jet by adjusting ultrasonic frequency and flow rate of 
the carrier stream. The droplets were collected in a beaker containing 0.5% (w/v) PVA solution, 
before they were stirred continuously for ~2 h, filtered and rinsed with an equal volume of 
distilled water to remove residual PVA from the microspheres. Finally, the microspheres were 
freeze-dried for 3 days and stored at -20°C under desiccant. To prepare microspheres loaded with 
doxorubicin in the PLGA core phase, a stock solution of doxorubicin was first prepared in water 
(50 mg/ml), before an appropriate amount of drug solution was further diluted in water and 
added to 10 ml of PLGA/DCM solution to obtain the desired drug to polymer loading. The 
resultant mixture was sonicated using a Model 500 Sonic Dismembrator (Thermo Fisher 
Scientific, Inc.; Pittsburgh, PA) at 30% amplitude in an ice bath for 90 s to form a stable 
emulsion. 
 
4.2.3. Particle size distribution 
The size distributions of the hardened double-walled microspheres were determined using a 
Multisizer 3 (Beckman Coulter, Inc.; Fullerton, CA) with a 120 μm aperture. The microspheres 
were suspended in Isoton II Diluent (Beckman Coulter, Inc.; Fullerton, CA) before measurement. 
At least 10,000 microspheres were measured for every sample. 
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4.2.4. Optical microscopy 
The hardened double-walled microspheres were examined using an Invertoskop inverted 
microscope (Carl Zeiss Microscopy LLC; Thornwood, NY). A few droplets of the aqueous 
microsphere suspension were placed directly onto a microscope slide. Images were captured 
using Digital Microscope Suite software. 
 
4.2.5. Drug loading 
The drug loading was determined by dissolving approximately 50 mg of microspheres (2% 
(w/w) theoretical loading of doxorubicin with respect to PLGA) in 1 ml of HFIP. The samples 
were allowed to stand until complete dissolution of the polymers. The samples were then 
centrifuged at 10,000 rpm for 10 min, and the supernatants were carefully extracted. In order to 
measure doxorubicin concentration, the supernatant was added in triplicate in a 96-well plate, 
and the absorbance was analyzed using a SpectraMax 340PC spectrophotometer (Molecular 
Devices LLC; Sunnyvale, CA) at a wavelength of 480 nm. 
 
4.2.6. In vitro drug release 
The release profile was determined by suspending approximately 150 mg of microspheres (2% 
(w/w) theoretical loading of doxorubicin with respect to PLGA) in 5 ml of PBS in centrifuge 
tubes. The tubes were placed in an incubator maintained at 37°C and shaken at 240 rpm. At 
selected time points, the tubes were centrifuged at 10,000 rpm for 10 min before 1 ml of 
supernatant was collected and 1 ml of fresh PBS was replaced. This is done to ensure sink 
conditions. In order to measure doxorubicin concentration, the supernatant was sufficiently 
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diluted in PBS before adding in triplicate in a 96-well plate, and the fluorescence was analyzed 
using the fluorescence spectrophotometer at excitation and emission wavelengths of 480 and 590 
nm, respectively. 
 
4.2.7. In vitro degradation 
The in vitro degradation study was performed by suspending approximately 20 mg of 
microspheres (0.06% (w/w) loading of doxorubicin with respect to PLGA) in 660 μl of PBS in 
centrifuge tubes. Similar to the in vitro drug release study, the tubes were placed in an incubator 
maintained at 37°C and shaken at 240 rpm. Based on the in vitro drug release time points, the 
tubes were centrifuged at 10,000 rpm for 10 min before 132 μl of supernatant was removed, and 
132 μl of fresh PBS was replaced. This is done to ensure sink conditions. At pre-determined time 
points, the tubes were centrifuged, and PBS was removed. The microspheres were then rinsed 
twice with distilled water, and imaged using scanning electron microscopy (SEM) and laser 
scanning confocal microscopy. Samples were also collected for gel permeation chromatography 
(GPC) analysis. In this case, the samples were further freeze-dried for 3 days before dissolving 
them in HPLC-grade THF. 
 
4.2.8. Scanning electron microscopy 
The surface morphology of the degrading double-walled microspheres was examined using a 
JEOL JSM-5600LV scanning electron microscope (SEM) (JEOL Ltd.; Tokyo, Japan). A few 
droplets of the aqueous microsphere suspension were placed directly onto a SEM sample holder 
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coated with conductive carbon tape and air-dried overnight. The samples were sputter-coated 
with gold palladium prior to imaging at 10 kV. 
 
4.2.9. Laser scanning confocal microscopy 
The distribution of doxorubicin in the degrading double-walled microspheres was examined 
using a Fluoview FV1000 laser scanning confocal microscope (Olympus Corp.; Tokyo, Japan) 
equipped with argon ion laser tuned to 488 nm. A few droplets of the aqueous microsphere 
suspension were placed directly onto a microscope slide and sealed with a cover glass. The 
samples were then visualized using an oil immersion objective lens under x60 magnification and 
x1 zoom with the following calibrations: 4.0 μs/pixel sampling speed, laser at 720 V and 
transmissivity of 10%. The fluorescence emission was collected using a 505 nm long pass 
interference filter. These settings were used for all the samples to ensure consistency. Optical 
cross-sections were taken at various depths for each sample in order to determine drug 
distribution at the centerline of the microspheres. Images were captured using Olympus 
Fluoview software. The fluorescence intensity profiles were obtained using ImageJ software. 
 
4.2.10. Molecular weight analysis 
The molecular weights of pure polymers and double-walled microspheres were determined using 
a gel permeation chromatography (GPC) system consisting of a Waters 1515 Isocratic HPLC 
Pump, Waters 717plus Autosampler and Waters 2414 Refractive Index Detector (Waters Corp.; 
Milford, MA). The samples were eluted in HPLC-grade THF through 5 μm Jordi Gel DVB 
1,000, 10,000 and 100,000 Ǻ columns (Jordi Labs LLC; Bellingham, MA) connected in series at 
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a flow rate of 1 ml/min and a temperature of 35°C. The samples were filtered before injecting 
into the column to remove insoluble particulates when present. The calibration curve was 
generated using polystyrene standards (Polymer Laboratories Ltd.; Church Stretton, Shropshire, 
UK) prepared at concentrations of 1 mg/ml. The semi-logarithmic calibration curve of molecular 
weight versus elution time is linear (R2 = 0.998). The weight-averaged and peak molecular 
weights of the samples were obtained using Waters Breeze software. The molecular weights 
were reported based on the average of two measurements. 
 
4.3. Results and Discussion 
4.3.1. Effect of polymer concentration and flow rate on the formation of double-walled 
PLLA(PLGA) microspheres 
The first experiment was conducted to examine the effect of polymer concentration and flow rate 
on the formation of double-walled PLLA(PLGA) microspheres. As shown in Table 4.1, the 
PLLA shell concentration was fixed at 5% (w/v) while the PLGA core concentration was 20, 30 
or 40% (w/v) in DCM. In addition, the PLGA core flow rate was maintained at 4 ml/h while the 
PLLA shell flow rate was 12, 24 or 36 ml/h, leading to various PLLA:PLGA mass ratios. 
 
Based on the above conditions, microspheres with a mean diameter ranging from 50 to 75 μm 
could be produced using the PPF apparatus, with each sample showing a narrow size distribution 
(Table 4.1). Overall, the increase in the PLLA flow rate led to an increase in the size of the 
microspheres since the ultrasonic frequency was fixed at 5 kHz, thus leading to a constant rate of 
droplet formation. Most importantly, the efficient production of fully formed double-walled 
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microspheres depended on the PLLA:PLGA mass ratio, and it occurred only above a critical 
polymer mass ratio. When using a PLGA core concentration of 20% (w/v) in DCM, the critical 
PLLA mass fraction was found to lie between 0.63 and 0.72. Similarly, when using a PLGA core 
concentration of 30% (w/v) in DCM, the critical PLLA mass fraction was found to lie between 
0.55 and 0.64. However, it appeared that a critical PLLA mass fraction higher than 0.59 was 
required when a PLGA core concentration of 40% (w/v) in DCM was used. Increasing the 
PDLLA flow rate may aid the spreading of the shell phase onto the more concentrated core phase 
to form core-shell structured microspheres (Berkland et al., 2004b). The PLGA core 
concentration, on the other hand, did not seem to have a significant effect on the critical polymer 
mass ratio needed for forming double-walled microspheres. 
 
Fig. 4.2 shows the optical images for various microsphere samples listed in Table 4.1. Partial 
encapsulation of PLGA core by PLLA polymer was found in microspheres when a PLLA shell 
flow rate below the critical polymer mass ratio was selected (Samples A1, A2, B1, B2 and C1-
C3). The polymer interface between PLLA and PLGA could be observed on the microsphere 
surface. Above the critical polymer mass ratio, fully formed double-walled microspheres were 
observed with no sign of partial encapsulation configuration (Samples A3 and B3). 
 
4.3.2. Encapsulation efficiency and in vitro drug release study of double-walled 
PDLLA(PLGA) microspheres 
The formation of double-walled PDLLA(PLGA) microspheres could also be achieved by using 
different molecular weights of PDLLA as the shell layer. In addition, doxorubicin could be 
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encapsulated within the PLGA core successfully. Here, two microsphere formulations consisting 
of a doxorubicin-loaded PLGA core surrounded by a low PDLLA molecular weight shell layer 
(i.v. = 0.37 dL/g; formulation A) and a high PDLLA molecular weight shell layer (i.v. = 0.70 
dL/g; formulation B) were fabricated based on the same polymer concentrations and flow rates 
used to produce sample B3 microspheres. Based on the measured overall particle diameter (about 
65 µm) and known mass flow rates of the polymer solutions, and using an assumption of 
complete polymer phase separation, the shell thickness of both formulations is approximately 8 
µm. From the SEM images, the as-prepared microspheres for both formulations were fairly 
smooth with minimal surface pores (Fig. 4.3a and 4.3b). From the confocal images, doxorubicin 
was localized within the PLGA core, although microspheres having a high PDLLA molecular 
weight shell layer exhibited a better core-shell structure than those having a low PDLLA 
molecular weight shell layer (Fig. 4.4a(i) and 4.4a(ii)). 
 
Both microsphere formulations were further examined for their respective encapsulation 
efficiency and in vitro drug release profile. The encapsulation efficiency of doxorubicin in 
formulation A and B microspheres was 79.3 ± 1.5% and 80.0 ± 2.6%, respectively. The release 
profiles of doxorubicin for both formulations were similar (Fig. 4.5). Typically, the profiles 
showed a small initial burst (~2% for formulation A and ~10% for formulation B), before 
entering a lag phase of about 25 days. The drug subsequently released slowly (~55%) at nearly 
constant rate over a period of 100 days. It is interesting to note that the molecular weight of the 
PDLLA shell layer did not have a significant effect on the lag phase period and the subsequent 
drug release rate. These observations are not expected since slower polymer erosion rate and 
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hence slower water penetration rate are associated with the use of higher PDLLA molecular 
weight as the shell layer (Park et al., 1994). Consequently, it is predicted that formulation B 
microspheres would exhibit a longer lag phase period and a slower drug release rate than 
formulation A microspheres. In fact, the similar drug release behavior for both formulations is 
closely related to the degradation mechanism of these core-shell structured microspheres, and 
this phenomenon will be investigated in the next section. 
 
4.3.3. In vitro degradation study of double-walled PDLLA(PLGA) microspheres 
In an attempt to further examine the influence of the molecular weight of PDLLA shell layer on 
the drug release behavior, the degradation study of the microspheres was performed. From the 
drug release profiles, 26 days was determined to be the critical time point at which the drug 
release began. Thus, the degradation of the microspheres was monitored for a period of about 
nine weeks and analyzed using SEM, laser scanning confocal microscopy and GPC. The findings 
will be used to elucidate the underlying degradation mechanism and explain the similar drug 
release behavior for these microsphere formulations. 
 
4.3.3.1. Changes in surface morphology 
During degradation, surface defects such as pores and cavities are formed on the microspheres, 
and these features are important in evaluating the extent of water penetration. Fig. 4.3 presents 
visual evidence that the initial stage of the degradation process is characterized by water 
penetration into the microspheres and pore formation on the PDLLA shell layer. After 26 days of 
incubation, formulation A microspheres showed increase in surface roughness and presence of 
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numerous pores on the shell layer (Fig. 4.3c). Formulation B microspheres showed localized 
pore formation most likely due to slower PDLLA shell degradation (Fig. 4.3d). These surface 
defects formed by water penetration expand and extend into the PLGA core, leading to the 
formation of large cavities by 40 days. 
 
The next stage of the degradation process is characterized by fast erosion of the PLGA core and 
slow erosion of the PDLLA shell layer. By 40 days, formulation A microspheres showed 
continuous erosion of the PDLLA polymer, resulting in a high level of porosity that extends 
throughout the shell layer (Fig. 4.3g). Some large cavities were formed, resulting in the exposure 
of the PLGA core to the aqueous medium. Formulation B microspheres that showed localized 
pore formation continued to extend to a large cavity, resulting in the exposure of the PLGA core 
(Fig. 4.3h). The shell layer showed a slow erosion rate based on the level of porosity exhibited. 
By 47 days, formulation A microspheres showed a thin PDLLA shell layer that lacked the PLGA 
core (Fig. 4.3i). Formulation B microspheres showed bulk erosion of the PDLLA shell layer, 
leading to the formation of larger cavities (Fig. 4.3j). The PLGA core may be degraded partially 
or completely. Here, degradation proceeds faster internally than externally for the microspheres, 
likely due to internal build-up of acidic degradation products that catalyze the PLGA 
degradation, resulting in the formation of hollow microspheres. 
 
4.3.3.2. Changes in drug distribution 
Fig. 4.4 shows the confocal images and the fluorescence intensity profiles of doxorubicin for 
both microsphere formulations during the initial stage of the degradation process from 0 to 26 
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days. As mentioned, doxorubicin was initially localized within the PLGA core for both 
formulations (Fig. 4.4a(i) and 4.4a(ii)). Minimal or no fluorescence signal was detected for ~10 
μm from both ends of the microspheres (Day 0 profile in Fig. 4.4b and 4.4c), thus indicating a 
core-shell configuration. During 26 days of incubation, the fluorescence intensity profiles 
showed a gradual spread of fluorescence signal along the radial direction of the microspheres 
with time, from the core regions (Day 0 profile in Fig. 4.4b and 4.4c), into the shell layers, and 
then towards the external surfaces of the particles (Day 26 profile in Fig. 4.4b and 4.4c). The 
spread of fluorescence signal within the microspheres is consistent with the mass transfer of drug 
by diffusion via aqueous-filled pores. Despite the occurrence of outward drug diffusion from 
core regions as early as 12 days of incubation, the release of the drug was not detected in the 
release profiles (Fig. 4.5). Thus, during the lag phase period of 26 days, the PDLLA shell layer 
acts as an effective barrier preventing the premature release of the drug. After 26 days of 
incubation, fluorescence signal detected along the circumferential regions of the microspheres 
supports the commencement of drug release into the aqueous medium. 
 
4.3.3.3. Erosion extent of PDLLA and PLGA polymers 
Fig. 4.6 shows the transmitted light and confocal images for both microsphere formulations 
during the later stage of the degradation process from 33 to 40 days. In addition, a composite z-
stack consisting of five confocal sections of the same microspheres was captured to visualize the 
internal drug distribution three dimensionally, identify the locations of pores and/or cavities, and 
verify the erosion extent of PDLLA and PLGA polymers in the particles. After 33 days of 
incubation, optical images (Fig. 4.6a and 4.6b) reveal the presence of fluorescence-free cavities 
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within the microspheres and suggest that the PLGA core phase underwent partial degradation 
after significant water penetration. Here, formulation B showed more extensive cavity formation 
as compared to formulation A microspheres. In particular, the z-stack fluorescence images of 
formulation B microspheres after 33 days of incubation showed the presence of a cavity at the 
center plane (Fig. 4.6b, z-stack, center image) that extended continuously to the particle surface 
(Fig. 4.6b, z-stack, top image). After 40 days of incubation, both formulations showed multiple 
pore formation on the particle surface and significant degradation of the PLGA core. Intense 
fluorescence signal detected around the polymer region of the cavities is corroborative evidence 
of the eroded PLGA core (Fig. 4.6c and 4.6d). 
 
4.3.3.4. Changes in polymer molecular weight 
The degradation process was monitored by GPC, and the molecular weight profiles as a function 
of incubation time for both microsphere formulations are shown in Fig. 4.7. The initial weight-
averaged molecular weight of pure PLGA polymer (i.v. = 0.61 dL/g in HFIP) was measured to 
be about 46 kDa, while that of pure PDLLA polymer with i.v. 0.37 and 0.70 dL/g in chloroform 
was about 55 and 116 kDa, respectively. Thus, the initial double-walled microspheres before 
degradation (0.64:0.36 mass ratio of PDLLA:PLGA) would be expected to have a weight-
averaged molecular weight of 52 and 75 kDa for formulation A and B, respectively. As shown in 
Fig. 4.7a, the measured values of 42 and 74 kDa before degradation for formulation A and B, 
respectively, were in close agreement with the expected values. 
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Formulation A microspheres did not show appreciable change in weight-averaged molecular 
weight for the first 19 days, followed by a gradual decrease over the next 6 weeks (Fig. 4.7a). 
After 19 days of incubation, the average molecular weight decreased from 42 to 28 kDa (~67% 
of the initial value) by 47 days, to 17 kDa (~40%) by 54 days, and to only 11 kDa (~26%) by 61 
days. Increase in surface roughness and formation of numerous pores on the shell layer after 26 
days of incubation, as shown by SEM image in Fig. 4.3c, further supports the erosion of PDLLA 
polymer, and consequently a decrease in molecular weight in the following weeks of 
degradation. During degradation, distinct PDLLA and PLGA elution peaks were not observed as 
the molecular weights of PDLLA and PLGA polymers are comparable, and this makes tracking 
of individual polymer degradation difficult. 
 
Formulation B microspheres showed a similar trend in which the weight-averaged molecular 
weight remained relatively constant at 74 kDa for the first 19 days (Fig. 4.7a). The molecular 
weight then increased and peaked at 90 kDa after 33 days of incubation. After that, the molecular 
weight began to decrease to 40 kDa (~54% of the initial value) by 47 days, to 27 kDa (~36%) by 
54 days, and to only 12 kDa (~16%) by 61 days. Unlike formulation A microspheres, 
formulation B microspheres exhibited distinguishable PDLLA and PLGA elution peaks during 
19, 26 and 33 days of incubation (Fig. 4.7b). Here, the PLGA core showed rapid degradation 
between 19 and 33 days of incubation as estimated from the decrease in peak molecular weight 
from 51 to 8 kDa. On the other hand, the PDLLA shell only appeared to start degrading from 33 
days onwards, after PLGA has been degraded significantly. The peak at day 33 was due to the 
decrease in the amount of PLGA which led to an increase in the weight-averaged molecular 
  
106 
 
 
weight of the microspheres. Despite having a higher PDLLA molecular weight as the shell layer, 
a delayed decrease in molecular weight was not observed. Instead, the molecular weight 
decreased rapidly between 33 and 61 days of incubation. Significant bulk erosion of the PDLLA 
shell layer after 47 days of incubation as shown by SEM image in Fig. 4.3j further supports the 
rapid decrease in molecular weight. 
 
For both formulations, the microspheres reached a weight-averaged molecular weight of ~10 
kDa after 61 days of incubation (Fig 4.7a). Here, the degradation of the higher molecular weight 
PDLLA shell layer proceeded rapidly, and this could be attributed to the internal build-up of 
acidic degradation products of PLGA core that catalyze the degradation of the outer layer. 
However, for the lower molecular weight PDLLA shell layer, the acidic degradation products of 
PLGA core could be released into the aqueous medium more readily due to the porous surface, 
resulting in less accumulation of acidic degradation products. 
 
4.3.4. Drug release and degradation mechanism of double-walled PDLLA(PLGA) 
microspheres 
Given that most of the doxorubicin molecules were loaded in the PLGA core surrounded by a 
PDLLA shell layer for both microsphere formulations, a possible degradation mechanism for 
each formulation is proposed (Fig. 4.8). During the initial period of incubation from 0 to 26 days, 
the PDLLA shell layer was an effective barrier preventing the premature release of doxorubicin 
into the aqueous medium. This is despite the fact that drug diffusion was already occurring 
within the microspheres as early as 12 days of incubation, and no detectable drug was released 
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during the lag phase period of 26 days. By 26 days of incubation, formulation A microspheres 
were presented with numerous pore formation (Fig. 4.8a, Stage II), while formulation B 
microspheres were presented with localized pore formation on the shell layer (Fig. 4.8b, Stage 
II). Significant degradation of the PLGA cores accounted for the drug release after the lag phase 
period. By 40 days of incubation, formulation A microspheres exhibited high porosity and 
thinning of the shell layer (Fig. 4.8a, Stages III and IV), while formulation B microspheres 
exhibited large cavities and bulk erosion of the shell layer (Fig. 4.8b, Stages III and IV). During 
the later stage of the degradation process, the rapid degradation of the PDLLA shell layer no 
longer acts as an effective barrier for drug diffusion. The similar erosion time scale of PDLLA 
shell layers for both formulations is consistent with the similar drug release profile observed 
experimentally. 
 
4.4. Conclusions 
We report here a study of the drug release and degradation behavior of double-walled 
microspheres with a doxorubicin-loaded PLGA core surrounded by a PDLLA shell layer of 
different molecular weights. It was hypothesized that a higher molecular weight PDLLA shell 
layer could prevent water penetration into the inner drug-loaded core until a later time, and 
therefore control the drug release from the microspheres. The data presented herein show that 
different PDLLA molecular weights of the shell layer did not limit water penetration and 
formation of pores on the outer surface during the early stage of degradation. Water penetration 
into the microspheres resulted in the rapid erosion of the PLGA core inside the PDLLA shell 
within a time frame of about 40 days. Both microsphere formulations exhibited bulk erosion of 
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PDLLA on a similar time scale despite different PDLLA molecular weights. The molecular 
weight of the shell layer did not influence the subsequent drug release from the microspheres as 
evidenced by the release profiles obtained experimentally. The rate of water penetration, onset of 
surface pore formation and degradation rate of polymer core may be the critical factors affecting 
the drug release and degradation behavior of double-walled microspheres. 
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4.5. Figures 
 
 
 
Figure 4.1: Schematic diagram of precision particle fabrication apparatus for the production of uniform 
double-walled microspheres of controlled shell thickness. 
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Figure 4.2: Optical images depicting the surface morphology of double-walled PLLA(PLGA) 
microspheres for various microsphere samples listed in Table 4.1. Partial encapsulation was observed for 
samples A1, A2, B1, B2, and C1 to C3. Fully formed double-walled microspheres were observed in 
samples A3 and B3. Scale bar = 50 μm. 
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Figure 4.3: SEM images depicting the surface morphology of double-walled PDLLA(PLGA) 
microspheres with a low PDLLA molecular weight shell layer (formulation A) and a high PDLLA 
molecular weight shell layer (formulation B) at different stages of the degradation process. (a) and (b) are 
images of initial microspheres before degradation, (c) and (d) 26 days, (e) and (f) 33 days, (g) and (h) 40 
days, and (i) and (j) 47 days after degradation. The inserts show microspheres with pore or cavity 
formation. Scale bar = 50 µm. 
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Figure 4.4: Laser scanning confocal images and fluorescence intensity profiles depicting the distribution 
of doxorubicin in the double-walled PDLLA(PLGA) microspheres during the initial stage of the 
degradation process (0 to 26 days). (a(i)) and (a(ii)) are images of initial microspheres before degradation, 
(a(iii)) and (a(iv)) 12 days, and (a(v)) and (a(vi)) 26 days after degradation. Scale bar = 50 µm. (b) and (c) 
are the fluorescence intensity profiles of doxorubicin in representative microspheres of formulations A 
and B respectively. The inserts are the confocal images captured at the centerline of the microspheres, and 
the profile is based on the radial average fluorescence intensity from the center of the microsphere. 
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Figure 4.5: In vitro release of doxorubicin from double-walled PDLLA(PLGA) microspheres. 
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Figure 4.6: Laser scanning confocal images depicting the development of multiple pores and/or cavities in 
the double-walled PDLLA(PLGA) microspheres during the later stage of the degradation process (33 to 
40 days). A composite z-stack consisting of 5 confocal sections of the same microspheres was captured 
based on a z-interval of 12.5 μm between images measured above and below the center plane of the 
microspheres. (a) and (c) are the confocal images of formulation A microspheres after 33 and 40 days of 
degradation respectively. (b) and (d) are the confocal images of formulation B microspheres after 33 and 
40 days of degradation respectively. Scale bar = 50 μm. 
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Figure 4.7: Molecular weight profiles as a function of incubation time for double-walled PDLLA(PLGA) 
microspheres during degradation. (a) Weight-averaged molecular weight (Mw) profiles for formulations A 
and B microspheres. (b) Weight-averaged molecular weight (Mw) profile for formulation B microspheres 
together with the corresponding peak molecular weight (Mp) profiles of PDLLA and PLGA polymers 
from 19 to 33 days of degradation. 
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Figure 4.8: Schematic illustration of the proposed mechanism for the release of doxorubicin from double-
walled PDLLA(PLGA) microspheres. PLGA core and PDLLA shell layer are represented by light and 
dark brown respectively, while doxorubicin molecules are represented by green dots. (a) and (b) show the 
degradation process of formulations A and B microspheres respectively. Stage I: Initial microspheres 
before degradation. Stage II: Water penetration into the microspheres and pore formation on the PDLLA 
shell layer. Stage III: Increase in the number and size of pores on the PDLLA shell layer, and rapid 
erosion of the PLGA core. Stage IV: Release of doxorubicin into the aqueous medium through pores 
and/or cavities of the microspheres. 
  
117 
 
 
4.6. Tables 
 
Table 4.1: Summary of polymer concentrations and flow rates used to produce double-walled PLLA(PLGA) microspheres. The calculation of 
PLLA:PLGA mass ratio is based on the assumption that the volumes of polymer and solvent in the solution are additive. The following constant 
density values are used: ρPLLA = 1.34 g/cm3, ρPLGA = 1.24 g/cm3 and ρDCM = 1.33 g/cm3. 
 
Sample 
PLLA shell 
concentration 
(% (w/v)) 
PLGA core 
concentration 
(% (w/v)) 
PLLA shell 
flow rate 
(ml/h) 
PLGA core 
flow rate 
(ml/h) 
PLLA:PLGA 
polymer mass 
ratio 
Mean 
diameter (μm) 
Full PLGA 
encapsulation 
(Yes/No) 
A1 5 20 12 4 0.46:0.54 50.1 ± 3.6 No 
A2 5 20 24 4 0.63:0.37 57.2 ± 2.0 No 
A3 5 20 36 4 0.72:0.28 74.9 ± 4.2 Yes 
B1 5 30 12 4 0.37:0.63 49.2 ± 2.3 No 
B2 5 30 24 4 0.54:0.46 59.6 ± 3.6 No 
B3 5 30 36 4 0.64:0.36 66.1 ± 2.5 Yes 
C1 5 40 12 4 0.32:0.68 58.7 ± 1.6 No 
C2 5 40 24 4 0.49:0.51 65.6 ± 1.3 No 
C3 5 40 36 4 0.59:0.41 74.0 ± 2.7 No 
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CHAPTER 5 
COMBINED MODALITY DOXORUBICIN-BASED CHEMOTHERAPY 
AND CHITOSAN-MEDIATED P53 GENE THERAPY USING DOUBLE-
WALLED MICROSPHERES FOR TREATMENT OF HUMAN 
HEPATOCELLULAR CARCINOMA 
 
5.1. Introduction 
The tumor suppressor p53 is a transcriptional regulator that preserves genomic stability, and cells 
with p53 deficiencies accumulate DNA damage, while the abilities to activate cell cycle arrest 
and apoptosis are generally lost, favoring transformation into malignant cells (Whibley et al., 
2009; Millau et al., 2009). In addition, the loss of p53-mediated apoptosis significantly reduces 
the tumor response to many chemotherapeutics (Millau et al., 2009). Gene therapy is a promising 
strategy for cancer treatment (El-Aneed, 2004; Samaranayake et al., 2010). Recent attempts in 
correcting malfunctioning p53 gene through anticancer gene delivery have been reported to 
sensitize cancer cells towards anticancer drugs (Xu et al., 2001; Wiradharma et al., 2009; Lu et 
al., 2011). In one study, the simultaneous delivery of p53 gene and doxorubicin using an 
oligopeptide amphiphile carrier resulted in a synergistic cytotoxic effect towards a human 
hepatocarcinoma cell line (Wiradharma et al., 2009). Similarly, the co-delivery of p53 gene and 
doxorubicin using a cationic β-cyclodextrin-polyethylenimine carrier promoted the inhibition of 
breast tumor growth in vivo and prolonged the survival time of tumor-bearing mice (Lu et al., 
2011). Thus, the combination of gene therapy and chemotherapy may increase the therapeutic 
efficacy in the treatment of cancer patients. 
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The focus of this work is to develop a system capable of simultaneous delivery of a gene 
delivery vector and chemotherapeutic small molecule providing controlled and sustained release. 
Double-walled microspheres (Lee T.H. et al., 2002; Yang et al., 2003; Shi et al., 2003; Rahman 
and Mathiowitz, 2004; Berkland et al., 2004a, 2004b; Pollauf et al., 2005a, 2005b; Tan et al., 
2005; Zheng, 2009; Kokai et al., 2010a, 2010b; Choi et al., 2010; Nie et al., 2010a, 2010b; Lee 
W.L. et al., 2011) offer several advantages as compared to more conventional monolithic 
microspheres. Drug encapsulated in the core of double-walled microspheres may overcome the 
problem of high initial burst release commonly encountered in microspheres (Lee T.H. et al., 
2002; Rahman and Mathiowitz, 2004; Tan et al., 2005; Zheng et al., 2009). Higher drug loads 
with improved drug stability may be achieved by using materials in the core phase that offer 
increased drug solubility (Berkland et al., 2004b). Drug release rates may be controlled by 
controlling the shell material or thickness (Berkland et al., 2004a; Pollauf et al., 2005a). Finally, 
drugs can be released either in a sequential or simultaneous manner by selectively loading them 
into the core or shell phase, thereby potentially enhancing drug efficacy (Choi et al., 2010; Nie et 
al., 2010a, 2010b; Lee W.L. et al., 2011). 
 
We have reported the use of a precision particle fabrication (PPF) technique for fabrication of 
microspheres (Berkland et al., 2001), double-walled microspheres (Berkland et al., 2004a, 
2004b; Pollauf et al., 2005a, 2005b), and microcapsules (Berkland et al., 2007) with 
unprecedented control of the particle size and morphology. Here, we report the use of PPF to 
produce monodisperse double-walled microspheres loaded with Dox and gene delivery vectors 
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comprising chitosan and a plasmid DNA encoding p53 (chi-p53 nanoparticles) in the poly(D,L-
lactic-co-glycolic acid) (PLGA) core and poly(lactic acid) (PLA) shell phases, respectively. The 
aim is to evaluate the therapeutic efficiency of these microspheres in human hepatocellular 
carcinoma (HCC) HepG2 cells, which express wild-type p53. First, chi-DNA nanoparticles were 
characterized in terms of their particle size, zeta potential and degree of DNA condensation as 
well as transfection efficiency and cytotoxicity in HepG2 cells. The microspheres were further 
characterized for drug encapsulation, intraparticle distribution and in vitro release of these two 
drugs. Next, the therapeutic efficiencies of delivering Dox and/or chi-p53 as free drug or 
microsphere formulations were compared and evaluated in terms of growth inhibition, and 
cellular expression of tumor suppressor p53 and apoptotic caspase 3 proteins. Growth inhibition 
was determined by cell viability assay, while expressions of p53 and caspase 3 were analyzed by 
enzyme-linked immunosorbent assay (ELISA) and immunofluorescence staining of treated cells. 
 
5.2. Materials and Methods 
5.2.1. Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA) copolymer (50:50 lactic acid:glycolic acid; inherent 
viscosity (i.v.) = 0.61 dL/g in hexafluoroisopropanol), poly(D,L-lactic acid) (PDLLA) (i.v. = 
0.37 and 0.70 dL/g in chloroform) and poly(L-lactic acid) (PLLA) (i.v. = 1.05 dL/g in 
chloroform) were purchased from Lactel Absorbable Polymers (Pelham, AL). Poly(vinyl 
alcohol) (PVA) (Mw = 25,000 Da), 88 mol% hydrolyzed, was purchased from Polysciences, Inc. 
(Warrington, PA). Doxorubicin, in the form of hydrochloride salt with more than 99% purity, 
was purchased from LC Laboratories (Woburn, MA). Medium molecular weight chitosan (Mw = 
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190,000 - 310,000 Da) with degree of deacetylation of 75 - 85% and polyethylenimine (PEI, 
branched, Mw = 25,000 Da) were purchased from Sigma-Aldrich Corp. (St. Louis, MO). Plasmid 
DNA (pCMV-pRL) of 4.1 kb size encoding Renilla luciferase protein driven by CMV promoter 
was obtained from Promega Corp. (Madison, WI). Plasmid DNA (pCMV-p53) of 5.2 kb size 
encoding tumor suppressor wild-type p53 protein driven by CMV promoter was obtained from 
Clontech Laboratories, Inc. (Mountain View, CA). Plasmid DNA of 2.7 kb size labeled with 
CyTM3 (pCy3) was obtained from Mirus Bio LLC (Madison, WI). Dichloromethane (DCM), 
HFIP, sodium acetate and sodium sulfate were acquired from Sigma-Aldrich Corp. Phosphate-
buffered saline (PBS) with a pH of 7.4 was acquired from Mediatech, Inc. (Manassas, VA). 
 
5.2.2. Synthesis and characterization of chi-DNA nanoparticles 
5.2.2.1. Preparation of plasmid DNA 
The pCMV-pRL and pCMV-p53 plasmid DNA were amplified in Escherichia coli DH5α cells 
and purified using the HiSpeed Plasmid Maxi Kit (Qiagen, Inc.; Valencia, CA). The DNA 
concentration was quantified by using the Quant-iT PicoGreen dsDNA Kit (Molecular Probes, 
Inc.; Eugene, OR). 
 
5.2.2.2. Preparation of chi-DNA nanoparticles 
Chi-DNA nanoparticles were formed according to a previously reported technique (Mao et al., 
2001). A chitosan solution in 5 mM sodium acetate buffer, pH 5.5, and a DNA solution (5 mM 
sodium sulfate solution, pH 7.0) were preheated to 50 - 55°C separately. Equal volumes of both 
solutions were quickly mixed and vortexed for 30 s. The final volume of the mixture in each 
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preparation was limited to less than 500 μl in order to yield uniform nanoparticles. Chi-DNA 
nanoparticles with different N/P ratios were prepared by varying the amount of polymer added to 
a constant amount of plasmid DNA. Chi-p53 nanoparticles loaded in the double-walled 
microspheres were prepared at amine to phosphate ratio (N/P ratio) of seven. 
 
5.2.2.3. Particle size of chi-DNA nanoparticles 
Particle size measurements of chi-DNA nanoparticles were performed by dynamic light 
scattering (DLS), using a 90Plus particle size analyzer (Brookhaven Instruments Corp.; 
Holtsville, NY), at 25°C with a scattering angle of 90°. The nanoparticles were diluted in equal 
volume of 5 mM sodium acetate buffer and 5 mM sodium sulfate solution before measurement. 
Each sample was analyzed in ten cycles (30 s for each cycle). The data were expressed as mean 
and standard deviation of three replicate samples. 
 
5.2.2.4. Zeta potential of chi-DNA nanoparticles 
Zeta potential measurements of chi-DNA nanoparticles were performed with dilution in equal 
volume of 5 mM sodium acetate buffer and 5 mM sodium sulfate solution, using a Nicomp 380 
ZLS (Particle Sizing Systems; Santa Barbara, CA). The measurements were performed at 25°C 
with a scattering angle of 14.7° and electric field strength of 2.5 V/cm. Each sample was 
analyzed in five cycles (60 s for each cycle). The data were expressed as mean and standard 
deviation of three replicate samples. 
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5.2.2.5. Morphology of chi-DNA nanoparticles 
The morphological examination of chi-DNA nanoparticles was performed using a JEOL 2100 
Cryo transmission electron microscope (TEM) (JEOL Ltd.; Tokyo, Japan) operated at 200 kV to 
achieve a high image resolution. All images were recorded digitally using a Gatan UltraScan 2k 
x 2k CCD (Gatan, Inc.; Warrendale, PA). 
 
5.2.2.6. Gel retardation assay of chi-DNA nanoparticles 
The binding efficiency of chitosan with DNA was determined by agarose gel electrophoresis. A 
series of chi-DNA nanoparticles of various N/P ratios, prepared as described above, were loaded 
into the wells of a 1% agarose gel in Tris-acetate-EDTA (TAE) buffer. A 1:6 dilution of loading 
dye was added to each well and electrophoresis was carried out at a constant voltage in TAE 
buffer. The agarose gel was later soaked in ethidium bromide solution before visualizing the 
DNA bands under an ultraviolet transilluminator. Images were acquired using a gel-doc system 
(Bio-Rad Laboratories, Inc.; Hercules, CA). 
 
5.2.3. Synthesis and characterization of Dox- and/or chi-p53-loaded double-walled 
microspheres 
5.2.3.1. Preparation of Dox- and/or chi-p53-loaded double-walled microspheres 
Solutions of 30% (w/v) PLGA and 5% (w/v) PLA in DCM were passed through a coaxial nozzle 
to produce a jet of core PLGA surrounded by an annular stream containing PLA, protected by a 
0.5% (w/v) PVA carrier stream, and disrupted into uniform double-walled droplets by an 
ultrasonic transducer controlled by a frequency generator. The droplets were collected in 0.5% 
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(w/v) PVA, stirred continuously for ~2 h, filtered, and rinsed with an equal volume of distilled 
water. The microspheres were freeze-dried and sterilized using ethylene oxide before performing 
in vitro cell culture experiments. 
 
For microspheres loaded with Dox, 1.2 ml of 50 mg/ml Dox in water was emulsified with 10 ml 
of PLGA/DCM solution using a Model 500 Sonic Dismembrator (Thermo Fisher Scientific, Inc.; 
Pittsburgh, PA) at 30% amplitude in an ice bath for 90 s to form a stable emulsion. For 
microspheres loaded with chi-p53, chi-p53 nanoparticles were prepared as described above and 1 
ml containing 200 μg of DNA was emulsified with 10 ml of PLA/DCM solution. These 
emulsions were then used for fabrication of double-walled microspheres using PPF as described 
above. PLGA microspheres loaded with Dox only were also fabricated by using a single nozzle 
in the PPF technique. 
 
5.2.3.2. Microscopy 
The double-walled microspheres were examined using an Invertoskop inverted microscope (Carl 
Zeiss Microscopy LLC; Thornwood, NY). Images were captured using Digital Microscope Suite 
software. The surface morphology of the double-walled microspheres was examined using a 
JEOL JSM-6060LV scanning electron microscope (SEM) (JEOL Ltd.; Tokyo, Japan). The 
microspheres were placed directly onto a SEM sample holder coated with conductive carbon 
tape and sputter-coated with gold palladium prior to imaging at 10 kV. The intraparticle 
distributions of Dox and/or chi-DNA were examined using a TCS SP2 laser scanning confocal 
microscope (Leica Microsystems GmbH; Wetzlar, Germany). To visualize chi-DNA, chi-DNA 
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nanoparticles were prepared with pCMV-p53 and fluorescently labeled pCy3 plasmid DNA 
(Mirus Bio LLC; Madison, WI) at 9:1 (w/w) ratio before preparing the microspheres. Samples 
were imaged using a 40× oil-immersion objective with 1.25 numerical aperture. Dox was excited 
with an argon laser at 488 nm, and the fluorescence emission was collected at 500 to 545 nm. 
The pCy3 plasmid DNA was excited with a helium-neon laser at 543 nm, and the fluorescence 
emission was collected at 545 to 600 nm. Optical cross-sections were taken at various depths for 
each sample in order to determine drug distribution at the centerline of the microspheres. Images 
were captured using Leica confocal software. The fluorescence intensity profiles were obtained 
using ImageJ software. 
 
5.2.3.3. Fourier transform infrared spectroscopy 
Fourier transform infrared (FTIR) spectroscopy was performed using a Thermo Nicolet Nexus 
670 spectrophotometer (Thermo Electron Corp.; Madison, WI) based on the diffuse reflectance 
spectroscopy method in order to verify the polymer comprising the shell phase of the double-
walled microspheres. FTIR spectra were recorded in a frequency range of 4000 to 800 cm-1, with 
a resolution of 0.25 cm-1 and 32 scans per spectrum, and were processed using OMNIC software. 
 
5.2.3.4. Drug loading 
The drug loading was determined by dissolving ~50 mg of microspheres in 1 ml of 
hexafluoroisopropanol. The samples were allowed to stand until complete dissolution of the 
polymers, added to 5 ml of dilute acetic acid and incubated at 37°C for 1 h. To measure Dox 
concentration, the aqueous supernatant was transferred in triplicate to a 96-well plate, and the 
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absorbance was analyzed using a SpectraMax 340PC spectrophotometer (Molecular Devices 
LLC; Sunnyvale, CA) at a wavelength of 480 nm. To measure DNA concentration in the 
supernatant, chitosan was digested with chitosanase and lysozyme at 37°C for 4 h. The DNA 
concentration was determined by using the Quant-iT PicoGreen dsDNA Kit in triplicate, and the 
fluorescence was analyzed using a Cary Eclipse fluorescence spectrophotometer (Varian, Inc.; 
Palo Alto, CA) at excitation and emission wavelengths of 480 and 520 nm, respectively. 
 
5.2.3.5. Integrity of pCMV-p53 plasmid DNA 
Agarose gel electrophoresis was performed to determine the integrity of pCMV-p53 plasmid 
DNA extracted from double-walled microspheres. Approximately 50 mg of microspheres were 
dissolved in 0.5 ml of DCM, added to 0.5 ml of PBS, incubated at 37°C for 1 h, and centrifuged 
at 10,000 rpm for 10 min. A portion of the aqueous supernatant was digested with chitosanase 
and lysozyme as described above. Samples were mixed with loading dye before loading in a 1% 
(w/v) agarose gel in TAE buffer. Naked pCMV-p53 plasmid DNA was loaded as control. 
Electrophoresis was carried out as described in Section 5.2.2.6. 
 
5.2.3.6. In vitro drug release 
Approximately 150 mg of microspheres was suspended in 5 ml PBS in centrifuge tubes. The 
tubes were maintained at 37°C with shaking at 240 rpm. At selected time points, the tubes were 
centrifuged at 10,000 rpm for 10 min before 1 ml of supernatant was collected and 1 ml of fresh 
PBS was replaced. To measure Dox concentration, supernatant fluorescence was analyzed at 
excitation and emission wavelengths of 480 and 590 nm, respectively. To measure DNA 
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concentration, the supernatant was digested with chitosanase and lysozyme, and analyzed by the 
Quant-iT PicoGreen dsDNA Kit. 
 
5.2.4. Cell culture and maintenance 
The cell line used was HepG2 cells (ATCC Number: HB-8065TM) and was derived from the liver 
tissue of a 15 year old Caucasian American male with a well differentiated hepatocellular 
carcinoma. The cells were cultured in growth medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco; Life Technologies Corp.; Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS) (HyClone; Thermo Fisher Scientific, Inc.; Logan, UT) and 1% penicillin-
streptomycin (PAN-Biotech GmbH; Aidenbach, Germany) in a humidified incubator under the 
conditions of 37°C and 5% CO2. After reaching confluence, the cells were prepared by washing 
with PBS and detached from the flask with trypsin-EDTA (PAA Laboratories GmbH; Pasching, 
Austria). 
 
5.2.5. In vitro gene expression 
To determine the efficiency of chitosan to induce gene expression in HepG2 cells, the Renilla 
luciferase reporter gene (pCMV-pRL) was used to form chi-pRL nanoparticles at various N/P 
ratios. Briefly, cells were seeded onto 96-well plates at a density of 12,000 cells per well, and 
cultivated in 100 μl of DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. 
After 48 h, the culture medium was replaced with 50 μl of either fresh DMEM without FBS or 
DMEM with 10% FBS, and 50 μl of nanoparticle solution containing 0.2 μg of pCMV-pRL 
plasmid DNA added to each well. Cells transfected with naked DNA were used as a negative 
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control while cells transfected with PEI-pRL nanoparticles formed at an N/P ratio of 10, the 
optimum N/P ratio at which PEI induced the highest gene expression in the absence of FBS, 
were employed as a positive control. After 6 h of incubation, the cells were washed once with 
PBS, replaced with growth medium, and grown for another 42 h. The gene expression was then 
determined using a Renilla Luciferase Assay System (Promega Corp.; Madison, WI). The culture 
medium was removed, and the cells were washed once with PBS, before 50 μl of lysis buffer was 
added to each well to lyse the cells. After 15 min, 20 μl of cell lysate was mixed with 100 μl of 
luciferase substrate. The relative light units (RLU) were measured using a luminometer (Lumat 
LB9507; Berthold Technologies GmbH & Co. KG; Bad Wildbad, Germany) and normalized to 
protein content measured using a Coomassie Plus (Bradford) Protein Assay (Thermo Fisher 
Scientific, Inc.; Rockford, IL). The data were expressed as mean and standard deviation of nine 
replicates. 
 
5.2.6. Cytotoxicity of polymeric gene carriers 
The cytotoxic effects of chitosan and PEI on HepG2 cells were determined using a MTT cell 
viability assay. Briefly, cells were seeded onto 96-well plates at a density of 12,000 cells per 
well. After 48 h, the culture medium was replaced with 50 μl of fresh DMEM with 10% FBS and 
50 μl of either chitosan or PEI solutions of various concentrations that correspond to N/P ratios 
of 1, 3, 5, 7, 10, 13, 15 and 20 (based on 0.2 μg of plasmid DNA) added to each well. For 
chitosan, the corresponding concentration was 2.4, 7.3, 12.2, 17.1, 24.4, 31.7, 36.6 and 48.8 
μg/ml at each N/P ratio. For PEI, the corresponding concentration was 3.1, 9.4, 15.6, 21.9, 31.3, 
40.7, 46.9 and 62.5 μg/ml at each N/P ratio. The untreated cells were used as a control. After 6 h 
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of incubation, the cells were washed once with PBS, replaced with growth medium, and grown 
for another 42 h. The cell viability was then determined using a CellTiter 96® Non-Radioactive 
Cell Proliferation Assay (Promega Corp.; Madison, WI). The culture medium was removed, and 
the cells were washed once with PBS. After that, 100 μl of growth medium and 15 μl of dye 
solution were added to each well, and the cells were further incubated for 4 h. During the 4 h 
incubation, the living cells would convert the tetrazolium component of the dye solution into a 
formazan product. Following that, 100 μl of solubilization solution was added to each well, and 
the plate was incubated at 37°C overnight to completely solubilize the formazan product. The 
absorbance was measured at 570 nm with a reference wavelength of 650 nm. The cell viability 
was calculated as [([Abs570]sample - [Abs650]sample) / ([Abs570]control - [Abs650]control)] × 100%. The 
data were expressed as mean and standard deviation of nine replicates. 
 
5.2.7. Delivery of drug and/or gene 
5.2.7.1. Cytotoxicity of Dox and/or chi-p53 
To examine the viability of HepG2 cells resulting from short-term exposure to Dox and/or chi-
p53, cells were seeded onto 96-well plates at a density of 12,000 cells per well and grown for 48 
h. For Dox treatment, the cells were treated with 100 μl of Dox (1, 5 and 10 μg/ml) for 3 h. For 
chi-p53 treatment, the cells were treated with 100 μl of chi-p53 (N/P ratio of 7; 50 μl of DMEM 
with 10% FBS and 50 μl of nanoparticle solution containing 0.2 μg of plasmid DNA) for 6 h. 
The N/P ratio of 7 was chosen based on the optimal N/P ratio to induce the highest luciferase 
expression. For combined Dox and chi-p53 treatment, the cells were first treated with 100 μl of 
chi-p53 (N/P ratio of 7; 50 μl of DMEM with 10% FBS and 50 μl of nanoparticle solution 
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containing 0.2 μg of plasmid DNA) for 3 h, before 100 μl of Dox was added to form a final drug 
concentration of 2, 4, 8 and 10 μg/ml. The cells with the Dox and chi-p53 mixture were then 
incubated for another 3 h. The untreated cells were used as a control. After the respective 
treatments, the cells were washed once with PBS, replaced with growth medium, and grown for a 
total of 48 h, before the cell viability was determined. The data were expressed as mean and 
standard deviation of nine replicates. 
 
To examine the long-term cytotoxic effect of Dox- and/or chi-p53-loaded double-walled 
microspheres, cells were seeded onto 24-well plates at a density of 75,000 cells per well. After 
48 h, the culture medium was replaced with 0.5 ml of fresh growth medium containing various 
microspheres. The microsphere groups included a control group (blank microspheres), a drug 
treated group (Dox microspheres), a gene treated group (chi-p53 microspheres), and a combined 
drug and gene treated group (Dox and chi-p53 microspheres). The Dox microspheres were first 
suspended in PBS, incubated at 37°C with shaking at 240 rpm for 26 days, before they were 
centrifuged, washed using PBS and resuspended in growth medium for cytotoxicity study. 
Equivalent amounts of free Dox and/or chi-p53 corresponding to their amounts released from the 
microspheres after five days from in vitro release profiles were administered as free drug groups. 
In particular, for Dox treatment, the cells were treated with 0.5 ml of Dox (0.9 µg/ml) for 3 h. 
For chi-p53 treatment, the cells were treated with 0.5 ml of chi-p53 (N/P ratio of 7; 0.25 ml of 
DMEM with 10% FBS and 0.25 ml of nanoparticle solution containing 1 µg of plasmid DNA) 
for 6 h. For combined Dox and chi-p53 treatment, the cells were first treated with 0.5 ml of chi-
p53 (N/P ratio of 7; 0.25 ml of DMEM with 10% FBS and 0.25 ml of nanoparticle solution 
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containing 1 µg of plasmid DNA) for 3 h, before 0.5 ml of Dox was added to form a final drug 
concentration of 0.9 µg/ml. The cells with the Dox and chi-p53 mixture were then incubated for 
another 3 h. The untreated cells were used as a control. After the respective treatments in the free 
drug groups, the cells were washed once with PBS, replaced with growth medium, and further 
incubated. The cell viability for all the groups was determined one, three and five days after the 
commencement of treatment. The data were expressed as mean and standard deviation of four 
replicates. 
 
5.2.7.2. In vitro expression of p53 and caspase 3 
After the short-term or long-term treatments described in Section 5.2.7.1, the cellular expression 
of p53 and caspase 3 was evaluated by using a Pierce® Colorimetric In-Cell ELISA Kit (Thermo 
Fisher Scientific, Inc.; Rockford, IL). Briefly, the cells were fixed for 15 min using 4% 
methanol-free formaldehyde, permeabilized for 15 min using 0.1% Triton X-100, quenched for 
endogenous peroxidase for 20 min using 1% hydrogen peroxide, and blocked for non-specific 
sites for 1 h using blocking buffer. The cells were incubated with either anti-p53 or anti-cleaved 
caspase 3 antibody overnight, washed and detected using a horseradish peroxidase (HRP)-
conjugated reagent. Subsequently, the cells were washed after 1 h of incubation, before color 
reaction was achieved using tetramethylbenzidine (TMB substrate) and stopped using acid 
solution (TMB stop solution). The absorbance was measured at 450 nm. Cells treated with all 
reagents except the primary antibody were used as a control to account for non-specific signals. 
Whole-cell staining of the cells was also performed using Janus Green solution to control for 
differences in cell plating, and the absorbance was measured at 615 nm. The expression levels 
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were calculated as ([Abs450]sample - [Abs450]control) / [Abs615]sample and normalized to the respective 
control groups. The data were expressed as mean and standard deviation of three replicates. 
 
5.2.7.3. Immunofluorescence staining of p53 and caspase 3 
To examine the cellular expression of p53 and caspase 3 using laser scanning confocal 
microscope, cells were seeded onto 24-well plates with glass cover slips (75,000 cells per well) 
and grown for 48 h, before receiving the respective treatments described in Section 5.2.7.1. The 
immunofluorescence staining of p53 and caspase 3 in the cells was performed by using 
Cellomics® p53 Detection Kit (Thermo Fisher Scientific, Inc.; Rockford, IL) and Caspase 3 
Activation Kit (Thermo Fisher Scientific, Inc.; Rockford, IL), respectively. Briefly, the cells 
were fixed for 15 min using 4% methanol-free formaldehyde, permeabilized for 15 min using 
0.1% Triton X-100, and blocked for non-specific sites for 15 min using blocking buffer. The 
cells were incubated with either p53 or caspase 3 primary antibody, washed, and stained with 
Hoechst dye and DyLightTM 549 conjugated goat anti-rabbit IgG secondary antibody. The cells 
were washed before the cover slips were mounted onto microscope slides and visualized using a 
Fluoview FV1000 laser scanning confocal microscope (Olympus Corp.; Tokyo, Japan) equipped 
with diode and helium-neon lasers tuned to 405 and 543 nm, respectively. Briefly, cells were 
visualized using a 60x water-immersion objective with 1.00 numerical aperture and under the 
following calibrations: 4.0 μs/pixel sampling speed, line Kalman integration, 405 nm laser 
(Hoechst) at 449 V with transmissivity of 1.0%, and 543 nm laser (DyLightTM 549) at 807 V 
with transmissivity of 20.0% for p53 and at 686 V with transmissivity of 20.0% for caspase 3. 
The fluorescence emission of the Hoechst dye was collected at 430 to 470 nm. The fluorescence 
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emission of the DyLightTM 549 dye was collected at above 560 nm. The parameters were used 
for all the samples to ensure consistency. Confocal images were captured using Olympus 
Fluoview software. 
 
5.2.8. Statistical analysis 
The comparison of means of multiple groups was done by one-way ANOVA followed by Tukey 
post hoc test, whereas two groups were compared by Student’s t-test. Differences were 
considered statistically significant when p < 0.05. 
 
5.3. Results 
5.3.1. Chi-DNA nanoparticles 
5.3.1.1. Synthesis and characterization of chi-DNA nanoparticles 
Chitosan is a linear polysaccharide which consists of randomly distributed 2-N-acetyl-2-deoxy-
glucose (N-acetyl-glucosamine) and 2-amino-2-deoxy-glucose (glucosamine) residues with β-
1,4-linkage. The primary amine of chitosan has a pKa value of ~6.5 (Liu et al., 2005). Thus, at 
pH 5.5, most of the amino groups will be protonated, and hence solubilizing chitosan in acidic 
solution, while at physiological pH, most of the positive charges will be neutralized, and the 
hydrophobic chitosan becomes insoluble. This unique property ensures that nanoparticles formed 
at low pH can remain physically stable at physiological pH (Mao et al., 2001). Furthermore, the 
hydrophobic nature of the nanoparticles at neutral pH suggests that chi-DNA nanoparticles may 
offer an effective protection to the encapsulated DNA from nuclease attack (Mao et al., 2001). 
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The N/P, amine-to-phosphate, ratio describes the molar quantities of positively-charged polymer 
and negatively-charged DNA in the formation of nanoparticle complex. This parameter affects 
the complex size and overall charge which are critical factors in the cellular uptake of 
nanoparticles. The size of chi-pRL nanoparticles was ~160 nm, and decreased slightly with 
increasing N/P ratio from 1 to 13 (Fig. 5.1a). The zeta potential of chi-pRL nanoparticles was 
slightly positive, which increased gradually from ~1.8 to 9.2 mV with increasing N/P ratio from 
1 to 13 (Fig. 5.1a). The TEM image further confirmed the presence of chi-pRL nanoparticles 
(Fig. 5.1b). The degree of DNA condensation by chitosan was verified by gel retardation assay 
(Fig. 5.2). The electrophoretic mobility of DNA was completely retarded and condensed by 
chitosan at N/P ratios 3 and above. This indicates that chitosan could bind with DNA effectively. 
Overall, the small size and net positive charge of the chi-DNA nanoparticles may provide 
desirable properties for cellular uptake and gene delivery. 
 
5.3.1.2. In vitro gene expression 
In determining the optimal N/P ratio for gene delivery, the transfection efficiency of chi-pRL 
nanoparticles was evaluated in HepG2 cells. As shown in Fig. 5.3, chitosan mediated the highest 
transfection efficiency of ~1.4 x 104 RLU/µg protein at an N/P ratio of 7. The luciferase 
expression was enhanced by ~19-fold in the presence of serum than without serum. The 
luciferase expression induced by chitosan was not comparable to that mediated by 25-kDa 
branched PEI, which was higher by ~34-fold. However, with ~220-fold higher luciferase 
expression than naked DNA, the results validate the applicability of chitosan as an effective 
carrier for gene delivery. 
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5.3.1.3. Cytotoxicity of polymeric gene carriers 
The cytotoxicity effects of chitosan and PEI of various concentrations that correspond to N/P 
ratios from 1 to 20 were evaluated in HepG2 cells. As shown in Fig. 5.4, chitosan remained non-
toxic even at high concentrations, and results were consistent with other reported studies (Mao et 
al., 2001). In contrast, PEI showed an inverse relationship between polymer concentration and 
cell viability. Thus, despite its high transfection efficiency, the inherent toxicity of PEI limits its 
clinical applications (Kircheis et al., 1999; Ogris et al., 1999). 
 
In comparison to chitosan, PEI could induce high gene expression. This has been attributed to its 
high buffering capacity, especially at the acidic pH found in the endosomal vesicles, which leads 
to trapping of positive ions by the amines (proton sponge effect), followed by subsequent 
endosomal rupture and escape into the cytoplasm (Köping-Höggård et al., 2001). While positive 
charges can facilitate cellular uptake by electrostatic interaction with negatively-charged cell 
membrane, PEI’s positive charge density is one critical factor that is thought to contribute to 
cytotoxicity (Fischer D. et al., 2003). Though the mechanism is not fully understood, it has been 
demonstrated that polycations can cause significant membrane damage (Choksakulnimitr et al., 
1995). The minimal cytotoxicity effect of chitosan shows its suitability for repeated or long-term 
administration of chi-DNA nanoparticles for gene delivery. 
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5.3.2. Double-walled microspheres 
5.3.2.1. Fabrication and characterization of double-walled microspheres 
An important advantage of the PPF technique is the capability of producing monodispersed 
double-walled microspheres with uniform shell thickness by varying the flow rates of core and 
shell polymer solutions. Moreover, microspheres with two agents loaded in the respective core 
and shell phases can be fabricated in a single step, and the agents can be released either in a 
sequential or parallel manner. In this study, the PPF technique was used to produce double-
walled microspheres loaded with Dox and chi-p53 nanoparticles in the PLGA core and PLA 
shell phases, respectively. 
 
For double-walled microsphere fabrication, a solution of PLGA (30% (w/v) in DCM) was 
arranged as the core stream while PLA (5% (w/v) in DCM) flowed as the annular stream. Three 
different molecular weights of PLA (i.v. = 0.37, 0.70 and 1.05 dL/g) were used to form the shell 
layer. The particle diameter ranged between 65 and 75 μm (Table 5.1). The shell thickness, 
calculated from the measured overall particle diameter and known mass flow rates of the 
polymer solutions assuming complete polymer phase separation, was ~8 to 17 μm. For blank 
double-walled PLA(PLGA) microspheres, the ratio of core diameter (Dcore) to overall particle 
diameter (Dparticle) is related to the volume fraction of PLGA in the microsphere as shown in 
Equation 3.17. 
 
For drug loaded double-walled PLA(PLGA) microspheres with the creation of water-in-oil 
emulsion in core and/or shell phase(s), Equation 3.17 is modified to include the pore volume 
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originally occupied by the water phase that contributed to the total volume of the microsphere as 
shown below. 
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where vwater,core and vwater,shell are the flow rates of water in the core and shell phases respectively 
(cm3 of water/h), xwater,core and xwater,shell are the volume fractions of water in the core and shell 
solutions respectively, and Vwater,core and Vwater,shell are the volume ratios of water to DCM used to 
create the emulsion in the core and shell solutions respectively. 
 
Then, the shell thickness (tshell) can be calculated in the same way using Equation 3.19. 
 
Particles containing chi-p53 nanoparticles in the shell were slightly larger than those without chi-
p53, which may be attributed to the emulsion that formed the shell phase (Table 5.1). While the 
core diameter of various microsphere formulations was comparable to one another, the shell 
thickness of particles containing chi-p53 nanoparticles was larger than those without chi-p53. In 
this case, the water/organic volume ratio of the chi-p53 emulsion is 1/10. However, the organic 
phase is 5% (w/v) polymer. Thus, the volume of pores resulting from the aqueous phase is on the 
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order of the volume of polymer after solvent removal. The presence of the emulsion then roughly 
doubles the volume of the polymer shell, which explains the increase in shell thickness observed. 
 
Optical micrographs suggest that fully formed double-walled microspheres were produced in all 
the formulations, with no sign of partial or incomplete encapsulation (Fig. 5.5). FTIR 
spectroscopy was used to investigate the polymer composition of the particle surfaces (Fig. 5.6). 
The FTIR spectra of PLA and PLGA produced distinguishable spectra between 1300 and 1500 
cm-1. In particular, PLA exhibited a C-H bending vibration of methyl group at 1391 and 1463 
cm-1 while PLGA showed a C-H bending vibration of methyl group at 1402 and 1462 cm-1, and 
an additional C-H vibration of methylene group at 1431 cm-1. The spectrum of PLA showed a 
CH2 wagging mode, and a mixture of C-H and O-H bending modes associated with PVA at 1371 
and 1441 cm-1, respectively. The microspheres thus appear to contain traces of PVA, the non-
solvent carrier stream used for droplet breakup and solvent extraction. The spectra of blank 
double-walled microspheres also showed the corresponding peaks associated with PVA.  In 
comparison to the spectra of PLA and PLGA microspheres, the spectra of double-walled 
microspheres showed a broad peak at ~1380 to 1410 cm-1 that appears to result from a mixture of 
the corresponding PLA (1391 cm-1) and PLGA (1402 cm-1) peaks. This indicates that the shell 
phase of the blank double-walled microspheres may contain both PLA and PLGA. 
 
Blank and Dox-loaded microspheres (formulations A and B) typically exhibited smooth 
morphology with relatively few small pores on the surface (Fig. 5.7). On the other hand, 
microspheres encapsulating chi-p53 nanoparticles or combined Dox and chi-p53 nanoparticles 
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(formulations C and D) presented a rough and porous surface structure, likely due to the presence 
of the chi-p53 emulsion in the shell layer. In fact, the emulsion in the shell phase appeared to 
have a significant effect on the drug distribution, initial burst release of drug and subsequent drug 
release rates (see below). 
 
Distinct core-shell particles, encapsulating Dox in the core were produced with high molecular 
weight of the PLA shell layer (i.v. = 0.70 and 1.05 dL/g) (Fig. 5.5f, 5.5j and 5.8d, 5.8g). On the 
other hand, microspheres containing low molecular weight PLA shell (i.v. = 0.37 dL/g) exhibited 
irregular Dox distributions (Fig. 5.8a). For formulation C microspheres, chi-p53 fluorescence 
was present mainly at the particle periphery, corresponding to the PLA shell (Fig. 5.8b, 5.8e, 
5.8h). For formulation D microspheres, Dox was homogeneously distributed throughout the 
microsphere (Fig. 5.8c, 5.8f, 5.8i). However, chi-p53 remained near the particle edge, similar to 
that for formulation C microspheres. 
 
In order to load Dox and chi-p53 in PLGA core and PLA shell phases, respectively, a water-in-
oil emulsion of drug in polymer/DCM solution was created in each phase. During the DCM 
extraction process, the water phases created in both core and shell phases of the PLA(PLGA) 
droplets may spread and coalesce, resulting in the diffusion of Dox and chi-p53 into the 
neighboring phase. Since Dox is a hydrophilic drug, the presence of a water-in-oil emulsion in 
the shell phase may facilitate Dox diffusion from the PLGA core into the PLA shell layer. Thus, 
Dox was homogeneously distributed in formulation D microspheres, resulting in co-localization 
of Dox and chi-p53 in the shell layer. 
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5.3.2.2. Encapsulation efficiency of doxorubicin and chi-p53 nanoparticles 
To investigate the effect of the PLA shell, PLGA microspheres loaded with Dox (formulation E) 
were fabricated with particle diameter of 50 μm corresponding to the approximate diameter of 
the PLGA core encapsulated within the double-walled microspheres. The encapsulation 
efficiency of Dox in double-walled PLA(PLGA) microspheres (formulation B, ~80%; Table 5.1) 
was higher than that in single-polymer PLGA microspheres (formulation E, 61%). Thus, it 
appears that the presence of the PLA shell layer inhibits the premature release of Dox into the 
PVA solution during DCM extraction. However, the encapsulation efficiency of Dox decreased 
(~32 to 47%) when the drug was loaded together with chi-p53 nanoparticles. The emulsion 
created in the PLA shell phase likely facilitated the diffusion of Dox out of the microspheres 
during DCM extraction. The encapsulation efficiency of chi-p53 nanoparticles for formulations 
C and D microspheres was similar (~25 to 37%). The rather low encapsulation efficiency of chi-
p53 nanoparticles could be due to the exposure of the PLA shell phase emulsion to the PVA 
solution during DCM extraction. Overall, the encapsulation efficiency of Dox and chi-p53 
nanoparticles was observed to improve with increasing molecular weight of the PLA shell layer. 
 
5.3.2.3. Integrity of plasmid DNA encapsulated within microspheres 
Agarose gel electrophoresis was performed to determine the integrity of pCMV-p53 plasmid 
DNA complexed with chitosan within the double-walled PLA(PLGA) microspheres (formulation 
C; Fig. 5.9). No bands were observed for chi-p53 nanoparticles extracted from PLA(PLGA) 
particles, indicating that chitosan effectively bound plasmid DNA. After enzymatic digestion of 
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chitosan to release the plasmid DNA, the observed bands matched those of the unencapsulated 
pCMV-p53. This indicates that the plasmid DNA retained its structure through particle 
fabrication, solvent extraction and freeze-drying processes. 
 
5.3.2.4. In vitro release of doxorubicin and chi-p53 nanoparticles 
For formulation B microspheres, release of Dox showed a small initial burst (~2 to 10%) before 
entering a lag phase of about 25 days (Fig. 5.10a). The drug was subsequently released slowly 
over a period of ~100 days. On the other hand, when chi-p53 was present in the shell 
(formulation D), release of Dox exhibited a larger initial burst (~18 to 29%) before entering a lag 
phase of about 25 days (Fig. 5.10c) followed by slow release at a relatively constant rate. The 
release profiles of chi-p53 nanoparticles were similar regardless of Dox content (Fig. 5.10b, 
5.10d). The nanoparticles were released quickly over the first week and then at a decreased rate 
over a period of 120 days. The initial burst of Dox and chi-p53 varied inversely with PLA 
molecular weight. However, the molecular weight of the PLA shell layer had a minimal effect on 
the subsequent release rates of Dox and chi-p53. 
 
5.3.3. Free drug (FD) formulations 
5.3.3.1. Cytotoxicity of Dox and/or chi-p53 
Fig. 5.11 shows the growth inhibition of HepG2 cells from combined Dox and chi-p53 FD 
treatment in comparison to that from Dox FD or chi-p53 FD treatment. The IC50 of Dox, 
inhibitory concentration at which 50% of the cells are killed, was found to decrease from ~4.5 
µg/ml upon Dox FD treatment to ~1.6 µg/ml upon combined Dox and chi-p53 FD treatment. In 
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the presence of chi-p53, the IC50 of Dox could potentially be lowered by ~3-fold to achieve a 
comparable growth inhibition of cells. 
 
5.3.3.2. Expression of p53 from free drug treatments 
Fig. 5.12a shows the expression of tumor suppressor p53 protein at 6, 24 and 48 h after the start 
of free drug treatments. HepG2 cells are known to express wild-type p53 gene, and the changes 
in expression level resulting from the treatments were reported with reference to the basal level 
by normalizing to the control group. For each treatment, elevated p53 expression was observed at 
24 h. By 48 h, cells treated with combined Dox and chi-p53 FD resulted in a higher p53 
expression than those treated with Dox FD or chi-p53 FD. The expression level of p53 from 
combined Dox and chi-p53 FD treatment was significantly higher than that from Dox FD 
treatment (p = 0.006), chi-p53 FD treatment (p = 0.005) or untreated cells (p = 0.002). 
Immunofluorescence staining of p53 was also performed at 48 h (Fig. 5.12b). Minimal p53 was 
expressed by untreated cells. The p53 was expressed in all treated cells, and lowest number of 
cells was showed by Dox FD, and combined Dox and chi-p53 FD treatments. 
 
5.3.3.3. Expression of caspase 3 from free drug treatments 
Fig. 5.13a shows the expression of apoptotic caspase 3 protein at 6, 24 and 48 h after the start of 
free drug treatments. Since cleavage of caspase 3 occurs during apoptosis, the expression of 
cleaved caspase 3 is expected to be indicative of cells prepared for imminent apoptosis and 
reflective of cellular cytotoxicity. The changes in expression level resulted from the treatments 
were reported with reference to the basal level by normalizing to the control group. Caspase 3 
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was expressed at 6 h shortly after each treatment, with the highest shown by combined Dox and 
chi-p53 FD-treated cells. The expression level of caspase 3 from combined Dox and chi-p53 FD 
treatment was significantly higher than that from untreated cells (p = 0.025). 
Immunofluorescence staining of caspase 3 was also performed at 6 h (Fig. 5.13b). No caspase 3 
was expressed in untreated cells. Significant caspase 3 was expressed in combined Dox and chi-
p53 FD-treated cells. 
 
5.3.4. Microsphere (MS) formulations 
Results indicated that combined Dox and chi-p53 FD treatment achieved greater therapeutic 
efficiency than either Dox FD or chi-p53 FD treatment. Due to the short and acute exposure of 
free drugs, expression of p53 and caspase 3 occurred over a limited time period. Thus, the 
combined treatment could greatly benefit from the controlled and sustained release of 
microspheres. In this study, formulation D microspheres were used to examine their cytotoxicity 
effect, and the expression of p53 and caspase 3 in HepG2 cells. The Dox MS were first 
suspended in PBS for 26 days to bypass the lag phase so that in combination with the chi-p53 
MS, they could deliver Dox (0.9 μg/ml) and chi-p53 (1.0 μg DNA) simultaneously over a five-
day period of study. Free drugs delivering equivalent amounts of Dox and chi-p53 were used as 
controls for comparison. 
 
5.3.4.1. Cytotoxicity of Dox- and/or chi-p53-loaded microspheres 
Fig. 5.14 shows the viability of HepG2 cells at one, three and five days after the treatment with 
Dox and/or chi-p53 either as free drug or microsphere formulations. For chi-p53 groups, cells 
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treated with chi-p53 FD showed ~100% viability the day after treatment. Although cell viability 
decreased to ~84% after three days, cellular recovery was observed after five days. On the other 
hand, no significant change in cell viability was observed in cells treated with chi-p53 MS. The 
cell viability decreased to ~90% after five days. For Dox groups, there was greater cytotoxicity 
effect than chi-p53 groups. While Dox FD-treated cells showed a decrease in viability to ~85% 
three days post-treatment, the Dox MS-treated cells displayed a more drastic drop to ~45%. 
Further antiproliferative effects resulted in ~82 and 21% viability after five days for Dox FD-
treated and Dox MS-treated cells, respectively. For combined Dox and chi-p53 groups, cell 
viability immediately declined to ~88% one day after combined Dox and chi-p53 FD treatment. 
The decline continued to ~73%, and then to ~65% after three and five days, respectively. In 
contrast, cells treated with combined Dox and chi-p53 MS showed a decrease in viability from 
~94, to 41, and then to only 15% after one, three and five days, respectively. 
 
Overall, the antiproliferative effect was more substantial in cells treated with microspheres than 
those treated with free drugs. The difference in cell viability between microsphere and free drug 
treatments was most significant after five days when the equivalent doses were achieved in 
microsphere groups. Regardless of whether the cells were treated with free drugs or 
microspheres, the combination of Dox and chi-p53 produced greater cytotoxicity than either of 
the treatments alone. This implies that there is an apparent advantage of combined Dox and chi-
p53 treatment. Taken together, the combined Dox and chi-p53 treatment by means of 
microspheres produced the greatest antiproliferative effect. 
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5.3.4.2. Expression of p53 from microsphere treatments 
Fig. 5.15 shows the expression level of p53 in HepG2 cells at one, three and five days after the 
treatment with Dox and/or chi-p53 either as free drug or microsphere formulations. Cells treated 
with chi-p53 FD or chi-p53 MS did not show any significant increase in p53 expression. Only 
slight elevation in p53 expression was detected in chi-p53 MS-treated cells the day after 
treatment. For treatments with Dox or in combination with chi-p53, the free drug groups likewise 
had no appreciable increase in p53 expression. On the other hand, immediate upregulation of p53 
by ~3-fold could be observed one day after treatment with either Dox MS or combined Dox and 
chi-p53 MS. While a slight dip was observed on the third day, p53 expression levels remained 
high at ~2-fold greater than that of the control group. On the fifth day, p53 expression level in 
combined Dox and chi-p53 MS-treated cells was higher than that in Dox MS-treated cells, 
resulting in ~3.8-fold and 2.9-fold higher than that of the control group, respectively. 
 
For free drug groups, p53 expression was observed one day after treatment, particularly for Dox 
FD-treated, and combined Dox and chi-p53 FD-treated cells as shown in Fig. 5.12, but it was not 
reflected in Fig. 5.15. The p53 expression in Dox FD-treated, and combined Dox and chi-p53 
FD-treated cells may be dependent on the dose of Dox used. On the other hand, the continual 
cellular exposure to Dox contributed by the sustained release of microspheres was able to 
stabilize high levels of p53 expression over the five-day period. In addition, combined Dox and 
chi-p53 MS-treated cells demonstrated significantly higher p53 expression than Dox MS-treated 
cells, suggesting that the enhanced expression was contributed by the chitosan-mediated delivery 
of p53 plasmid DNA into the cells. 
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5.3.4.3. Expression of caspase 3 from microsphere treatments 
Fig. 5.16 shows the expression level of caspase 3 in HepG2 cells at one, three and five days after 
the treatment with Dox and/or chi-p53 either as free drug or microsphere formulations. Cells 
treated with chi-p53 FD or chi-p53 MS did not show any significant increase in caspase 3 
expression. Conversely, elevated levels were detected in cells treated with Dox. Dox FD-treated 
cells showed at most ~1.4-fold higher caspase 3 expression than the control group by the fifth 
day, while combined Dox and chi-p53 FD-treated cells showed a further increase from ~1.4-fold 
on the third day to ~1.7-fold on the fifth day. In contrast, cells treated with microspheres 
demonstrated faster and greater caspase 3 activation. An immediate ~1.5-fold higher caspase 3 
expression than the control group was first observed the day after treatment, after which the level 
continued to increase to ~2.2-fold and 1.9-fold for Dox MS-treated, and combined Dox and chi-
p53 MS-treated cells, respectively. Though there was a slight decline in caspase 3 expression on 
the fifth day for Dox MS-treated cells, the level remained relatively high at ~1.9-fold. On the 
other hand, caspase 3 expression continued to increase to ~2.4-fold for combined Dox and chi-
p53 MS-treated cells. 
 
Unlike the caspase 3 expression profiles exhibited by the free drug groups shown in Fig. 5.13, 
the delayed expression in Dox-treated cells in Fig. 5.16 may be due to the lower cellular 
accumulation of Dox, and hence, slow induction of apoptosis. Similar to the p53 expression 
profiles, further enhancement in caspase 3 expression was achieved in combined Dox and chi-
p53 MS-treated cells as compared to that in Dox MS-treated cells. This indicates that the 
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combined Dox and chi-p53 MS treatment induces greater apoptotic activation, which is likely to 
be facilitated by the correspondingly high p53 expression. Furthermore, the caspase 3 expression 
profiles are in agreement with the cytotoxicity analysis. 
 
5.3.4.4. Immunofluorescence staining of p53 from microsphere treatments 
Fig. 5.17 shows the immunofluorescence staining of p53 in HepG2 cells one, three and five days 
after free drug and microsphere treatments. Apart from the occasional fluorescent spots, the 
intensity of p53 expression in Dox FD-treated or combined Dox and chi-p53 FD-treated cells 
was generally low (Fig. 5.17a to 5.17c, Panels N and T). On the other hand, the corresponding 
intensity in Dox MS-treated or combined Dox and chi-p53 MS-treated cells was brighter and 
more uniform across the cluster of cells (Fig. 5.17a to 5.17c, Panels Q and W), with the highest 
exhibited by combined Dox and chi-p53 MS-treated cells on the fifth day (Fig. 5.17c, Panel W). 
The results were consistent with the p53 expression profiles in Fig. 5.15. 
 
During DNA damage, p53 gets imported into the nucleus, undergoes tetramerization (el-Deiry et 
al., 1992), and binds and activates DNA damage-response genes (Jimenez et al., 1999). It was 
found that the type of treatment influenced the cellular localization of p53. For Dox FD-treated 
cells, nuclear localization of p53 was observed on the first day, but by the fifth day, the protein 
was found mainly in the cytoplasm rather than in the nuclei (Fig. 5.17a to 5.17c, Panels O and 
U). In contrast, for Dox MS-treated, and combined Dox and chi-p53 MS-treated cells, nuclear 
localization of p53 was observed during the five-day period (Fig. 5.17a to 5.17c, Panels R and 
X). Since active p53 functions in the nuclei during DNA damage, this explains the higher p53-
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mediated apoptotic signaling, and hence, higher cytotoxicity for the microsphere groups (Fig. 
5.14). 
 
5.3.4.5. Immunofluorescence staining of caspase 3 from microsphere treatments 
Fig. 5.18 shows the immunofluorescence staining of caspase 3 in HepG2 cells one, three and five 
days after free drug and microsphere treatments. Similar to the p53 staining, the intensity of 
caspase 3 expression in cells treated with free drugs was generally low with only sporadic spots 
of high intensity (Fig. 5.18a to 5.18c, Panels N and T). In contrast, the intensity in Dox MS-
treated or combined Dox and chi-p53 MS-treated cells was brighter and more widespread (Fig. 
5.18a to 5.18c, Panels Q and W), with the highest exhibited by combined Dox and chi-p53 MS-
treated cells on the fifth day (Fig. 5.18c, Panel W). The results were consistent with the caspase 3 
expression profiles in Fig. 5.16. 
 
As a critical apoptosis executioner, caspase 3 becomes activated and then enters into the nucleus 
to cleave its nuclear substrates (Kamada et al., 2005; Takemoto et al., 2003), resulting in 
characteristic apoptotic nuclear changes such as DNA fragmentation, chromatin condensation 
and nuclear disruption (Earnshaw et al., 1999; Fischer U. et al., 2003; Sahara et al., 1999). 
Particularly, for the combined Dox and chi-p53 treatment, a majority of the cells were 
abnormally-shaped, and had shrunken and strongly-stained nuclei (Fig. 5.18c, Panel X). 
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5.4. Discussion 
The use of combination therapies has been proven effective for the treatment of cancer. While 
chemotherapeutic drugs are usually associated with undesirable side effects, the administration 
of multiple agents directed at different targets and exhibiting different toxicity profiles can 
enhance the therapeutic index either in the form of better efficacy or in the form of comparable 
efficacy and reduced toxicity (Greco and Vicent, 2009). Among various combination therapies, 
studies on chemotherapy and p53 gene therapy are of particular interest (Wiradharma et al., 
2009; Lu et al., 2011). In this study, the aim is to evaluate the therapeutic efficiency of Dox 
and/or chi-p53 when released in a controlled and sustained manner from double-walled 
microspheres, and to compare them with those from free drugs. 
 
It is evident that free drug administration can only provide a short and acute cytotoxicity effect 
on the cancer cells. Cellular recovery was observed five days post-treatment with free Dox, free 
chi-p53, or their combination (Fig. 5.14) while the extent of apoptosis from caspase 3 expression 
was relatively weak (Fig. 5.16). These observations are indicative of the possible limitations in 
systemic administration of drugs and are consistent with what is observed in clinical practice 
(Nie et al., 2010a, 2010b). The microsphere formulations, on the other hand, can potentially 
impose greater cytotoxicity or use lower dosage of drug to achieve a comparable cytotoxicity 
level in the cancer cells. Notably, on the third day before the prescribed dose of Dox was 
reached, there was already more than 50% decrease in cell viability after Dox MS or combined 
Dox and chi-p53 MS treatment (Fig. 5.14). By the fifth day, the viability of cells treated with 
Dox MS or combined Dox and chi-p53 MS was significantly lower than those treated with free 
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drugs (Fig. 5.14). Similar findings were observed in other cancer cells treated with drug-loaded 
microspheres (Muvaffak et al., 2004; Lin et al., 2005). 
 
Dox is a common drug used in the management of HCC that causes DNA damage by 
intercalating with the base pairs of DNA and inhibiting nucleic acid replication (Momparler et 
al., 1976; Hortobágyi, 1997), and kills cancer cells mainly by apoptosis (Lee T.K. et al., 2002). 
Increased production of reactive oxygen species is also associated with Dox-treated cells (Tsang 
et al., 2003). These cellular stresses can activate p53 and halt cell cycle progression. Here, the 
continual exposure of cancer cells to Dox via microspheres could produce a long-term stressful 
environment and enable significantly higher and sustainable p53 expression than free Dox (Fig. 
5.15). The upregulation of endogenous p53 in Dox-treated cells has a critical role in apoptosis 
because of its involvement in DNA damage-induced G1 arrest, apoptosis (Clarke et al., 1993; 
Lotem and Sachs, 1993; Lowe et al., 1993b), and DNA repair (Bakalkin et al., 1994). The 
appearance of the G1 arrest parallels p53 nuclear accumulation (Lee T.K. et al., 2002). The arrest 
is believed to allow DNA repair to maintain chromosomal fidelity for survival (Hartwell, 1992). 
Although the upregulation of p53 does not always induce apoptosis (Slee et al., 2004), the 
corresponding trend of increasing caspase 3 expression was observed over the five-day 
incubation with Dox MS (Fig. 5.16). Similar trends of cellular apoptosis were observed for other 
drug-loaded microspheres (Nie et al., 2010a, 2010b). 
 
The p53 gene is frequently mutated in HCC, and most HCCs have defects in the p53-mediated 
apoptotic pathway although they carry wild-type p53 (Guan et al., 2007). The effective 
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restoration of the p53 function could allow reestablishment of normal cell growth control and 
restore appropriate response to chemotherapeutic drugs (Lowe et al., 1993b, 1994; Galmarini et 
al., 2001, 2002). It is proposed that Dox-mediated apoptosis may be further enhanced if p53 
expression is promoted. Chi-p53 promoted growth inhibition when combined with Dox, 
regardless of the type of formulation (Fig. 5.14). Analysis of p53 expression suggests that the 
higher level in combined Dox and chi-p53 MS-treated cells than that in Dox MS-treated cells on 
the fifth day was contributed by the exogenous p53 plasmid DNA from chitosan nanoparticles 
(Fig. 5.15). The higher p53 expression also resulted in a higher caspase 3 expression in the 
combined Dox and chi-p53 MS-treated cells than that in the Dox MS-treated cells on the fifth 
day (Fig. 5.16). 
 
Chitosan was shown to be effective in delivering the plasmid DNA and inducing luciferase 
expression in HepG2 cells (Fig. 5.3). However, when the luciferase gene was replaced with the 
p53 gene, an expected increase in p53 expression could not be detected (Fig. 5.15), most likely 
because p53 expression is tightly regulated by MDM2 (murine double minute 2) (Millau et al., 
2009; Whibley et al., 2009). In normal unstressed cells, p53 is an unstable protein with a short 
half-life that exists at very low cellular levels owing to continuous degradation largely mediated 
by MDM2. Hence, in the event of over-expression of p53 under unstressed conditions, MDM2 
will facilitate its degradation back to the basal level. Conversely, the presence of Dox-induced 
DNA damage can lead to rapid stabilization of p53 via a block of its degradation. 
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Here, we make use of the advantages of double-walled microspheres to allow a simultaneous 
release of Dox and chi-p53 at near zero-order rates. Zero-order release rates are advantageous 
because a constant quantity of drug is being delivered with respect to time. If drug elimination is 
also at the same constant rate, the drug concentration can, in theory, be maintained within the 
ideal therapeutic window for maximum efficacy. Overall, we demonstrated that the simultaneous 
delivery of Dox and chi-p53 at near zero-order rates via double-walled microspheres was able to 
enhance growth inhibition, provide sustained p53 expression and increase apoptotic effect in 
HepG2 cells. 
 
5.5. Conclusions 
In this study, several formulations of double-walled PLA(PLGA) microspheres loaded with Dox 
and/or chi-p53 nanoparticles have been fabricated and characterized as potential agents for 
combined gene therapy and chemotherapy. The drug loaded microspheres exhibited an early 
release of chi-p53 nanoparticles from the PLA shell layer, followed by a sustained release of Dox 
from the PLGA core. The simultaneous delivery of Dox and chi-p53 through sustained release 
from double-walled microspheres achieved a higher therapeutic efficiency in suppressing 
proliferation of HepG2 cells when compared to Dox- or chi-p53-loaded microspheres, or the 
corresponding free drugs. Moreover, cellular expression of tumor suppressor p53 and apoptotic 
caspase 3 proteins was maintained at elevated levels during the treatment period. These findings 
suggest that double-walled microspheres can be an effective carrier to deliver drug and gene 
simultaneously for improved cancer therapy. 
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5.6. Figures 
 
 
 
Figure 5.1: (a) Particle size and zeta potential of chi-pRL nanoparticles. Particle sizes for chi-pRL 
nanoparticles with N/P ratios from 1 to 13 were plotted as a column chart. Zeta potentials for DNA 
solution and chi-pRL nanoparticles with N/P ratios from 1 to 13 were plotted as a line chart. Data 
represent mean ± standard deviation, n = 3. (b) Transmission electron micrograph of chi-pRL 
nanoparticles. Scale bar = 100 nm. 
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Figure 5.2: Gel retardation assay of chi-pRL nanoparticles to determine the binding efficiency of chitosan 
with DNA. Lane 1 contains 1 kb DNA ladder. Lane 2 contains naked DNA. Lanes 3 to 10 contain chi-
pRL nanoparticles with N/P ratios 1, 3, 5, 7, 10, 13, 15 and 20, respectively. All samples were 
electrophorezed on a 1% agarose gel, stained with ethidium bromide solution and visualized under a 
ultraviolet transilluminator. 
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Figure 5.3: Expression of luciferase in HepG2 cells after transfection with chi-pRL nanoparticles in the 
absence and presence of serum at various N/P ratios from 1 to 20. The relative light units (RLU) were 
normalized to protein content. Data represent mean ± standard deviation, n = 9. 
 
 
 
 
Figure 5.4: Viability of HepG2 cells after incubation with chitosan or PEI polymer solutions of various 
concentrations that correspond to various N/P ratios from 1 to 20. Data represent mean ± standard 
deviation, n = 9. 
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Figure 5.5: Transmitted light and laser scanning confocal (overlay) micrographs depicting blank and drug 
loaded double-walled PLA(PLGA) microspheres. The distribution of doxorubicin in formulations B and 
D microspheres is indicated in green. The distribution of chi-p53 nanoparticles in formulations C and D 
microspheres is indicated in red and yellow (colocalization of red and green), respectively. Scale bar = 50 
μm. 
 
 
 
 
Figure 5.6: FTIR spectra of blank double-walled PLA(PLGA) microspheres (formulation A) in 
comparison to those of pure PLGA and PLA microspheres. 
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Figure 5.7: Scanning electron micrographs depicting the surface morphology of blank and drug loaded 
double-walled PLA(PLGA) microspheres. Scale bar = 50 μm. 
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Figure 5.8: Radially averaged fluorescence intensity profiles of doxorubicin and/or chi-p53 nanoparticles 
in representative double-walled PLA(PLGA) microspheres. The inserts are the confocal images captured 
at the centerline of the microspheres. (a), (d) and (g) are the profiles of doxorubicin (green) for 
formulation B microspheres with increasing molecular weights of PLA shell layer, i.v. = 0.37, 0.70 and 
1.05 dL/g, respectively. (b), (e) and (h) are the profiles of chi-p53 nanoparticles (red) for formulation C 
microspheres with increasing molecular weights of PLA shell layer, i.v. = 0.37, 0.70 and 1.05 dL/g, 
respectively. (c), (f) and (i) are the profiles of doxorubicin (green) and chi-p53 nanoparticles (yellow) for 
formulation D microspheres with increasing molecular weights of PLA shell layer, i.v. = 0.37, 0.70 and 
1.05 dL/g, respectively. 
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Figure 5.9: Agarose gel electrophoresis of chi-p53 nanoparticles extracted from double-walled 
PLA(PLGA) microspheres (formulation C). Lane 1: naked pCMV-p53 plasmid DNA. Lanes 2 to 4: chi-
p53 nanoparticles, N/P = 7, from microspheres with increasing molecular weights of PLA shell layer, i.v. 
= 0.37, 0.70 and 1.05 dL/g, respectively, before chitosanase and lysozyme digestion. Lanes 5 to 7: chi-
p53 nanoparticles, N/P = 7, from microspheres with increasing molecular weights of PLA shell layer, i.v. 
= 0.37, 0.70 and 1.05 dL/g, respectively, after chitosanase and lysozyme digestion. 
  
160 
 
 
 
 
Figure 5.10: In vitro doxorubicin and chi-p53 release from double-walled PLA(PLGA) microspheres: (a) 
doxorubicin from formulation B microspheres, (b) chi-p53 nanoparticles from formulation C 
microspheres, (c) doxorubicin from formulation D microspheres, and (d) chi-p53 nanoparticles from 
formulation D microspheres. 
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Figure 5.11: Comparison of combined Dox and chi-p53 FD treatment with Dox FD or chi-p53 FD 
treatment on growth inhibition of HepG2 cells. Data represent mean ± standard deviation, n = 9. 
 
 
 
 
Figure 5.12: (a) Expression of p53 in HepG2 cells at 6, 24 and 48 h after commencement of treatment. 
The cells were either untreated or treated with Dox FD (IC50, 2 µg/ml) and/or chi-p53 FD (0.2 µg DNA). 
The absorbance values were normalized to cell number, followed by normalizing to the control group. 
Data represent mean ± standard deviation, n = 5. Statistical significance (*p < 0.05) was determined by 
one-way ANOVA analysis as compared to the control, while (**p < 0.05) was determined by Student's t-
test comparison between the two samples. (b) Immunofluorescence staining of p53 in HepG2 cells at 48 h 
after commencement of treatment. Scale bar = 50 µm. 
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Figure 5.13: (a) Expression of caspase 3 in HepG2 cells at 6, 24 and 48 h after commencement of 
treatment. The cells were either untreated or treated with Dox FD (IC50, 2 µg/ml) and/or chi-p53 FD (0.2 
µg DNA). The absorbance values were normalized to cell number, followed by normalizing to the control 
group. Data represent mean ± standard deviation, n = 5. Statistical significance (**p < 0.05) was 
determined by Student's t-test comparison between the two samples. (b) Immunofluorescence staining of 
caspase 3 in HepG2 cells at 6 h after commencement of treatment. Scale bar = 50 µm. 
 
 
Figure 5.14: Viability of HepG2 cells at one, three and five days after commencement of treatment. The 
groups include blank and free drug (FD) groups (blank, chi-p53 FD, Dox FD, and combined Dox and chi-
p53 FD) as well as blank and drug-loaded microsphere (MS) groups (blank MS, chi-p53 MS, Dox MS, 
and combined Dox and chi-p53 MS). The free drug groups represent equivalent amount(s) of Dox (0.9 
μg/ml) and/or chi-p53 (1 μg DNA) released from the drug-loaded microsphere groups after five days 
determined from in vitro release profiles. Data represent mean ± standard deviation, n = 4. Statistical 
significance (*p < 0.05) was determined by one-way ANOVA analysis as compared to the control group, 
while (**p < 0.05) was determined by Student's t-test comparison between the two samples. 
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Figure 5.15: Expression of p53 in HepG2 cells at one, three and five days after commencement of 
treatment. The groups include blank and free drug (FD) groups (blank, chi-p53 FD, Dox FD, and 
combined Dox and chi-p53 FD) as well as blank and drug-loaded microsphere (MS) groups (blank MS, 
chi-p53 MS, Dox MS, and combined Dox and chi-p53 MS). The free drug groups represent equivalent 
amount(s) of Dox (0.9 μg/ml) and/or chi-p53 (1 μg DNA) released from the drug-loaded microsphere 
groups after five days determined from in vitro release profiles. The absorbance values were normalized 
to cell number, followed by normalizing to the respective control groups. Data represent mean ± standard 
deviation, n = 3. Statistical significance (*p < 0.05) was determined by one-way ANOVA analysis as 
compared to the control group, while (**p < 0.05) was determined by Student's t-test comparison between 
the two samples. 
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Figure 5.16: Expression of caspase 3 in HepG2 cells at one, three and five days after commencement of 
treatment. The groups include blank and free drug (FD) groups (blank, chi-p53 FD, Dox FD, and 
combined Dox and chi-p53 FD) as well as blank and drug-loaded microsphere (MS) groups (blank MS, 
chi-p53 MS, Dox MS, and combined Dox and chi-p53 MS). The free drug groups represent equivalent 
amount(s) of Dox (0.9 μg/ml) and/or chi-p53 (1 μg DNA) released from the drug-loaded microsphere 
groups after five days determined from in vitro release profiles. The absorbance values were normalized 
to cell number, followed by normalizing to the respective control groups. Data represent mean ± standard 
deviation, n = 3. Statistical significance (*p < 0.05) was determined by one-way ANOVA analysis as 
compared to the control group, while (**p < 0.05) was determined by Student's t-test comparison between 
the two samples. 
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Figure 5.17: Immunofluorescence staining of p53 in HepG2 cells at (a) one day, (b) three days, and (c) 
five days after commencement of treatment. The groups include blank and free drug groups as well as 
blank and drug-loaded microsphere groups. The cell nuclei were stained by Hoechst dye and indicated in 
blue. The p53 was stained by DyLightTM 549 dye and indicated in red. Scale bar = 50 µm. 
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Figure 5.17 (cont.) 
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Figure 5.18: Immunofluorescence staining of caspase 3 in HepG2 cells at (a) one day, (b) three days, and 
(c) five days after commencement of treatment. The groups include blank and free drug groups as well as 
blank and drug-loaded microsphere groups. The cell nuclei were stained by Hoechst dye and indicated in 
blue. The caspase 3 was stained by DyLightTM 549 dye and indicated in red. Scale bar = 50 µm. 
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Figure 5.18 (cont.) 
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5.7. Tables 
 
Table 5.1: Sizes and encapsulation efficiencies of double-walled PLA(PLGA) microspheres. 
 
Formulation Drug 
PLA i.v. = 0.37 dL/g PLA i.v. = 0.70 dL/g PLA i.v. = 1.05 dL/g Avg  
size 
(μm) 
Core 
diameter 
(μm) 
Shell 
thickness 
(μm) Size (μm) E.E. (%) Size (μm) E.E. (%) Size (μm) E.E. (%) 
A Blank 64.5 ± 4.3 - 65.2 ± 4.0 - 62.3 ± 3.7 - 64.0 46.2 8.9 
B Dox 63.6 ± 4.5 79.3 ± 1.5 64.5 ± 4.2 80.0 ± 2.6 65.2 ± 2.9 82.8 ± 1.5 64.4 49.4 7.5 
C Chi-p53 71.9 ± 3.6 24.7 ± 2.1 73.5 ± 3.7 32.5 ± 1.7 72.2 ± 4.1 36.8 ± 1.1 72.5 38.7 16.9 
D 
Dox 
74.1 ± 3.6 
32.3 ± 0.6 
72.1 ± 3.6 
40.5 ± 2.1 
74.5 ± 3.7 
46.8 ± 0.7 
73.6 42.8 15.4 
Chi-p53 27.0 ± 2.2 32.6 ± 1.6 36.8 ± 1.4 
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
 
For the first study, the motivation is to construct a CFD model for the CEHDA process so that it 
could be used to predict the production of consistent compound droplets, and hence, the expected 
double-walled microspheres obtained experimentally. Process conditions, including nozzle 
voltage and polymer solution flow rates, as well as solution parameters, such as polymer 
concentrations, were investigated to ensure the formation of double-walled microspheres with a 
doxorubicin-loaded PLGA core surrounded by a relatively drug-free PDLLA shell layer. 
Numerical simulation of CEHDA process was performed using the CFD model in Fluent by 
employing the process conditions and fluid properties used in the experiments. Overall, the 
particle size, core diameter and shell thickness predicted from the simulated compound droplets 
compare well with those obtained experimentally, although the predicted sizes overestimate the 
sizes of the microspheres that were obtained experimentally. 
 
One important assumption for the comparison to be valid requires the polymer solutions to be 
dilute so that the physical properties of polymer solutions, such as density, viscosity, electrical 
permittivity and surface tension, are similar to those of pure solvent. The viscosity of polymer 
solution, for instance, increases with the polymer concentration, and this may influence the cone-
jet formation and droplet breakup process. More studies need to be conducted to test the 
applicability of the CFD model when the polymer is present in the organic solvent. Besides, for 
both experimental and simulation work, the core and shell fluids were based on the same organic 
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solvent, and comparative similar polymer solutions with similar physical properties were used. 
The applicability of the CFD model may also be tested for different liquid or polymer solution 
combinations. 
 
For the second study, the drug release and degradation behavior of two double-walled 
microsphere formulations consisting of a doxorubicin-loaded PLGA core (~46 kDa) surrounded 
by a PDLLA shell layer (~55 and 116 kDa) were examined. It was postulated that different 
molecular weights of the shell layer could modulate the erosion of the outer coating and limit the 
occurrence of water penetration into the inner drug-loaded core on various time scales, and 
therefore control the drug release from the microspheres. For both microsphere formulations, the 
drug release profiles were observed to be similar. The degradation of the microspheres was 
monitored for a period of about nine weeks and analyzed using scanning electron microscopy, 
laser scanning confocal microscopy, and gel permeation chromatography. Interestingly, both 
microsphere formulations exhibited occurrence of bulk erosion of PDLLA on a similar time 
scale despite different PDLLA molecular weights forming the shell layer. The shell layer of the 
double-walled microspheres served as an effective diffusion barrier during the initial lag phase 
period and controlled the release rate of the hydrophilic drug independent of the molecular 
weight of the shell layer. 
 
Water penetration into the microspheres resulted in the rapid erosion of the PLGA core inside the 
PDLLA shell within a time frame of about 40 days. The rapid erosion of PLGA could be 
explained by the internal generation of acidic degradation products that catalyze the erosion 
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process. Microspheres may tend to be a closed system and as degradation products cannot freely 
diffuse out of the microsphere matrix, a shift towards an acidic microclimate inside the eroding 
microspheres can be assumed (Brunner et al., 1999). The changes in pH and osmotic pressure 
inside eroding microspheres can be monitored to explain the rapid erosion of PLGA core within 
the double-walled microspheres. The degradation behavior of PLGA and PDLLA polymers can 
also be explained by changes in their glass transition temperatures that could be measured using 
differential scanning calorimetry (Houchin and Topp, 2009). 
 
For the third study, we have designed and evaluated double-walled microspheres as a dual 
anticancer delivery system to provide combined gene therapy and chemotherapy. Double-walled 
microspheres consisting of a PLGA core surrounded by a PLA shell were fabricated via the PPF 
technique. We make use of the advantages of double-walled microspheres to deliver chi-p53 
and/or doxorubicin, loaded in the shell and core phases, respectively. Different molecular 
weights of PLA were used to form the shell layer for each formulation. The microspheres were 
monodisperse with a mean diameter of 65 to 75 μm and uniform shell thickness of 8 to 17 μm. 
The encapsulation efficiency of doxorubicin was significantly higher when it was encapsulated 
alone compared to co-encapsulation with chi-p53. The encapsulation efficiency of chi-p53, on 
the other hand, was not affected by the presence of doxorubicin. As desired, chi-p53 was 
released first, followed by simultaneous release of chi-p53 and doxorubicin at a near zero-order 
rate. Next, the therapeutic efficiencies of doxorubicin and/or chi-p53 in microsphere 
formulations were compared to free drug(s) and evaluated in terms of growth inhibition, and 
cellular expression of tumor suppressor p53 and apoptotic caspase 3 proteins. Overall, the 
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combined doxorubicin and chi-p53 treatment exhibited enhanced cytotoxicity as compared to 
either doxorubicin or chi-p53 treatments alone. Moreover, the antiproliferative effect was more 
substantial when cells were treated with microspheres than those treated with free drugs. High 
p53 expression was maintained during a five-day period, and was largely due to the controlled 
and sustained release of the microspheres. Moreover, increased activation of caspase 3 was 
observed, and was likely to have been facilitated by high levels of p53 expression. 
 
This work is a proof of concept that double-walled microspheres are suitable delivery carriers for 
chi-p53 and doxorubicin. Although the double-walled microspheres presented here are somewhat 
complex and challenging to produce, the primary advantage of loading two therapeutics in the 
same particles is that the two drugs would be necessarily colocalized with a single administration 
and a single-component formulation. In addition, both CEHDA and PPF processes provide 
superior control of the particle morphology (size and shell thickness) and drug release rates. 
Unlike conventional microspheres, these double-walled microspheres could be tailored such that 
drug release schedules between the two different agents may be controlled by selectively varying 
the shell material or thickness for combined modality cancer treatment as proposed in this work. 
 
Double-walled microspheres can load hydrophobic drugs with high encapsulation efficiencies, 
but may be limited when loading hydrophilic drugs, such as doxorubicin used in this study. 
When doxorubicin was loaded in double-walled microspheres, the encapsulation efficiency was 
~80% and was higher than that in single-polymer PLGA microspheres (61%). However, the 
encapsulation efficiency of doxorubicin decreased (~32 to 47%) when the drug was loaded 
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together with chi-p53. The encapsulation efficiency of chi-p53 was also limited (~25 to 37%). 
Potential drug loss during the microsphere fabrication process, particularly in the PPF technique, 
may be attributed to the emulsion created in the PLGA core and PLA shell phases that likely 
facilitated the diffusion of doxorubicin and chi-p53 out from the microspheres during DCM 
extraction. Studies on improving the encapsulation efficiency of water soluble drug have been 
reported, such as i) adjusting the pH of the external phase (Bodmeier and McGinity, 1987), and 
ii) using salt-containing external phase (Uchida et al., 1996). These may be useful in improving 
the encapsulation efficiency of doxorubicin and chi-p53 in double-walled microspheres. While 
encapsulation of doxorubicin and chi-p53 in double-walled microspheres was not tried in the 
CEHDA technique, the encapsulation efficiencies of chi-p53 and doxorubicin should likely be 
improved due to the absence of the DCM extraction process. 
 
As observed from the in vitro release profiles, the lag phase for doxorubicin may have an impact 
on the therapeutic efficacy of the microspheres. While the work is a proof of concept, these 
microspheres could be optimized to reduce the lag phase, particularly the first 25 days. This 
could be done by reducing the thickness of the PLA shell layer and/or using PLGA with a lower 
molecular weight. By reducing the thickness of the PLA shell layer, water penetration into the 
microspheres may be quicker due to the shorter distance from the surface to the PLGA core. 
Polymer molecular weight can affect polymer degradation and drug release rates. As one might 
expect, a decrease in molecular weight of the PLGA core could increase diffusivity and therefore 
drug release rate. 
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While several studies have been conducted to improve the transfection efficiency, so long as the 
exogenous gene is not integrated into the host genome, non-viral methods are inherently limited 
by providing only a temporary expression of the gene. For substantial therapeutic efficacy, 
repeated administration would be required to produce sustained level of protein expression. 
Elevated expression of therapeutic protein from chitosan-mediated DNA delivery to hemophilia 
A mice was maintained through repeated weekly administration, but regressed markedly a week 
after the last treatment (Dhadwar et al., 2010). Sustained release gene delivery systems have 
been investigated to avoid the problem of repeated administration. It has been demonstrated that 
sustained release of wild-type p53 plasmid DNA from polymeric nanoparticles produced greater 
anti-proliferative activity than naked DNA and commercial transfection agent Lipofectamine 
(Prabha and Labhasetwar, 2004). Overall, double-walled microspheres present a promising dual 
anticancer delivery system for combined chemotherapy and gene therapy, as demonstrated in this 
work. 
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